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Immunological memory is the hallmark of the adaptive immune system. The humoral 
branch of the immunological memory is mediated by memory B-cells (mB).  Memory 
B cells are marked by longevity, expression of antibodies with high affinity, and 
ability to generate robust antibody responses upon reencountering pathogens.  
However, requirements for the activation of mB cells and the induction of humoral 
memory responses are not well understood.  This thesis examines the role of Toll-like 
receptors (TLRs) in mB activation using an immunized mouse model.  TLRs are a 
family of receptors that recognize common molecular patterns of microbial pathogens 
and stimulate innate immune responses.  Our study found that mouse mB expressed 
TLR9 and 4, and responded to their agonists in vitro by differentiating into high 
affinity IgG secreting plasma cells.  However, TLR agonists alone were not sufficient 
to activate memory B cells in vivo.  Antigen was required for the clonal expansion of 
  
antigen-specific memory B cells, the differentiation of mB cells to high affinity IgG 
secreting plasma cells, and the recall of high affinity antibody responses.  The Ag-
specific B cells that had not yet undergone isotype switching showed a relatively 
higher expression of TLR4 than memory B cells, which was reflected in a heightened 
response to its agonist, but in both cases of TLR4 and 9 yielded mostly low affinity 
IgM secreting plasma cells.  When immunized together with the antigen, TLR 
agonists not only boosted the antigen-specific titers, but also increased affinity and 
isotype switching of the immunoglobulin.  Thus, while TLR agonists alone are unable 
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Chapter 1: General Introduction 
 
 
Immune systems are necessary for multicellular organisms to protect themselves from 
harmful substances and invading organisms.  Plants and fungi rely primarily on the 
production of toxic chemicals to prevent reproduction of the microorganisms that 
infect them.  Animal defenses rely predominantly on digesting pathogenic 
microorganisms, which is carried out by specialized phagocytic cells (reviewed by 
Menezes and Jared, 2002) [1].  Phagocytosis is especially efficient with opsonized 
microorganisms.  Several different mechanisms of opsonization have evolved in the 
animal kingdom.  One of them, which arose in gnathostomes (jawed vertebrates; 
reviewed by Pancer and Cooper, 2006) [2], is opsonization by specific antibodies 
(Ab; reviewed by Aderem and Underhill, 1999) [3].  In addition, Abs are useful tools 
for activating the complement cascade to opsonize and lyse foreign cells (reviewed by 
Ochsenbein and Zinkernagel, 2000) [4], and Abs can also directly neutralize and 
inactivate viruses and bacteria (reviewed by Law and Hangartner, 2008; Bebbington 
and Yarranton, 2008) [5, 6].  The first advantage of specific Ab is the ability to afford 
a large repertoire of different receptor specificities.  This is useful for competition 
against microorganisms that can evolve quicker due to their relatively short 
generation time.  Second, the large Ab repertoire can recognize completely new 
microorganisms and thus allows the jawed vertebrate to travel in search of food rather 
than being tied to one ecological niche.  Third, the repertoire can be specifically 




life experiences (immunological memory) (reviewed by Danilova, 2006) [7].    Of 
course the repertoire must be selected to be minimally self-reactive.  A mis-trained 
repertoire on the one hand creates specific disease susceptibility and on the other 
hand allows for the development of allergies and autoimmune diseases. 
 
In this thesis, the organisms of interest are humans and mice.  The mouse, Mus 
musculus, was used as the model organism.  Mammals, including human and mouse, 
have evolved a complicated immune system with many different specialized immune 
cell types and cross-talk pathways.  Traditionally, the immune system can be divided 
into the two branches of innate and adaptive immune responses (reviewed by Pone et 
al., 2010) [8, 9].  The innate branch includes a broad range of white blood cells whose 
receptor repertoires are limited to recognize general patterns of microorganisms.  Any 
changes in innate immune receptors are due to evolution of the host organism.  Innate 
immune cells include macrophages, neutrophils, basophils, eosinophils, dendritic 
cells, and natural killer cells. In addition, the barrier functions of the epithelium and 
stomach acidity, entrapment of microbes by platelet clotting, zymogens secreted from 
liver cells, and control of body temperature by the hypothalamus contribute to innate 
immune protection.  However, the cells responsible for creating the trainable Ab 
repertoire in the previous example are different:  They are the effector cells of the B 
lymphocyte branch, which forms one arm of the adaptive branch of the immune 
system.  The adaptive branch is evolutionarily younger than the innate branch and is 
mediated by B and T lymphocytes.  B cells are responsible for the humoral immune 




adaptive immune cells (B and T cells) can generate a large repertoire of receptors by 
DNA recombination, a random gene reassembly process.  B cells express a large 
repertoire of immunoglobulin (Ig), which has both secretory and membrane form.  
Membrane Ig is a part of the B cell receptor (BCR).  T cells express a large repertoire 
of T cell receptor (TCR).  Both BCR and TCR serve for recognition of foreign 
substances, and their ligands (L) are broadly called antigen (Ag).  Receptor binding 
with Ag activates B and T cells to proliferate and to become effector cells.  Other 
activation signals are also required in primary immune responses, without which the 
lymphocyte will undergo an abortive activation and become tolerant.  The humoral 
effect of fully active primary immune responses initially is secretion of IgM 
antibodies by plasma cells.  The cellular effect is secretion of cytokines by helper T 
cells and secretion of cytolytic proteins by cytotoxic T cells.  Some of the activated B 
and T cells become memory cells to provide immunity in subsequent exposures to 
pathogens with that Ag.  Activation of memory immune cells induces a secondary 
immune response, which is typically faster and more robust than primary immune 
responses.  Immunological memory is the hallmark of the adaptive immunity and has 
been exploited by immunization (reviewed by Rappouli et al, 2002) [10].  
Immunization is the most effective prevention method against infectious diseases. 
 
Interactions between different immune cells are essential for providing the system of 
checks and balances.  The spleen and lymph nodes are organs that facilitate the 
adaptive immune cells’ encounter with Ag as well as with other activated immune 




immunologically naïve T and B cells while they interact with Ag presented by 
dendritic cells (DCs) and follicular dendritic cells (fDCs), their respective Ag 
presenting cells (APCs) (reviewed by Mueller and Germain, 2009) [11].  Sometimes 
interaction with Ag and the APC is sufficient for complete lymphocyte activation.  
For B cells this is called T cell-independent (TI) activation. TI activation of B cells is 
often associated with Ag that are high in valency and organization (i.e. viral coat 
“quasicrystals”) and the presence of polyclonal activators (adjuvants) (reviewed by 
Hinton et al, 2008) [12].  The activation of B cells is enhanced through direct 
interaction with helper T (TH) cells, which leads to T cell-dependent (TD) responses. 
The T-B cell interaction is primarily mediated through CD40 and CD154 (CD40L) 
and through cytokines that activated TH cells secrete (paracrine stimulation) 
(reviewed by McHeyzer-Williams et al, 2005) [13].  Ag-activated B cells request and 
reciprocate the T cell help by processing and presenting Ag in the context of major 
histocompatibility complex class II (MHC-II) to TH cells, providing costimulatory 
signals such as through CD28 and CD80/CD86, and secreting cytokines (reviewed by 
Harris et al, 2000) [14].  For these events to take place, B cells and T cells that 
recognized the same Ag (B cell in its native form, T cell in its processed form) have 
to find each other [13].  Segregating un-activated B and T cells in the secondary 
lymphoid structure keeps them out of the way of activated lymphocytes trying to find 
each other on the borders between B and T cell zones to enhance each other’s 
activation [11].  T-B cell interaction induces rapid proliferation of B cells, leading to 
germinal center (GC) formation for fine-tuning of antibody responses and developing 




structures to spatially separate competing B cells that must interact with an fDC from 
mutating ones that can interact with other fibroblasts (reviewed by Mueller and 
Germain, 2009) [11]. 
Section 1 B cells 
B cells were first discovered in chickens.  They are named for the bursa of Fabricus, a 
specialized organ in birds for B cell development (reviewed by Warner and Szenberg, 
1964) [15].  In mammals, B cells develop in the liver of fetuses and in the bone 
marrow of adults (reviewed by Duchosal, 1997) [16].  B cells can be divided into 
many phenotypically and functionally distinct subsets (Table 1.1).  This thesis 
focuses on memory B cells (mB) that are responsible for generating robust secondary 
humoral immune responses.  So far, the majority of studies have focused on follicular 
naïve B cells (FO). 
 
Naïve FO B cells are mature B cells found in blood and secondary lymphoid organs.  
Each B cell expresses Ig of a unique specificity as the Ag recognition subunit of its 
BCR.  The Ig in the BCR contains two Ig light chains (IgL) and two Ig heavy chains 
(IgH) with an extended transmembrane domain in their C-terminals. The BCR is 
composed of a membrane Ig and two signaling chains (Igα and Igβ) (Figure 1.1).  The 
specificity of the BCRs is determined by variable domains of the IgH and IgL. The Ig 
genes are assembled by a recombination activating genes 1 and 2 (RAG1/2) enzyme-
dependent mechanism during B cell development.  The IgH gene is assembled during 
Pro-B cell stage with over 6000 possible combinations of variable (V), diversity (D), 




cell stage with almost 400 possible combinations of its V and J gene segments. The 
IgH and IgL gene repertoires are further expanded by insertion of up to 20 random 
nucleotides between the Ig segments by a terminal deoxynucleotidyl transferase 
(TdT) (reviewed by Hardy and Hayakawa, 2001) [17].  Even after accounting for 
silent mutations (same protein sequence after translation), out-of-frame Ig genes 
(check-points at end of Pro- and Pre- B cell stages), and elimination of self-reactive 
cells (negative selection in immature B cell stage), an individual’s naïve B cell  
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Figure 1.1: The B cell receptor (BCR).  This is a diagram of an IgM isotype BCR as 
it would appear on a mature naïve B cell when it has first bound an antigen.  Antigen 
binding site is near the tip of the variable domains, composed of three hypervariable 
loops on each domain.  The Cμ3 constant domains are held apart from each other by 
glycosylation.  Immunoregulatory tryrosine-based activation motifs (ITAMs) are 




repertoire is estimated to contain 107-109 different BCRs (Abbas and Lichtman, Eds., 
2005) [9].  Importantly, the rearrangement of the immunoglobulin heavy chain (IgH) 
in one chromosome suppresses the rearrangement and expression of IgH on the other 
chromosome, so that each B cell expresses BCRs of only one unique specificity [42-
46].  Constant regions (C) of the Ig gene determine the isotypes of Ig and do not 
undergo RAG-dependent rearrangement. The default isotype of the BCR is IgM.  FO 
B cells also express IgD isotype BCRs, an alternate splice form of the IgM segment 
(reviewed by Preud’homme et al, 2000) [47, 48]. 
 
Memory B cells (mB) are descendants of antigen-experienced FO B cells (Figure 1.2) 
(reviewed by McHeyzer-Williams, 2005) [13].  In the primary immune response, 
antigen encounter by the mature yet immunologically naïve B cell (nB) with stimuli 
from TH cells (TD) or adjuvants (TD or TI) lead to full B cell activation.  Activated B 
cells undergo a burst of proliferation and have two possible cell fates: terminal 
differentiation into short-lived plasma cells (sl-PC) (reviewed by Calame, 2003) [49] 
or formation of a germinal center (GC) (reviewed by Tarlinton, 2006; MacLennan, 
1994) [50, 51].  Sl-PCs have direct effector function, secreting antibody.  These 
antibodies are encoded in the same rearranged DNA as the BCR, only spliced to an 
alternate 3’ ending to produce the secretory form, and hence the antibody specificity 
and affinity for antigen are exactly the same as those of the BCR of the responding 
naïve B cell.  In TD responses, germinal centers for the formation of memory B cells 
(mB) and long-lived plasma cells (ll-PC) is possible with B cell interaction with the 







complex and through CD40-CD40L interactions [52, 53].  In the GC, activated B 
cells will undergo isotype switching and affinity maturation.   These processes require 
activation-induced cytidine deaminase (AID) [54-62].  AID mediates somatic 
hypermutation (SHM) of the immunoglobulin (Ig) gene (reviewed by Stavnezer, 
1996; McHeyzer-Williams, 2005) [13, 63] as B cells divide in the “dark zone” of GCs 
[64, 65].  SHM is also frequently accompanied by Ig isotype class switching.  Which 
isotype a B cell switches to is determined by the cytokines secreted by TH cells and 
the properties of antigens [66-70].  Whether TH cells are required for the class switch 
recombination (CSR) [54, 69, 71-79] and whether all B cells in GC reaction undergo 
CSR are controversial questions (reviewed by Klein, 1998) [80-84].  Between rounds 
of division, B cells migrate to the GC “light zone” containing resident follicular 
dendritic cells (fDC) (reviewed by Mueller and Germain, 2009) [11, 64].  Interaction 
with antigen displayed on the fDCs provides survival signals to B cells.  B cells 
expressing high affinity receptors, resulting from somatic hypermutation, are better 
able to compete with other B cells to interact with the fDC, and thus are selected to 
survive.  In a typical immune response, the B cells undergo 25-60 rounds 
proliferation and competition [51, 65, 85-87] until the GC eventually dissolves [85, 
86].  Therefore, post-GC B cells have a higher affinity for the specific antigen than 
the original cell that formed the GC [50].  Many of the post-GC cells also undergo 
terminal differentiation into PCs [38-40].  The major cell type to provide survival 
signals to long-lived (ll-)PCs are bone marrow stromal cells, and hence most ll-PC are 
found in the bone marrow where they occupy a limited number of specific niches [38, 




memory B cells that are precursors to ll-PCs.  In contrast to ll-PCs, mB do not secrete 
Ab until re-exposure to the antigen.  Then the memory B cells can lend immunity in 
subsequent waves of recurrent epidemics, such as measles (reviewed by McHeyzer-
Williams and McHeyzer-Williams, 2005; Andersen et al., 2006; Höfer et al., 2006; 
and Lanzavecchia et al., 2006) [13, 88-90].  Both the mB and ll-PC contribute to 
humoral immune memory. 
 
Memory B cells (mB) are high affinity antigen-specific B cells that persist long after 
an infection is resolved.  Most reports can only present anecdotal evidence for the 
duration of immunological memory, however, a few controlled studies exist: 
According to Dr. Peter Ludvig Panum, among the elderly inhabitants of the Faroe 
Islands (life expectancy 80-90 years, excluding infant mortality) 100% of those who 
had contracted the measles in the 1781 outbreak had immunity in 1846—a 
maintenance of memory over a span of 65 years after single exposure to the virus 
[91].  Isolation of the faroese villages from each other provided an ideal age-matched 
control population who had been successfully quarantined in the first outbreak, and 
all of these were as susceptible as their younger kinsfolk, ruling out age as a 
confounding variable to disease resistance [91].  Due to the unique circumstances of 
this population, this epidemiological report is the first to be able to include an 
immunologically naive control population.  However, since the 19th century Faroese 
were also insulated from other infectious diseases, it was uncertain if memory 
maintainance to this extent could be achieved in larger populations with exposures to 




studying a group of non-isolated smallpox vaccine recipients more than 25 years after 
extinction of the virus for variola-specific antibodies and lymphocytes.  The antigen-
specific mB were maintained at ~0.1% of IgG+ B lymphocytes in blood of volunteers 
who had received the vaccine 8-60 years before.  These mB were able to respond to 
re-vaccination [92].  Dr. Erika Hammarlund and collegues performed similar studies 
and found that although T cell memory gradually declined, in their cohort variola-
specific antiserum titers maintained at similar levels from 1-75 years after 
immunization (mB cells were not quantified) [93].  Dr. Mark Slifka’s laboratory 
performed a longitudinal study of antibody maintainance to common vaccines and 
pathogens including measles, mumps, rubella, Epstein-Barr virus, varicella-zoster 
virus, vaccinia, tetanus, and diphtheria.  They determined 95% confidence intervals 
for IgG antiserum half-lives, which ranged from 10-14 years (tetanus) up to 104-∞ 
years (measles) [94].  This means that ll-PCs keep secreting these antibodies, because 
human IgG molecules in serum only have a half-life of 21 days [95].  Memory B cells 
were also quantified in the blood of the volunteers and for most vaccines correlated 
with the titers (except tetanus) [94].   This longevity of immunological memory is 
remarkable and still raises many questions:  Which cells are responsible for future 
immunity and how can they be distinguished from other B cells prior to re-infection?  
What is the mechanism to maintain the pool of antigen-specific memory B cells?  






Identifying memory B cells is a controversial subject.  At the basic definition, 
memory B cells simply are those B cells that provide the specific protection in re-
exposure to a pathogen.  Which properties uniquely define a memory B cell or are 
essential to the function of producing the secondary immune responses, opposed to 
features that are just common in memory B cells but are not definitive, or whether the 
memory pool might actually consist of several distinct subpopulations of cells is 
unclear.  In human, the majority of memory B cells express a TNF-receptor family 
member that serves as a cell surface marker for memory B cells: CD27 [81].  Cross-
linking of the CD27 prevents differentiation into plasma cells and enhances 
production of memory B cells [96].  For the mouse model, to date no single marker 
for memory B cells has been found. 
 
Most mouse memory B cells are generated in response to T cell-dependent antigens 
in germinal centers [97].  The most reliable feature of these memory B cells is that 
they carry mutations in the gene segments for the immunoglobulin heavy and light 
chain variable domains that are absent in other cell types (Lalor et al., 1992) [98].  
However, determining somatic hypermutation in memory B cells requires sequencing 
of PCR-amplified sections of the V gene segments of individual cells, which is 
difficult, expensive, and impractical for experiments. 
 
Isotype switched B cells appear to be enriched in memory B cells by 20-30-fold [99, 
100].  This was also shown by their adoptive transfer into immunologically naïve 




cells, while both B cell subsets are protective in early challenges [101, 102].  The 
isotype-switched cell population also contains germinal center cells from on-going 
immune responses [86, 98] and cells that switched outside of germinal centers [103, 
104].  One interesting debate concerns a small population of hyper-mutated cells that 
express IgM.  In Klein et al. and Kruetzman et al. the human memory B cell marker 
CD27 also stains some IgM-expressing B cells, and these cells had undergone 
somatic hypermutation [81, 84].  These cells may be memory B cells that underwent 
germinal center reaction without isotype switching.  They may also have received 
signals to switch back to IgM using the second immunoglobulin allele, which has 
been shown to occur in some cancer lines [105].  (Switching between different 
alleles, although not necessarily to IgM, has been shown to occur in about 5% of CSR 
in rabbits [106].  The signals that drive trans-switching are unknown.)  Weller and 
colleagues provide an alternative explanation for this phenomenon: fetal marginal 
zone B cells may undergo somatic hypermutation as part of their diversification [82, 
83].  Studies of human tonsil B cells revealed that a subset of adult marginal zone B 
cells can form germinal centers and undergo hypermutation as well [107].  Whether 
these IgM+ isotype switched cells are memory B cells is unclear.  McHeyzer-
Williams and collegues also described a population of mB that have downregulated 
their B220 B cell marker expression [108].  Typically, however, a loss of B220 
indicates differentiation into plasma cells [97]. 
 
We chose to study the least controversial memory B cell subpopulation in the mouse: 




immunization at least six weeks earlier and are isotype switched.  We identify these 
cells by flow cytometry using fluorescently labeled antibodies against B220 (pos), 
CD138 (neg), IgM (neg), IgD (neg), and the antigen (pos).  The majority of mouse 
serum antibodies is of IgM and IgG isotypes; so some investigators choose to show 
isotype switching by determining if it is IgG+ [109, 110].  For studies in mice, this is 
not recommended as all commercially available anti-mouse IgG antibodies developed 
against all subtypes of IgG have a strong tendency to cross-react with IgM antibodies.  
Furthermore, B cells display captured IgG via Fcγ receptors on their surface [111].  
Therefore, it was necessary that we used the indirect measurement of lack of IgM and 
IgD to represent isotype switching.  Probably most of these cells are IgG+.  
 
Several studies have addressed the requirements for mB maintainance. Whether 
antigen (Ag) is required for memory B cell re-activation is controversial [112].  Ag 
appears to be required for the survival of adoptively transferred mB cells [113, 114].  
Ag can be maintained at pg-levels in immune complexes on follicular dendritic cells 
(fDCs) (reviewed in Tew et al., 1990; Mandel et al., 1980) [115-118]. Since it would 
be impossible to remove Ag completely after immunization, whether the maintained 
Ag actually is relevant for the maintainance of mB could not be tested until the 
advent of transgenic mice.  In mice that cannot form immune complexes due to being 
restricted to the membrane-bound form of IgM antibody [119] and in mice where the 
BCR is engineered to switch to the second IgH allele to recognize the phycoerythrin 
dye rather than the Ag specifically in antigen-experienced (memory + GC) B cells 





ll-PCs survive by resisting apoptosis rather than homeostatic proliferation.  ll-PCs are 
known to be maintained without antigenic stimulation in the bone marrow, where 
stromal cells provide the necessary environment for their longevity [90, 121-130].  ll-
PCs also intrinsically express high levels of anti-apoptotic genes [131-133].  In 
specific pathogen free-housed laboratory mice, about 10% of the Ag-specific ll-PCs 
generated in GCs are maintained for more than one year [123, 125].  In humans this 
frequency over an equivalent time frame adjusted for lifespan is likely to be lower 
due to increased diversity of microbial exposures putting selective pressure on 
availability of bone marrow niches [124, 134].    However, in ex vivo cell culture all 
PC, including ll-PC, die within a few days [122].  In contrast, although circulating 
memory B cells may visit the bone marrow, they are predominantly found in the 
spleen [84, 103, 135, 136].  The BCR is required for mB maintainance [137], but 
tonic BCR signaling is required for the survival of all B cells [138, 139] (except PCs 
[126]).  In addition, both the Tangye and Noelle labs showed that antigen-stimulated 
memory B cells become more responsive to anti-apoptotic effects of the B cell 
activating factor (BAFF), a TNF family member, due to increased expression of one 
of its receptors B cell maturation antigen (BCMA) [128, 140].  Resting memory B 
cells in mice, however, only express the TACI receptor for BAFF, but blocking this 
receptor with antibodies did not impact mB survival significantly [141].  Recently 
activated mB also down-regulate surface expression of the major interacting partner 
with TH cells CD40, which serves to stimulate B cell proliferation [140, 142], but TH 




allow follicular dendritic cell (fDC) maturation, and consequently cannot form GCs 
or develop mB.  However, when mB were adoptively transferred into these mice, they 
were still present one year later, indicating that fDCs are not required for mB 
maintainance either [144].  Several labs showed that during the GC phase and during 
in vitro stimulation, activated B cells express telomerase [145-150].  Telomerase 
function is to lengthen chromosome telomeres, which is associated with greater 
proliferation potential.  In general, the gene expression profiles of resting mB, as 
analyzed by micro-array, are very similar to those of resting FO B cells despite large-
scale cell-program changes during GC reaction [151].  Whether mB can sporadically 
leave the G0 cell cycle phase for homeostatic proliferation [120, 152-154] and which 
cellular signals are required for the maintenance of resting memory B cells are 
presently unknown. 
 
Ag activation of memory B cells leads to the high affinity secondary immune 
responses.  At re-encounter with the antigen, mB are thought to differentiate into ll-
PC directly [13, 50].  A few gene expression differences have been identified between 
mB and naïve B cells sofar that may impact mB activation.  Tangye and colleagues 
and Klein and colleagues found an approximately 100-fold increased expression of 
the interleukin-2 receptor (IL-2R) on human memory B cells [142, 151].  This 
suggests that mB may be more sensitive to this cytokine, at least in the human.  In 
vitro stimulation with IL-2 in addition to CD40 and IL-10 increased the number of in 
vitro formed antibody secreting cells (ASCs) from mB origin compared with only 





Whether mB cell activation requires help from TH cells and/or adjuvant is debated. 
While TH cells are not required for mB maintainance [143], for some antigens mB re-
activation required MHC-II expression [155], suggesting necessity for TH cell 
interaction.  In vitro, human mB were significantly less responsive to CD40L than 
naïve FO B cells for IL-10 secretion [156].  BCR cross-linking plus stimulation with 
CD40L caused FO B cells to switch from secreting IL-10 to secreting lymphotoxin 
(LT) and TNFα. In this regard, mB produced significantly more LT and TNFα than 
naïve B cells [156].  CD40 stimulation of human mB leads to rapid differentiation 
into ASCs, where they produce 5-8 fold more ASCs than naïve FO B cells [157, 158].  
Therefore, Memory B cells are generally considered to be more sensitive to 
stimulation, however, inhibitors of activation, such as CD200R, are up-regulated in 
mB as well [159]. 
 
Polyclonal activation of mB has been proposed as a mechanism for re-activation to 
form ll-PCs by Dr. Bernasconi and colleagues [112].  This model is still controversial.  
While human mB up-regulated expression of the Toll-like receptors implicated for 
this type of activation [160] and B cells activate well in response to their ligand in 
vitro [112, 160-162], this has so far not been observed in vivo.  Some periodic turn-
over of mB into PCs may indeed be necessary to maintain the ll-PC pool as in the 
absence of mB, ll-PCs were shown to decline [125, 158].  However, to date the only 






Thus, naïve FO B cells and mB differ in several ways, including the isotype of their 
receptors, their gene expression profiles, their ability to respond to polyclonal stimulation 
in vitro, and their cytokine secretion.  Our interest lies in studying the signals that allow 
mB to activate to form ll-PC and to maintain their own population.  The next section 
looks at the mechanism of activation to identify where there may be differences between 
naïve FO B cells and mB. 
 
Section 2 Antigen-specific B cell activation through the BCR 
Signaling mechanisms in memory B cells are not well understood.  Most current 
knowledge of BCR-mediated signaling is based on the data generated in FO B cells.  
BCR signaling leading to B cell activation underlies the important B cell functions of 
antigen presentation to T cells and differentiation into plasma cells.  The cell 
signaling for both of these processes occur simultaneously.  B cell signaling induced 
by encounter with antigen leads the B cells to spread and contract, accumulating 
antigen on its BCR in the process (reviewed by Harwood and Batista, 2008) [165].  
Then BCR and bound Ag are internalized by clathrin-mediated endocytosis [166-
169].  The signaling events described herein start upon first contact with the antigen 
and continue through internalization [166, 170, 171]. 
 
BCR signaling is initiated by engagement with antigens or receptor cross-linking with 
anti-IgM antibodies, which causes oligomerization of the BCRs into microclusters on 




antigen contact, forming either a B cell cap (soluble antigens) [170, 175, 176]  or an 
immune synapse (membrane-bound antigens) [177-180].  The conformational change 
in the BCR associated with oligomerization allows recruitment of the adapter B cell 
linker protein (BLNK, also named SLP-65) [181, 182] and the BCR Igα-Igβ signaling 
chains to spread out [174, 183].  Within the first minute of contact with multivalent or 
membrane-associated antigen, Förster/fluorescence resonance energy transfer (FRET) 
efficiency between the membrane-bound Ig and the Igα chain decreases, indicating a 
conformational change in the majority of the BCRs from closed to open conformation 
[183, 184].  These events likely precede even the earliest tyrosine phosphorylation-
based signaling events since they are not affected by treatment with the src-family 
kinase inhibitor PP2 [183, 185].  BCR microclusters transiently interact with lipid 
rafts [183, 186], where Src family tyrosine kinases, such as Lyn, phosphorylate the 
Igα and Igβ chains on their ITAM (D/E- x7-D/E-x2-Y-x2-L/I-x7–Y-x2-L/I; where x is 
any amino acid) (reviewed by Dykstra et al, 2001) [187].  Phosphorylated ITAMs 
provide a binding site for  spleen tyrosine kinase (Syk) via its two SH2 domains 
(reviewed by Sada et al, 2001) [188].  Binding to the Igα-Igβ ITAMs activates Syk by 
interfering with Syk auto-inhibition (reviewed by Kulathu, 2009) [173, 189, 190].  
Syk phosphorylates the adaptor protein BLNK, which can then recruit Syk 
downstream targets [191, 192]. 
 
Among the most important Syk targets for B cell activation are phospholipase Cγ2 
(PLCγ2), Bruton’s typrosine kinase (Btk), and Vav.  PLCγ2 is responsible for 




trisphosphate (IP3) (reviewed by Cambier and Campbell, 1992) [193, 194].  Calcium 
signaling is required for the activation of transcription factors NF-κB and NFAT and 
the MAPK c-Jun NH2-terminal kinase (JNK) [195].  Btk provides positive feedback 
for the signaling downstream of Syk, including activation of PIP5K that generates 
PI(4,5)P2, the substrate for PLCγ2 and PI3K (reviewed by Kurosaki and Hikida, 
2009) [194, 196].  Btk is involved in mediating B cell spreading through crosstalk 
with the actin cytoskeleton [197].  Btk and Syk together recruit and activate the 
adaptor B cell cytoplasmic adaptor protein (BCAP) [196] that recruits the 
constitutively active class I phosphatidylinositide-3-kinase (PI3K) [198].  Mutations 
in Btk cause B cell immunodeficiency diseases, XLA (X-linked agammaglobulin-
emia) in humans [199], Xid in mice [200].  Recruitment of  PI3K increases the local 
concentration of  PI(3,4,5)P3 (PIP3) , the membrane docking sites of both Btk and 
PLCγ2 to PIP3 via their pleckstrin homology (PH) domain [194, 196, 201] as well as 
activating the serine/threonine-specific protein kinase Akt with anti-apoptotic effect 
(reviewed by Deane and Fruman, 2004) [201].  Vav is the guanine nucleotide 
exchange factor (GEF) of Rho family small G proteins Rac1 and Cdc42 [195].  These 
GTPases, regulate MAPK p38 activation.  In concert with calcium signaling, this 
cascade also leads to activation of JNK [195, 202].  Ras protein is involved in 
activating the MAPKs extracellular signal-related kinases 1 and 2 (ERK1/2).  In 
summary, the BCR orchestrates signaling in micro-clusters that are transiently 
associated with lipid rafts [186].  BCR oligomerization triggers the activation of Syk, 
which propagates the BCR signaling cascade at the local membrane through PLCγ2, 




activation of small G proteins, and activation of MAP kinase cascades to induce 
transcription factor activation. 
 
BCR internalization also depends on actin rearrangement (reviewed by Schafer, 
2002) [203, 204].  Internalized antigens are transported to antigen processing 
compartments in a BCR signaling and phospholipase D (PLD)-dependent pathway 
[205].  Here, antigens are digested to short peptides and deposited into major 
histocompatibility class II complexes (MHC-II) (reviewed by Clark et al, 2004; 
McHeyzer-Williams et al, 2006) [206-208].  Peptide-loaded MHC-II complexes are 
targeted to the B cell surface.  BCR signaling also leads to the display of activation 
markers on the B cell surface, including B7-1 and B7-2 that interact with CD28 on T 
cells, providing co-stimulatory signals for CD4+ TH cells [208].   Thus, these antigen-
experienced B cells can interact with antigen-binding CD4+ TH cells.  PI3K is 
involved with regulating microtubule assembly [209, 210], important for transport to 
and from the immune synapses, including antigen presentation to CD4+ TH cells.  The 
binding of TCR to peptide-loaded MHC-II triggers T cell activation, which leads to 
CD40L expression and cytokine secretion for B cell activation [207, 208].     
 
BCR activation can also result in plasma cell differentiation (reviewed by Calame, 
2003) [49].  BCR signaling suppresses the transcription factor Pax-5, which functions 
to maintain B cell phenotype and the expression of the master regulator of plasma cell 
differentiation, Blimp-1 [211].  Under the control of Blimp-1, transcription factor 




interferon regulatory factor 4 (IRF-4) is associated with the B-cell intrinsic cell fate 
decision of either developing into a plasma cell or transition to GC B cell state.  IRF-
4 is a critical transcription factor of both the Prdm1 (Blimp-1) and Aicda (AID) loci, 
at low and high IRF-4 expression level, respectively [214, 215].   
 
The rapid and robust secondary antibody response suggests a lower signaling 
threshold and faster kinetics of mB activation.  IgG-expressing B cells were recently 
shown to be more efficient than IgM-expressing B cells in their ability to form 
microclusters and gather antigen [216].  This must be especially important since mB 
cells express fewer BCR complexes than their naïve counterparts [217].  As 
previously noted, the majority of memory B cells generated in response to T cell-
dependent antigen immunization have undergone isotype switching to IgG.  The 
cytoplasmic tail of IgG molecules is 25 amino acids longer than that of IgM 
molecules, which is necessary for secondary immune responses [218].  Several 
signaling pathways for the IgG tail have been proposed.  The Tsubata laboratory 
showed that the IgG tail can inhibit the phosphorylation of CD22, a negative regulator 
of B cell signaling [219].  However, expression of transgenic IgG1 tail expression did 
not increase global levels of BCR signaling [220].  Using mice in which the 
transmembrane and intracellular tails on their IgM have been substituted with those 
from IgG1 (IgMG), the Goodnow laboratory showed enhancement of antibody 
secretion in naïve IgMG B cells similar to those by transgenic IgG1-expression in B 
cells [221].  The IgMG-expressing B cells do have robust calcium signals in response 




cells for more than half of the molecules that are associated with B cell activation in 
microarray, including IRF-4, IL-1R, and Myc [220].  The ERK, NFAT, and NF-κB 
pathways were unchanged by the IgG1 tail [220].  The IgG tail also contains a 
conserved tyrosine which can be phosphoylated by Syk [222].  Mutation of this 
tyrosine results in lower phosphorylation of Igα/Igβ, BLNK, and PLCγ2, while 
phosphorylation of this tyrosine allows recruitment of the adaptor Grb2 and enhanced 
calcium signaling and MAPK activity [222].  However, the ability to gather more 
antigen was associated with the membrane-proximal amino acids of the IgG tail 
rather than the tyrosine [216]. The other feature of mB is a higher affinity for the 
specific Ag after GC reaction.  Not surprisingly, high affinity of the BCR for its 
antigen also allows more potent activation of B cells in IgM and IgG expressing B 
cells [216].  By definition, a BCR has higher affinity for its Ag if it spends more time 
in contact with the Ag within a given time frame compared to lower affinity 
receptors.  Thus, high affinity receptors have more opportunities to signal through the 
BCR. 
 
B cell activation is modified by other cell surface receptors.  BCR signaling can be 
markedly enhanced by co-engagement of the co-receptor CD19 through complement 
factor C3d opsonized antigen. CD19 complexes with CD21, a complement receptor, 
and CD81, a tetraspan membrane protein [223].  CD19 recruits PI3K and Vav, 
effectively lowering the antigen threshold for B cell activation by 1,000-10,000-fold 
(reviewed by Tedder et al. 1997) [223-225].  CD19 may be necessary for B cell 




vivo as CD19 is required for B cell development [223].  When B cells encounter 
antigen-antibody complexes, the BCR co-engaged with Fcγ receptor IIB, which 
activates Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP-1) and 
leads to a conversion of PIP3 to PIP2 and inhibition of Btk, PLCy2, and PI3K 
(reviewed by Takai, 2005) [226].  Additional regulatory co-receptors of the BCR 
include Toll-like receptors. 
 
Section 3 Polyclonal B cell activation through Toll-like receptors (TLR) 
Toll-like receptors (TLRs) are a class of pattern recognition receptors (PRRs) that 
bind to pathogen associated molecular patterns (PAMPs) and play essential roles in 
innate immunity.  This family of receptors was first discovered in Drosophila where 
one of its function is in preventing fungal infections [227].  Thus far 14 mammalian 
homologs have been described, TLRs 1-13 and a 105 kDa radioprotective protein 
(RP105) [228-241].  Their natural and synthetic ligands, where known, are listed in 
table 1.2.  TLRs fall into two broad categories: (1) those that are localized to the 
plasma membrane and detect bacterial/fungal/viral surface components (TLRs 1, 2, 4-
6, 10, 11 and RP105) and (2) those that are localized to endosomes and lysosomes, 
and recognize nucleic acids (TLRs 3, 7, 8, and 9) [242, 243].  The intracellular 
localization of these TLRs may be necessary to prevent receptors from interacting 
with DNA and RNA leaked from dying host cells, which could provoke an 
autoimmune reaction.  However, their endosomal location requires pathogen’s 





Table 1.2 Mammalian Toll-like receptors and their ligands. 
Receptor Ligands Reference 
TLR1 (Dimerizes with TLR2) Lipoproteins, 
Pam3CSK4 
[245] 






TLR3 Double-stranded RNA, poly(I:C) [251] 
TLR4 Lipopolysaccharides (LPS), Monophosphoryl 
lipid A, Endotoxin, taxol, some Glycoproteins 
[229, 230, 
234, 237] 
TLR5 Flagellin [252] 
TLR6 (Dimerizes with TLR2), Mycoplasma 
lipopeptides, Zamosan 
[245] 





TLR8 Single-stranded RNA, viral RNA, 
imidazoquinolines 
[245, 254] 
TLR9 Hypomethylated CpG-motif containing 
oligodeoxynucleotides, oligoDNA 
phosphodiester sugar backbone, Hemozoin 
[161, 231, 
256-262] 
TLR10 (Dimerizes with TLR1, 2) [263] 
TLR11 Profilin-like protein, uropathogenic bacteria [238, 264] 
TLR12 (unknown, high degree of homology with 
TLR11) 
[239] 
TLR13 (unknown, high homol. w/ TLR3, ↑ in yeast 




RP105 (Modifies TLR2 and TLR4 function), LPS [268, 269] 
 
 
All known TLRs are type 1 transmembrane proteins with an extracellular domain 
composed of tandem leucine-rich repeats (LRR), a transmembrane domain, and an 
intracellular Toll/IL-1R (TIR) domain [270].  The LRR domain mediates the 
interaction with their ligands as well as TLR oligomerization.  The transmembrane 
domain aids in the oligomerization, which appears to be necessary for the initiation of 
TLR signaling events.  The TIR domain is responsible for interaction with TLR 




myeloid differentiation primary response gene 88 product (MyD88) and TIR domain-
containing adapter inducing interferon beta (TRIF).  MyD88 can be recruited to all 
TLRs except TLR3.  MyD88 recruitment eventually leads to nuclear translocation of 
NF-κB and MAPK phosphorylation (particularly ERK1, ERK2, p38, and JNK) [270].  
TRIF is recruited to TLR3 and late TLR4 and leads to the activation of interferon 
regulatory factor 3 (IRF3) in addition to the NF-κB and the MAPKs, although use of 
different signaling pathways offsets the molecular kinetics [270]. 
 
B cells express a subset of TLRs [160, 263, 271-275], and the expression profile 
varies among B cell subsets and among species.  Existing data for mouse and human 
FO and mB B cell subsets are summarized in table 1.3.  Human naïve FO B cells do 
not express or only express very low levels of TLRs [160, 263, 271, 272].  
Lanzavecchia and collegues showed that BCR cross-linking dramatically up-
regulated the mRNA expression of TLR9 and TLR10 within 4 hours of BCR cross-
linking [160].  The same study showed that human mB show increased production of 
TLRs 6, 7, 9, and 10 on the transcriptional level [160].  In contrast, naïve FO B cells 
from mice express relatively high levels of TLR9 and TLR7, moderate levels of 
TLR1, TLR2, and TLR4, and low levels of TLR3 and TLR6, but do not express 
TLR5 and TLR8. There are no data available on the expression of the more recently 
discovered TLRs (TLR11, TLR12, and TLR13) in B cell subsets [273-275].  The 
TLR expression profile in different subsets of B cells has not been fully investigated. 
Gururajan and collegues tested expression level of TLRs in a mixed population of mB 




Table 1.3 Toll-like receptor expression in follicular and memory B cell subsets 
Receptor Mouse Human 
TLR1 mRNA(++or+++/?) mRNA(+/+)*  
protein(+/?) 
TLR2 mRNA(+or++/?)  
protein(+/?) 
mRNA(+/+) 
TLR3 mRNA(±/?) mRNA(-/-) 
TLR4 mRNA(+/?)  
protein(+/?)  
mRNA(±/-) 
TLR5 mRNA(±/-) mRNA(±/±) 
TLR6 mRNA(±/?) mRNA(-/+++) 
TLR7 mRNA(+or++/?) mRNA(+/++) 
TLR8 mRNA(±/-) mRNA(±/±) 
TLR9 mRNA(+++/?)  mRNA(+/+++)  
protein(+/++) 
TLR10 N/A mRNA(±/+)  
protein(+/?) 
TLR11 ? N/A 
TLR12 ? N/A 
TLR13 ? N/A 




References [269, 273-277] [160, 263, 271, 272, 278, 279] 
*(Naïve FO / Memory); - none, + low, ++ int, +++ high, ± none or low expression in 
different sources, ? unknown, N/A not applicable (no functional gene in this species) 
 
TLRs as FO B cells, but at approximately half of the level [275].  However, TLR 
expression is partially controlled post-translationally [276, 280, 281].  Spleen B cells 
express low levels of TLR2 protein [276].  TLR4 and RP105 protein expression is 
intermediate on FO B cells and decreases in GC B cells [269, 277].  TLR expression 
on mouse mB has not been examined on the protein level.  The TLR expression 
profile of the small memory B cell subset in mice remains elusive, and therefore is 
one of the subjects of this thesis.  One of the major goals of this project is to shed 






TLRs play an important role in B cell activation and B cell-mediated immune 
responses. MyD88-/- mice that have normal IgG1 responses to TD antigen vaccination 
with alum (no TLR agonists), are defective in generating antibody responses to 
immunogen containing complete Freund’s adjuvant (contains dead mycobacteria that 
presumably signal through TLRs) [282].  Furthermore, humans with mutations in 
IRAK-4, a kinase in the MyD88-dependent TLR signaling pathway, fail to attain 
humoral immunity to both T cell-dependent (TD) and –independent (TI) antigens 
[283].  These studies indicate a role for TLR signaling in B cell activation.  However, 
to what extend the direct effects from TLR signaling in B cells versus secondary 
effects from stimulation of innate cells and T cells contribute to B cell activation is 
debated.     The recognition of PAMPs by TLRs could serve as a danger signal to 
control a checkpoint preventing autoimmune B cell activation by helping B cells to 
distinguish foreign from self (reviewed by Ehlers and Ravetch, 2007; Deane and 
Bolland, 2006) [284-287].  In addition, in vitro TLR stimulation of human plasma 
cells has recently been shown to increase antibody production [279]. 
 
In support of direct activation of B cells by TLRs, Pasare and Medzhitov show by 
adoptive transfer of wt or MyD88-/- B cells into the B-cell deficient μMT animals that 
there was a B cell-intrinsic defect.  They first showed that this defect can account for 
at least 80% of the lack of antibody production seen in MyD88-/- mice.  In a second 
line of evidence, the MyD88-/- phenotype was only partially rescued in a conditional 
MyD88 knock-in with MyD88 expression limited to CD11c-expressing dendritic 




Nemazee lab shows that both TD and TI antibody responses are relatively normal in 
MyD88-/-TrifLps2/Lps2 mice where TLR signaling pathways are completely disabled 
[289].  This finding argues for a role of TRIF-dependent TLR signaling in inhibition 
of the humoral immune response.  A recent study using adoptive transfer of MyD88-/- 
B cells, similar to techniques used by Pasare and Medzhitov, showed that B-cell 
intrinsic TLR signaling (although able to transiently boost antibody responses in vivo) 
was not required for B cell activation [277]. 
 
TLRs can also activate B cells indirectly.  Macrophages, dendritic cells (DCs), and T 
cells are stimulated by TLRs resulting in upregulation of costimulatory molecules and 
secretion of cytokines.  MyD88 recruitment and subsequent nuclear factor κB (NF-
κB) activation and MAPK phosphorylation (particularly ERK1, ERK2, p38, and c-
Jun N-terminal kinase (JNK)) trigger pro-inflammatory cytokine production in 
macrophages and DCs (reviewed by Akira, 2006) [270].  Salmonella and Escherichia 
LPS can stimulate macrophages to secrete TNF-α through a TLR4- and MyD88-
dependent mechanism [237]. TRIF recruitment (TLR3 and late TLR4 signaling) leads 
to interferon regulatory factor 3 (IRF3) activation in addition to the NF-κB and the 
MAPKs (although use of different pathways from MyD88 offsets the timing of these 
molecules activation), which allows the additional up-regulation of IFN-α and IFN-β 
[270]. Imiquimod and resiquimod, two synthetic TLR7/8 agonists in the 
imidazoquinoline family, stimulate mouse IFNγ-treated macrophages to secrete TNF-
α and IL-12 in a dose-dependent and MyD88-dependent manner ex vivo [253].  




activation markers and costimulatory molecules CD40, CD80, and CD86 ex vivo, as 
well as stimulating secretion of IFN-α, TNF-α, and IL-12 in vivo [253].    And 
cytosine-guanine motif-containing oligodeoxynucleotide (CpG ODN) stimulation 
also triggers IFN-α, TNF-α, IL-6 release from DCs (different subset than the LPS-
activated DCs), as well as up-regulation of MHC-II, ICAM, CD40, CD54, CD80, and 
CD86 (reviewed by Krieg, 2002) [262].  TNF-α is required for formation of new B 
cell follicles and maturation of fDCs [290].  B cells are directly responsive to IL-6, 
which promotes their differentiation into plasma cells [291].  IFN-α, and IL-6 are also 
potent activators of inflammation, while MHC-II, ICAM, CD40, CD54, CD80, and 
CD86 serve for interaction with T cells.  IL-12 is the major stimulator in T cell 
maturation for Th1 response [292].   T cells can also directly respond to TLR agonists 
as co-stimulatory signals leading to T cell priming and clonal expansion (reviewed by 
Rahman et al, 2009) [293].  T cell cytokines such as IL-21 are potent stimuli for B 
cell differentiation into plasma cells [294-297].  Thus, it has been difficult to discern 
in what ways TLR signaling in B cells affects the immune response.  
 
Recent work using in vitro TLR stimulation of primary mouse and human B cells is 
beginning to shed light on the mechanism for TLR activation in B cells.  In vitro 
cultured B cells respond to TLR based activation by proliferation and differentiation 
into antibody-secreting cells.  Even the highly purified FACS-sorted naïve FO B cells 
became activated after incubation with TLR agonists in the absence of BCR cross-
linking, as measured by in vitro proliferation rates, up-regulation of activation 




factor activation profile,  and the amount of antibody or cytokines secreted into the 
culture medium [273-275].  Similar activation effects of TLRs were observed in 
human mB, but not FO B cells, after in vitro stimulation with TLR agonists [160].   
 
Recent studies have demonstrated a synergistic relationship between the activation of 
the BCR and TLR of mouse B cells (reviewed by Pone et al., 2010) [8, 160]. MyD88-
dependent TLR signaling stimulates activation of several transcription factors that are 
also downstream of the BCR, including ERK1/2, AP-1 (JNK and p38) and NF-κB 
(reviewed by Akira et al, 2006) [270].  Surface TLRs, such as TLR4, can engage with 
their ligands rather easily, requiring only activation of the co-receptors  MD2, CD14, 
and LPS-binding protein, which is readily expressed on the cell surface as well 
(reviewed by Akashi-Takemura and Miyaka, 2008) [298].  In contrast, the endosomal 
TLRs must first be recruited to compartments of antigen processing for exposure to 
potential agonists.  In vitro studies of primary mouse FO B cells show that upon BCR 
stimulation induced fusion of TLR9-containing endosomes with the antigen 
processing compartment in a PLD-dependent manner, thus exposing the TLRs to Ag-
associated PAMPs [206].  The interactions between the TLR and BCR signaling 
pathways have not been fully understood.  In vitro B cell co-culture with primed DCs, 
T cells, and gardiquimod elicited a 2-fold higher antibody secretion than the co-
culture without the TLR agonist [299].  Resiquimod was able to stimulate resting 
mouse B cells in B-cell enriched cultures to secrete Ab [300] and IL-6, IL-12, and IL-





The finding of up-regulated TLRs in human mB led the Lanzavecchia laboratory to 
hypothesize that human memory B cells may be prone to polyclonal activation 
through these receptors, but minimal non-specific antibody responses were detected 
in vivo by their study [112].  This does not preclude the possibility of polyclonal 
activation to maintain memory B cell pools without stimulating plasma cell 
differentiation.  In vitro experiments suggest the possibility of polyclonal B cell 
activation from exposure to TLR agonists in absence of BCR engagement [142, 160, 
302, 303].  
  
Whether TLRs actually play a role in directly activating B cells in vivo or are 
vestigial remnants is somewhat controversial.  Knocking out individual TLRs has led 
to a wealth of information regarding their functions (reviewed by Ehlers and Ravetch, 
2007; Deane and Bolland, 2006) [285, 286], but the results can be confusing as 
deficiency of different receptors have contrasting effects.  For example, the role of 
TLR9 in B cell activation appears to be two-fold. Activation of TLR9 signaling 
through CpG-ODN triggers B cell activation with enhanced proliferation and 
antibody production. On the other hand, in absence of agonist, TLR9 appears to 
suppress TLR7-mediated activation of autoimmune B cells [304-309].  MRL/lpr  
mice (with mutation in Fas) are autoimmune-prone and exhibit a systemic lupus 
erythematosous (SLE)-like phenotype [34], which is a B cell-mediated autoimmune 
disease.  In this SLE mouse model, TLR7 is required for induction of autoantibodies 
against RNA-containing self-antigens [304-306].  SLE phenotype is less severe in 




BCR engagement is necessary for autoimmune cell activation [305].  In addition, 
TLR7 gene duplication [308] and TLR7 protein over-expression by as little as two-
fold [309] lead to the autoimmune phenotype of Yaa mice. In contrast, TLR9-/- mice 
on the MRL/lpr genetic background have elevated IgG titers and succumb to 
autoimmune disease much earlier than TLR9+/+ MRL/lpr mice [304, 307]. TLR9-
deficiency also exacerbates autoimmunity in PLCγ2 mutant mice where B cells show 
hyper-reactive BCR signaling [310]. This contradicts the finding that TLR9 is 
required for anti-DNA and anti-chromatin autoantibody production in MRL/lpr mice 
[284, 304, 307, 310, 311].  The Shlomchik group more recently reports that TLR7 
and 9 double knock-out mice on the MRL/lpr background (as well as MRL/lpr 
MyD88-/-) do not develop the fatal kidney disease despite the presence of anti-
nucleosome antibodies [306].  Thus, although both TLRs 7 and 9 are expressed in B 
cells, located in endosomes, and signal through MyD88, their contributions to B cell-
mediated immune responses appear to be different from each other. 
 
Section 4 Toll-like receptor agonists as vaccine adjuvants 
Vaccination can substitute for infection to generate primary immune responses and 
build immunity.  Most successful vaccines (measles, polio, smallpox, yellow fever) 
stimulate primary humoral responses, generating a life-long supply of protective 
antibodies (reviewed by Plotkin, 2008) [312].  Current vaccines can be divided into 
two general categories: (1) attenuated versions of infectious organisms and (2) 
surface molecules of pathogens aided by adjuvant.  While the surface molecules 




increasing the antigenic response.  Two known mechanisms for increasing the 
antigenic response are: (1.) to slow the release of antigen and extend the duration of 
antigen interaction with immune cells (example: aluminum salts) and (2.) to activate 
innate immune pathways, thereby providing the necessary co-stimulation to adaptive 
immune pathways.  The live attenuated organism not only provides extended 
exposure of antigens due to its own replication, but also naturally expressed 
molecules with adjuvant activities.  The caveat of this type of vaccine is that antigens 
and adjuvant molecules are often responsible for the pathology of the microorganism.  
Thus specific surface molecules that can stimulate the immune response but are no 
longer able to carry out their other functions are often the safe choices for vaccines.  
Due to their formidable activation of innate immune cells (reviewed by Akira and 
colleagues) [270], synthetic TLR agonists have been suggested to be good candidates 
for vaccine adjuvants.  To date, one of the TLR agonists (TLR4 agonist 
monophosphoryl lipid A), has joined the non-TLR aluminum salts on the short list of 
adjuvants that have been approved by the FDA for human use [313].  Several more 
TLR synthetic agonists are undergoing clinical trials.  Due to the relatively high 
mRNA expression of TLRs7 and 9 in mouse FO B cells and activated human B cells, 
these agonists of these two receptors are particularly promising for enhancing B cell 
activation directly.   
 
Agonists of TLR4 include lipopolysaccharides (LPS) and monophosphoryl lipid A 
(MPL).  TLR4 binding of MPL and LPS leads to different signaling outcomes 




and organ failure in human, and thus is not safe for adjuvant usage (reviewed by 
Karima et al, 1999) [315].  In humans, MPL is thought to directly activate only innate 
immune cells for local cytokine responses and APC activation, since B cells and T 
cells were not able to respond to MPL stimulation [316].  In mice, LPS is much less 
harmful than in humans and is commonly used as adjvant.  LPS containing adjuvants 
include Complete Freund’s adjuvant (CFA) and Ribi adjuvant [317, 318].  Mouse 
vaccines using these adjuvants were shown to increase cytokine secretion, antigen 
specific antibody titers, and recently were also shown to increase antibody affinity 
maturation (ref) [319-326].  The adjuvant activity of TLR4 agonists was 
demonstrated by the finding that treatment of anti-TLR4 antibodies that block 
interaction of TLR4 with agonists decreased the number of germinal centers in the 
spleens and lymph nodes and reduced antibody affinity maturation in mice 
immunized with a T cell-dependent antigen + LPS [327].   
 
Agonists for TLR7 are single-stranded RNA (ssRNA) molecules.  The more stable 
synthetic agonists that structurally mimic ssRNA oligomers are in the imiquimod 
family (reviewed by Ferratini and colleagues) [328].  Imidazoquinolines are used 
topically in intradermal vaccines such as to human papilloma virus, hepatitis B and 
hepatitis C, and some cancer antigens [329-333]. The purpose of their usage is to 
recruit antigen-presenting cells.  A clinical trial with the gardiquimod, a new 
compound of the imidazoquionline family, as adjuvant in anti-tumor therapeutic 
vaccines has also been shown that it is safe and effective at 1 mg/kg dose [334], and 




imiquimod are required for TLR7 activation.  In the murine model system, 
gardiquimod has been shown to activate macrophages, DCs, T cells, NK cells, and 
NKT cells [299, 334, 335].  While one study found that addition of gardiquimod to 
sub-cutaneous immunization of TD antigen had no effect on antibody response in 
C57BL/6 mice [336], other studies show that usage of imiquimod increases of IgG1, 
IgG2a, IgG2b and IgG2c in Balb/c mice [336, 337].  However, Balb/c mice, Ag-
specific Ab titers did not respond differently to immunization with TD antigens with 
resiquimod, an imidazoquinoline that binds to both TLR7 and TLR8, or 
immunization without adjuvant by both subcutaneous and intramuscular routes [301].   
 
Agonists for TLR9 include phosphorothioated oligomers of DNA containing an 
unmethylated cytosine-guanosine (CpG) dinucleotide recognition motif (CpG-ODN).  
There are several classes of CpG-ODN-based TLR agonists.  Class A CpG-ODNs 
(CpG-A) have only one CpG motif but have a poly-G tail.  This class of CpG-ODN 
activates IRF-7 in plasmacytoid DCs to produce type 1 interferon [338].  This TLR9-
dependent pathway does not appear to be used in B cells, as B cell response to CpG-
A is low and B cell activation is not affected by Irf7 gene knockout [338].  Class B 
CpG-ODNs (CpG-B) contain multiple CpG motifs and are capable of triggering IL-
12 production in DCs (creating a TH1 cytokine environment) as well the activation of 
B cells (reviewed by Murad and Clay, 2009) [339].  The cytokines produced by B 
cells in response to CpG are typically also TH1 response cytokines [340-342], 
although with a different route of immunization, TH2 responses have been found to be 




specific antibody titers in mice [336, 340, 342-353] and in human clinical trials.  
Human clinical trials generally show that CpG-B is safe to use, noting mostly only 
mild side effects such as transient neutropenia [354-361]. Immunization using CpG 
ODN as adjuvant has been shown to require fewer boosters to reach maximum 
antigen-specific antibody titers in both malaria and hepatitis B vaccine trials in 
comparison with the same immunogen formulation lacking CpG ODN [354, 357].  
However, whether CpG ODN improves antibody affinity maturation and the 
generation and activation of memory B cells have not been addressed so far.   
 
Section 5 Hypothesis 
This project is focused on mB. Based on our understanding of TLR expression and 
stimulation on B cells we asked:  Do mouse mB cells also alter their expression 
profile TLRs?  And does TLR expression on memory B cells make them more 
sensitive to re-activation? If memory B cells are more sensitive to TLR activation, is 
there a chance that TLR stimulation may increase autoimmune disease?  If not, and 
polyclonal mB cell activation is suppressed, can it still directly enhance the activation 
of those mB cells that also interact with antigen; or does the re-activation depend on 
T cells and innate immune cells as well?  And finally, which of the TLR-based 
vaccine candidates is most efficient at stimulating high affinity antibody production 
and lasting immunity? 
 
 We hypothesize that in mice, the development of mB is associated with a change in 




hypothesize that TLR stimulation is sufficient for polyclonal activation of mB to 
differentiate into antibody secreting cells in vivo, similar to TLR-induced activation 
of immunologically naïve B cells.  Based on reports of TLR stimulation enhancing B 
cell activation in vitro, we hypothesize that TLR7 and 9 agonists can stimulate an 
increase in antibody affinity maturation and long term immunity in vivo. 
 
 
Section 6 Significance 
This study will enhance our understanding of mB generation and activation and will 
be useful for vaccine development and prevention of autoimmune diseases.   mB are 
the major players in humoral memory responses.  Generation of high quality mB is 
the optimal goal of vaccines.  Understanding how mB are activated upon re-exposure 
to antigen aids in the development of vaccines, particularly to improve booster 
vaccines to target and expand pre-existing mB populations.  Suppression of 
autoreactive mB is a major challenge for treating autoimmune diseases.  Current 
treatments that target B cells wipe out large populations of B cells, leaving patients 
immunodeficient.  Understanding how the activation is regulated in mB can lead to 
the discovery of drug targets and preventive treatments for autoimmune diseases such 
as systemic lupus erythematosus (SLE) that down-modulate hyperactive cells of 
certain reactivities rather than depleting the entire repertoire.  In this way, 





The generation of autoreactive B cells is a normal part of B cell development [362, 
363], but these cells are usually eliminated by induction of tolerance (reviewed by 
von Boehmer and Melchers, 2010) [364].  While in autoimmune disease, clearly, 
there is a breach of tolerance, this in itself cannot fully explain the development of 
disease symptoms.  The majority of healthy individuals also harbor mature 
autoreactive B cells as well as PCs that contribute to the auto-Ab titer [365].  
Subclinical auto-immune responses are speculated to be beneficial by speeding up the 
clearance of dying cells (personal communication Dr. J. Deane), which increase in 
frequency as the individual ages (REF).  Since autoimmune B cells are frequently 
exposed to their antigen, once tolerance is broken, most autoreactive B cells will 
generate mB and ll-PCs.  Isotype-switched autoantibodies, particularly the IgG 
subtypes, are associated with autoimmune diseases in mice and people [366-372].  
Targeting the ll-PCs that secrete IgG is difficult.  They are resistant to most 
immunotherapies such as anti-CD20 antibodies and irradiation [373-376].  The anti-
thymocyte globulin (used for treating organ rejection) has been able to deplete bone 
marrow PCs [377], but this antibody causes complete imunoablation and is associated 
with high risk of infection-related mortality.  In mice, blocking TACI (a receptor 
inducing an anti-apoptotic pathway in PCs and most B cell subsets in response to 
BAFF and APRIL survival factors) was also able to kill ll-PCs [141].  The problem 
with this approach is that it leaves the memory B cells, despite TACI being the only 
BAFF/APRIL receptor mB were shown to express [141], so new activation of 
autoimmune mB will repopulate the ll-PC compartment.  Although probably further 




to prevent the generation of new ll-PCs may be the most effective method to slow the 
onset of disease or its progression.   
 
It will be preferential to target only autoimmune B cells rather than all B cells for 
treatment of autoimmune disease in order to preserve existing non-autoimmune mB 
repertoire that the patient has acquired during her or his lifetime.  One hypothetical 
approach for this may be to quarantine the patient until all non-autoimmune immune 
responses have subsided and then target the activated B cells, which, in theory, should 
be the ones that are still exposed to the self-antigens.   However, maintaining 
quarantine for several weeks is tedious and expensive.  Most hospitals are not 
equipped with the space necessary for this type of endeavor.  Furthermore, it is 
unlikely that all autoimmune memory B cells are activated simultaneously, so that the 
patient may still retain resting auto-mB that could develop into PC at any future time 
point.  To make an autoimmune disease treatment more effective and available to the 
general population, resting mB should be blocked from activation, and the blocking 
agent should be conjugated to the patient’s own particular autoantigen(s), bypassing 
the need to wait for ongoing non-autoimmune immune reactions to settle before 
treatment is started.  Targeting resting autoreactive mB will prevent the development 
into new ll-PCs [125].  Natural competition for BM niches for ll-PC survival 
(reviewed by Radbruch, 2006; Tokoyoda et al, 2004) [124, 134], will ensure 
reduction of existing autoimmune ll-PCs as the mB activation blocking treatment 
would not require the continued use of immunosuppressive drugs.  This is expected to 




seek treatment earlier in their disease development.  Early treatment will lower the 
time required for the ll-PC competition to reduce autoimmune titers back to below the 
threshold of disease symptom development.   
 
So what shape might a mB activation-blocking agent have?  We already know that 
TLR stimulation is related to the development of autoimmune diseases in mice and 
humans [284-286, 304-311, 378-383].  One important question is whether TLR 
stimulation on B cells themselves is responsible for their ability to overcome 
tolerance or activation of autoreactive mB.  This is the question we try to address in 
this thesis.  If there is indeed a B cell-intrinsic mechanism of TLR-based activation in 
vivo, we can proceed to use molecular tools to dissect this mechanism in order to find 
differences that are unique to B cells.  As the TLR signaling pathway in B cells 
appears to interact with the BCR signaling pathway at least for the case of TLR9, 
molecules that enable this cross-talk may be good candidates for blocking targets.  
The reason we may still need to find the most effective blocker in B cells that will be 
ineffective in innate immune cells, is that due to being non-specific, innate immune 
cells are likely to encounter and interact with the therapeutic agent.  Conjugation to 
the patient’s particular self-antigens that she or he is forming an immune response 
against will ensure that only autoreactive B cells are targeted. 
 
For applications in vaccine development, adjuvants that can enhance induction of mB 
and their ability to activate at reencountering the antigen will be useful tools.  




vaccination, those we are still struggling to contain, and those that overrun our 
immune systems.  Current vaccination strategies are successful for protection against 
a wide range of human and livestock pathogens.  This has led to the eradication of 
smallpox [384] as well as dramatic reduction of the global incidence of poliomyelitis 
[385] and many other diseases.  The pathogens we are still struggling with require 
several cycles of immune boosting until protection is established and to maintain 
immunological memory, such as hepatitis B and tetanus vaccines [94].  Influenza 
vaccines are not included in this category as the viral antigen changes in each season 
and/or pandemic.  Immunity to any one strain of influenza does yield life-long 
protection with a single dose (reviewed by Couch and Kasel, 1983) [386].  For some 
tropical diseases, such as malaria, however, it is exceedingly difficult (though not 
completely impossible) to establish immune protection (reviewed by Langhorne et 
al., 2008; Marsh and Kinyanjui, 2006) [387, 388].  Even in endemic areas it takes 
about 10 years of recurrent exposure to build protection against the malaria pathogen 
Plasmodium falciparum, putting the population at risk each season, particularly 
children.  Many adults still develop parasitemia and mild disease [387-389].  As 
“hard-earned” as this protection is, it is not lasting immunity [387, 388, 390].  For 
infections with human immunodeficiency virus (HIV/AIDS) and Mycobacterium 
tuberculosis, no natural acquisition of memory is known and current vaccine 
strategies are ineffective (reviewed by Vekemans and Ballou, 2008) [391].  It is for 
the protection against these last two categories of pathogens that we need to change 





In the past, the most successful vaccines (measles, polio, smallpox) stimulated 
primary humoral responses [312].  New strategies include vaccinations targeting 
cellular immunity and use of new adjuvants.  Synthetic TLR-based adjuvants show 
particular promise for their relative safety and ability to enhance primary antibody 
titers (reviewed earlier in this chapter).  However, the effects on TLR adjuvants on 
mB cell formation and affinity maturation have not been sufficiently explored.  It is in 
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Section 1 Introduction 
Immunological memory is a hallmark of adaptive immunity. The humoral branch of 
immunological memory consists of memory B cells (mB), which are the precursors of 
high affinity Ab-secreting cells (ASCs), and long-lived plasma cells (ll-PC), which 
maintain serum Ab levels independent of antigenic stimuli. Recent studies have 
begun to characterize these two important humoral memory components [13, 88-90]. 
To date, no distinct surface markers identify mouse mB. In general, mB cells exhibit 
the characteristics of post-germinal center B cells. Most mB express BCRs that have 
undergone isotype switching, somatic hypermutation, and affinity maturation, and 
thus bind to Ags with high affinities. IgM-expressing memory B cells with somatic 
hypermutation have been reported in human [81, 84]; however, whether these cells 
are IgM-expressing memory B cells or marginal zone B cells remains controversial 
[82, 83]. Both long-lived plasma cells and memory B cells persist up to the lifetime of 
an individual as demonstrated by persistent Ab levels and the ability to mount rapid 
and robust Ab response to Ag challenge years after immunization. Memory B cells 
undergo rapid clonal expansion and differentiation to mount high affinity Ab 




and continue secreting Abs without antigenic stimulation in the bone marrow that 
provides the necessary environment for their longevity [90, 123, 124]. 
 
The requirements for the generation and maintenance of memory B cells have been 
studied in some detail [51]. The generation of both memory B cells and long-lived 
plasma cells requires germinal center reaction, although germinal center-independent 
generation of memory B cells has also been reported [103, 104]. Both Ag and the 
interaction of B cells with TH cells in the context of antigenic peptide-MHC class II 
complex and through CD40-CD40L are essential for the generation of germinal 
centers and memory B cells [52, 53]. In contrast, the maintenance of the B cell 
memory seems to be independent of Ag and TH cells [92, 120, 143]. Crotty et al. [92] 
reported that small pox vaccine-specific memory B cells in human were detected 60 
years post immunization and 25 years after small pox was eradicated worldwide. 
Maruyama et al. [120] showed that Ag-specific memory B cells persisted in 
transgenic mice where memory B cells switched their Ab specificity away from the 
immunizing Ag. Furthermore, mouse memory B cells have been shown to persist in 
the absence of TH [143] or follicular dendritic cells [144]. 
 
Although the requirements for the generation of B cell memory are becoming better 
understood, the requirements for the activation of memory B cells are still not clear. 
The rapid and robust responses of memory B cells to antigenic challenge suggest a 
low signaling threshold for memory B cell activation. Bernasconi et al. [112] reported 




differentiate into plasma cells in vitro, and that tetanus toxoid immunization increased 
serum Abs to unrelated Ags, suggesting that TLRs play a role in the polyclonal 
activation and long-term maintenance of human memory B cells in the absence of Ag 
in vivo. 
 
The ability of common microbial products to increase the efficacy of immunization 
has long been observed [317]. The discovery of TLRs reveals that some of the major 
components of commonly used adjuvant contribute to immune responses through 
TLRs. TLRs are responsible for the initiation of innate immune responses and the 
maturation of dendritic cells that activate T cells, triggering adaptive responses [230, 
270]. The importance of TLRs in humoral immune responses was demonstrated using 
MyD88-knockout mice, where TH cell activation and T-dependent Ab responses were 
reduced or completely abolished [282]. In addition to their role in activating TH cells, 
TLR agonists can directly act on B cells.  Mouse naive B cells express TLRs, 
including TLR2, 4, 7, and 9, and proliferate and differentiate into plasma cells in 
response to TLR agonists [161, 272, 319, 344]. In contrast, human naive B cells do 
not express TLRs, but are induced to express TLRs in response to Ag stimulation 
through the BCR [112, 160]. Human memory B cells constitutively express TLRs, 
including TLR2, 6, 7, 9, and 10, and proliferate and differentiate into plasma cells in 
response to TLR agonists alone in vitro. Using MyD88-knockout mice and LPS as 
adjuvant, Pasare and Medzhitov [288] demonstrated that TLR signaling in B cells 
was required for optimal Ab responses to T-dependent Ags. In contradiction, using 




independent Ags induced comparable humoral immune responses in the absence of 
TLR signaling. Thus, the exact role of TLR in the activation of humoral memory 
responses requires further examination. 
 
In this study, we examined the role of TLR9 and 4 in the activation of memory B 
cells in vitro and in vivo using 4-hydroxy-3-nitrophenylacetyl-keyhole limpet 
hemocyanin (NP-KLH)-immunized mice as a model. We show that TLR4 and 9 
agonists alone promote the differentiation of memory B cells into high affinity IgG 
ASCs in vitro; however, TLR agonists alone are not sufficient to effectively activate 
humoral memory responses in vivo. 
 
Section 2 Materials and Methods 
Immunization 
All work of this project was performed using wild type C57BL/6 mice, a strain 
commonly used for immunological studies.  This strain of mice expresses the IgG2c 
allele of IgG2a [392].  T cells from C57BL/6 mice have a stronger tendency to 
produce TH1 responses (proinflammatory cytokines) in the lungs and spleen 
compared to BALB/c and DBA/2 mice (reviewed by Fan et al, 2005) [393-395]. 
 
To generate humoral memory responses, 6 – 8 week old C57BL/6 mice (Charles 
River Laboratories, Wilmington, MA) were immunized twice, 28 days apart, with 
400 μg/mouse NP19-KLH (Biosearch Technologies, Novarto, CA) and Ribi adjuvant 




route.  To activate humoral memory responses in vivo, the immunized mice were 
rested for more than 6 weeks and boosted for the third time using 400 μg/mouse 
NP19-KLH and/or one of the following adjuvants: Ribi adjuvant, LPS (50 μg/mouse) 
from Escherichia coli (Sigma-Aldrich, St. Louis, MO) in oil in water (PBS) emulsion, 
or class B CpG containing phosphorothioated oligodeoxynucleotide (ODN) for 
mouse (50 μg/mouse) (5’-TCCATGACGTTCCTGACGTT-3’; Operon 
Biotechnologies, Inc., Huntsville, AL) in oil in water (PBS) emulsion. 
 
We immunized with (4-hydroxy-3-nitrophenyl)acetyl (NP), a well-characterized 
hapten, conjugated to keyhole limpet hemocyanin (KLH), a protein carrier for 
inducing TD responses. Although generation of mBs has been reported in some types 
of TI immunization, TD responses are the largest source of mB [396].  In C57BL/6 
mice, prior to germinal center reaction only B cells with λ1 light chain [397-399] and 
heavy chain composed of gene segments V186.2, D FL16.1, and JH2 [400-402] 
dominate the response to NP.  The use of λ1 light chain is relatively rare in C57BL/6 
mice [86].  The λ1 light chain-V186.2 pairing can also interact with closely related 
nitrophenols. The unmutated anti-NP antibody actually has a higher affinity for (4-
hydroxy-5-iodo-3nitropheny)acetyl (NIP) than for NP, only requiring about 1/10th of 
the free hapten competitor concentration in a competitive ELISA [403].  (This is a 
mouse-strain specific phenomenon: Only one of the mouse Ig alleles, the b-allele, is 
capable of producing these heteroclitic antibodies, and many other commonly used 
inbred mouse lines such as Balb/c and CBA have different alleles [397].)  As 




activation, and T cell help promotes GC reactions to promote generation of memory 
B cells.  In vaccination with other protein conjugates, such as NP-chicken γ-globulin, 
only a small fraction (less than 10%) of NP-specific antibodies cross-reacted with 
unrelated epitopes (certain myeloma proteins) [397].  During CSR, NP triggers Ig 
class switching predominantly to the IgG1 isotype in both C57BL/6 and CBA mice 
[397]. 
 
The timing of booster vaccination and sample collection was also carefully chosen.  
Primary immune responses have a lag period of approximately 5-7 days, and peak at 
two weeks past immunization (Figure 2.1).  Primary immune responses are typically 
very short-lived and serum titers return to levels close to baseline within one month.   
Secondary immune responses have a shorter or no lag period, and titers can be 
maintained high for a relatively long time.  Therefore we chose to administer booster 
vaccines after at least 28 days to wait for the contraction of the immune response, and 
we collected samples 5 days after the booster for re-activated memory B cells and 
their serum antibodies, and at least six weeks after the booster for resting memory B 
cells (Figure 2.1) [41, 86, 98, 404-406]. 
 
B cell isolation 
Single-cell suspension of splenocytes was treated with ACK lysis buffer to remove 
erythrocytes. After washing, cells were incubated with magnetic beads coated with 
anti-mouse CD4, CD8, CD11b, and CD11c Abs (Miltenyi Biotech), and cells binding 





Figure 2.1.  Humoral immune responses.   This chart depicts the typical kinetics of 
antigen-specific serum antibody titers.  Time windows for collecting activated 
memory B cells (5dpb) and resting memory B cells (6wpb) are indicated.  In our 
model, we do not administer a second antigen (antigen B), but if a second primary 







Flow cytometry analysis 
Purified B cells were first incubated with anti-mouse CD16/CD32 mAb (BD 
Biosciences, San Diego, CA) to block FcγRs, followed by FITC-anti-mouse IgD, 
FITC-anti-mouse IgM (SouthernBiotech, Birmingham, AL), PE-anti-mouse CD138, 
PerCP-Cy5.5-anti-mouse B220 Abs (BD Biosciences, San Diego, CA) and NP19-
allophycocyanin at 4°C in FACS buffer (1% FBS, 20 mM EDTA, and 0.02% NaN3 in 
PBS).  At time points after dissolution of germinal centers (3 weeks), the small 
population of antigen-binding B cells that have also undergone isotype switching 
consist primarily of mB.  This was confirmed by sequencing the V186.2 region of 
individual mB for evidence of somatic hypermutation [98, 100]. 
 
To label the surface TLR4, cells were incubated with PE-anti-mouse TLR4 Ab (BD 
Biosciences, San Diego, CA) or anti-mouse TLR4 Ab (IMGENEX) followed by a 
pacific blue-conjugated secondary Ab.  To label TLR9, cells that were labeled with 
FITC-anti-IgD, FITC-anti-IgM, PerCP-Cy5.5-anti-B220 Abs and NP19-allophyco-
cyanin were washed, fixed with 4% paraformaldehyde, and permeabilized with a 
permeabilization buffer (0.1% saponin, 10 mM HEPES, and 10 mM glycine in 
DMEM). Cells were incubated with anti-mouse TLR9 Ab (IMGENEX) in the 
permeabilization buffer, followed by a pacific blue- or Alexa Fluor 750-conjugated 
secondary Ab. After washing with the permeabilization buffer and PBS, cells were 
fixed with 1% paraformaldehyde and analyzed using CyAN flow cytometer (Dako 






Purified B cells were first incubated with anti-mouse CD16/CD32 mAb to block 
FcγRs, followed by FITC-anti-mouse IgD, FITC-anti-mouse IgM, PE-anti-mouse 
CD138, PerCP-Cy5.5-anti-mouse B220 Abs and NP19-allophycocyanin in 2% 
FBS/PBS.  After washing, cells were sorted using FACSAria (BD Biosciences, San 
Jose, CA) into four different populations: B220- IgD-IgM-CD138+NP- as plasma cells, 
B220+IgD-IgM-CD138-NP+ as memory B cells, B220+ IgD/IgM+ CD138- NP+ as NP-
binding unswitched B cells, and B220+ IgD/IgM+ CD138- NP- as non-NP-binding 
unswitched B cells. 
 
B cell in vitro stimulation 
Splenic B cells isolated from mice 5 days or 6 weeks after the second immunization 
and sorted plasma and B cell subpopulations were incubated at 5 x 105 cells/ml for 5 
days with graded concentrations of CpG ODN (Operon Biotechnologies, Inc., 
Huntsville, AL), LPS (Sigma-Aldrich, St. Louis, MO), or Gardiquimod (InvivoGen, 
San Diego, CA) at 37°C, 5% CO2 before ELISPOT analyses. 
 
ELISPOT analysis 
Assay plates (Millipore, Billerica, MA) were coated with 10 μg/ml NP3-BSA, NP30-
BSA (Biosearch Technologies, Novarto, CA), or anti-mouse IgG+M Ab (Jackson 
ImmunoResearch Laboratories, West Grove, PA) overnight at 4°C and blocked with 
10% FBS in PBS for 2 h at 37°C. Cells were serially diluted into wells and incubated 




Tween 20. Ab secreted by cells were detected with biotin-labeled anti-mouse IgM Ab 
(Jackson ImmunoResearch Laboratories, West Grove, PA) or a mixture of biotin-
labeled anti-mouse IgG1, IgG2a, IgG2b, and IgG3 Abs (Southern Biotech, 
Birmingham, AL), followed by HRP-conjugated streptavidin (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD), and visualized by HRP substrate True Blue 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD). Plates were sent to Cellular 
Technologies for scanning and spots were counted with software provided by Cellular 
Technologies Ltd. (Shaker Heights, OH). 
 
ELISA analysis 
ELISA plates (Nalge Nunc International) were coated with 40 ng/ml NP5-BSA, 
NP30-BSA (Biosearch Technologies, Novarto, CA), or 5 μg/ml anti-mouse IgG+M 
Ab (Jackson ImmunoResearch Laboratories, West Grove, PA) in 50 mM NaHCO3 
(pH 9.6) overnight at 4°C and blocked with PBS containing 0.3% milk, 1% FBS, and 
0.1% Tween 20 for 1 h at 37°C. Mouse serum was serially diluted into wells and 
incubated at room temperature for 2 h. After washing, the plates were incubated with 
a mixture of an equal amount of HRP-conjugated anti-mouse IgG1, IgG2a, IgG2b, 
and IgG3 Abs (SouthernBiotech, Birmingham, AL), and visualized by 2,2’-azino-
bis(3-ethylbenz- thiazoline-6-sulfonic acid) (Sigma-Aldrich, St. Louis, MO) and 
0.03% hydrogen peroxide in phosphate-citrate buffer (pH 5.0). The reaction was 
stopped after 5 min with 0.5% SDS. Absorbance at 405 nm was measured using a 
plate reader (Wallac Victor, PerkinElmer). Titers were determined as highest serum 




Section 3 Results 
B cell responses to TLR4, 7, and 9 agonists in vitro 
The ability of splenic B cells from NP-KLH-immunized mice to differentiate into NP-
specific IgG and IgM high affinity ASCs when cultured with TLR4, 7, and 9 agonists 
was determined. Mice were immunized with 400 μg/mouse NP19-KLH plus Ribi 
adjuvant, a LPS-based adjuvant, twice, 4 weeks apart. B cells were purified from 
spleens of NP-KLH-immunized mice 5 days after the second immunization and 
cultured with graded concentrations of CpG ODN or LPS for 5 days (Figure 2.2, A–
D). The number of NP-specific Ab ASCs was determined by ELISPOT using NP3-
BSA as the coating Ag to capture only high affinity Abs and NP30-BSA to capture 
both high and low affinity NP-specific Abs. In the absence of CpG ODN or LPS in 
the culture medium, the splenic B cells did not differentiate into a significant number 
of NP-specific ASCs (Figure 2.2, A–D). When cultured with CpG ODN or LPS, 
splenic B cells differentiated into NP-specific, IgG ASCs, a significant portion of 
which exhibited high affinity for NP (Figure 2.2, A and B). CpG ODN induced 
relatively fewer NP-specific IgM ASCs (Figure 2.2C) than LPS (Figure 2.2D). 
However, the majority of these ASCs showed low affinity for NP (Figure 2.2, C and 
D). The numbers of NP-specific ASCs generated in the B cell cultures peaked at 0.25 
μg/ml CpG ODN and 0.6 μg/ml LPS (Figure 2.2, A–D), suggesting that the 
stimulatory effect of TLR agonists CpG ODN and LPS was saturable. To test the 
presence of the precursor B cells for high affinity IgG ASCs in mice long after the 
immunization, splenic B cells from mice 6 weeks after the second immunization were 








FIGURE 2.2.  Differentiation of B cells to Ag-specific ASCs in response to TLR4, 
7, and 9 agonists in vitro. Splenic B cells were isolated from mice 5 days (A–D) or 6 
weeks (E–J) after the second immunization and cultured with different concentrations 
of CpG ODN (A, C, E, and H), LPS (B, D, F, and I), or Gardiquimod (G and J) for 5 
days. The numbers of NP-specific IgG (A, B, and E–G) and IgM (C, D, and H–J) 
ASCs were determined by ELISPOT using plates coated either with NP30-BSA for 
all NP-specific ASCs (total) or NP5-BSA for high affinity NP-specific ASCs (high 






Similar to the splenic B cells isolated at 5 days (Figure 2.2, A–D), when cultured with 
TLR4, 7, or 9 agonist, splenic B cells isolated at 6 weeks post the second 
immunization differentiated into NP-specific IgG ASCs, most of which exhibited 
high affinity (Figure 2.2, E–G). TLR4 agonist induced a greater number of NP- 
specific IgM ASCs than TLR7 and 9 agonists; however, a significant portion of those 
exhibited low affinity (Figure 2.2, H–J). These results are consistent with previous 
reports that showed that TLR agonists can stimulate the differentiation of B cells into 
plasma cells [161, 319]. Our results further showed that TLR4, 7, and 9 agonists 
induced similar numbers of high affinity IgG ASCs from splenic B cells from 5 days 
and 6 weeks post immunization, but TLR4 agonist predominantly activated splenic B 
cells to differentiate into low affinity IgM ASCs. 
 
B cells with memory phenotype differentiate into high affinity IgG secreting cells in response 
to TLR4 and 9 agonists in vitro 
Based on the general properties of memory B cells that have been described so far 
[13, 89], we defined Ag-specific memory B cells as isotype-switched, Ag-binding B 
cells (B220+ IgD- IgM- CD138- NP+). Using flow cytometry, NP-specific memory B 
cells in the spleen were undetectable in nonimmune mice (frequency of 0.03%) 
(Figure 2.3). Five days following the second immunization, the frequency of NP-
specific memory B cells in the spleen reached ~0.5% of splenic B cells (Figure 2.3). 
Six weeks after the second immunization, the frequency of NP-specific memory B 
cells in the spleen declined to ~0.1%, which was still higher than that of nonimmune 






FIGURE 2.3.  The frequencies of NP-specific memory B cells in the spleen of 
immunized mice. Splenic B cells were isolated from unimmunized mice 
(nonimmune) and mice 5 days and 6 weeks post the second immunization with NP-
KLH and Ribi adjuvant. Cells were stained with FITC-anti-IgD, FITC-anti-IgM, PE-
anti-CD138, PerCP-Cy5.5-anti-B220 Abs and allophycocyanin-NP19 and analyzed 





months (data not shown). The frequency of NP-binding, unswitched B cells (B220+ 
IgD/IgM+ CD138- NP+) was 1.1% in nonimmune mice, increased to 6.2% following 
immunization, and decreased to 1.6%, near nonimmune levels, by 6 weeks following 
the second immunization (Figure 2.3) in contrast to memory B cells. The relatively 
high frequency of these B cells in nonimmune mice as compared with the predicted 
frequency suggests that they may be very low affinity cells. These data show that 
immunization induced rapid increases in the frequencies of NP-specific B cells with 
the memory phenotype in the spleen. While the frequencies of memory B cells 
decreased with the time after the second immunization, a significant number of 
memory B cells persisted in the spleen for several months. 
 
B cells from NP-KLH-immunized mice 5 days after the second immunization were 
sorted into four different populations (Figure 2.4A): (I) B220- IgD/IgM- NP- CD138+ 
as plasma cells, (II) B220+ IgD/IgM- NP+ CD138- as NP-specific memory B cells, 
(III) B220+IgD/IgM+ NP+ CD138- as NP-binding unswitched B cells, and (IV) B220+ 
IgD/IgM+ NP- CD138- unswitched B cells that were not specific for NP. Population 
III, NP-binding unswitched B cells, might consist of Ag-experienced, unswitched B 
cells and NP-binding marginal zone B cells. Population IV, unswitched B cells that 
were not specific for NP, may contain naive B cells and marginal zone B cells 
specific for unrelated Ags. Before the in vitro culture, only population I, plasma cells, 
contained NP-specific ASC (Figure 2.4, B and E); however, these did not survive in 
the culture (Figure 2.4C, D, F, and G). After culture in vitro with CpG ODN and LPS, 









FIGURE 2.4.  B cells with the memory phenotype differentiated into Ag-specific, 
high affinity IgG ASCs in culture with CpG ODN and LPS.  A, Splenic B cells 
from NP-KLH-immunized mice were sorted into four populations: B220- IgM- IgD- 
NP- CD138+ (I, plasma), B220+ IgM- IgD- NP+ CD138- (II, memory), B220+ 
IgM/IgD+NP+CD138- (III, NP-binding, unswitched), and B220+IgM/IgD+NP-CD138- 
(IV, unspecific, unswitched). Naive B cells (V) were isolated from the spleen of 
unimmunized mice. The frequencies of high affinity and total NP-specific IgG (B–D) 
and IgM (E and F) ASCs were determined by ELISPOT before (B and E) and after 
culture in CpG ODN (2 μg/ml) (C and F) or LPS (5 μg/ml) (D and G) for 5 days. 






IgG ASCs, a large portion of which were high affinity (Figure 2.4C, D, F, and G). In 
contrast, populations III and IV containing unswitched B cells generated mostly low 
affinity IgM ASCs in response to CpG ODN and LPS (Figure 2.4C, D, F, and G). As 
expected, the NP-binding population of unswitched B cells generated a higher 
number of NP-specific IgM ASCs as compared with the non-NP-binding population 
(Figure 2.4, F and G). Response of the unswitched B populations to LPS was nearly 
10-fold greater than to CpG ODN (Figure 2.4, F and G). These results demonstrate 
that TLR agonists can directly activate memory B cells in vitro to differentiate into 
high affinity, isotype switched plasma cells and unswitched B cells to differentiate 
into low affinity, IgM ASCs. 
 
Differential expression of TLR4 and 9 in populations of B cells 
The differential responses of the B cell populations to TLR4 and 9 agonists shown in 
Figure 2.4 suggest different expression levels of TLR9 and 4. To test this hypothesis, 
the levels of expression of TLR4 and 9 in the different populations of splenic B cells 
isolated from NP-KLH-immunized mice 5 days after the second immunization were 
determined by flow cytometry. The analyses showed higher TLR9 expression in NP-
binding B cell populations (II and III) compared with naive B cells (population V) 
from nonimmune mice (Figure 2.5, left panels). In contrast, the TLR4 surface levels 
of naive (population V) and unswitched B cells (populations III and IV) were 
significantly higher than that of NP-specific memory B cells (population II) (Figure 








FIGURE 2.5.  Expression levels of TLR9 and TLR4 in different subpopulations 
of splenic B cells. Splenic B cells were isolated from unimmunized mice 
(nonimmune) and mice that were immunized with NP-KLH plus Ribi adjuvant. The 
splenic B cells were preincubated with the FcγR blocking Ab, followed by PerCP-
Cy5-anti-B220, FITC-anti-IgD, FITC-anti-IgM Abs, allophycocyanin-NP19, and PE-
anti-TLR4-MD2 Abs for staining TLR4. For staining TLR9, the cells were washed, 
fixed, permeabilized, and stained with anti-TLR9 Ab and a pacific blue-conjugated 
secondary Ab. The cells were analyzed by flow cytometry. B220high B cell 
populations of nonimmune mice (V), NP-specific memory B cells (II), NP-binding, 
unswitched B cells (III), and nonspecific, unswitched B cells (IV) of immunized mice 
were gated, and their TLR4 (right panels)- and 9 (left panels)- staining levels are 





the equivalent response of memory B cells to CpG ODN and LPS and the hyper- 
response of NP-binding unswitched B cells to LPS. 
 
The activation of B cell memory responses by TLR4 and 9 agonists in vivo 
To determine whether TLR4 and 9 agonists can stimulate memory B cells in vivo, 
mice were immunized with NP19-KLH plus Ribi adjuvant twice, 4 weeks apart, to 
establish a pool of NP-specific memory B cells. Six weeks later, the mice were 
challenged with NP19-KLH, Ribi adjuvant, CpG ODN, LPS alone, or NP-KLH plus 
either Ribi adjuvant, CpG ODN, or LPS. Five days after the challenge, high and low 
affinity serum titers of NP-specific IgG and the number of high affinity, NP-specific 
IgG ASCs in spleens were determined. A certain level of high affinity serum titer 
(Figure 2.6A) and a small number of high affinity, NP-specific IgG ASCs (Figure 
2.6B) existed in the spleens before the boost, indicating the persistence of NP-specific 
IgG ASCs in the spleen even 6 weeks after an immunization. The challenge with Ag 
alone significantly increased (~10-fold) the serum titer of high affinity NP-specific 
IgG and the number of high affinity, NP-specific IgG ASCs (Figure 2.6, A and B). 
However, the challenge with adjuvant alone, including Ribi adjuvant, CpG ODN, and 
LPS, did not significantly change either the serum titer of high affinity NP-specific 
IgG or the number of high affinity NP-specific IgG ASCs in comparison with those 
before the challenge (Figure 2.6, A and B). In contrast, challenging with Ag plus 
adjuvant dramatically increased the number of the high affinity IgG ASCs, with ~56-, 
~46-, and ~16-fold increases for Ag plus Ribi, LPS, and CpG ODN adjuvant, 




the adjuvant under this specific immunization condition. At 5 days post the third 
immunization, the serum titers of mice challenged with CpG or LPS plus Ag were 
significantly higher than those that did not receive the third immunization and those 
that were challenged with CpG or LPS alone, but lower than those that were 
challenged with Ag alone (Figure 2.6A). This did not completely mirror what was 
observed for the numbers of NP-specific ASCs (Figure 2.6B) and may reflect 
different kinetics and timing for B cell differentiation and for NP-specific plasma 
cells to exit from spleens in mice challenged with Ag alone and Ag plus adjuvant. 
 
Taking advantage of the ability of memory B cells to specifically differentiate into 
high affinity IgG ASCs in culture with CpG ODN, we estimated the relative 
frequencies of NP-specific memory B cells in spleen after the different challenges. A 
significant number of NP-specific, high affinity IgG ASCs was detected in the 5-day 
culture of B cells from mice rested for 6 weeks without the challenge (Figure 2.6C), 
indicating the persistence of memory B cells in the spleen long after an immunization. 
The number of high affinity IgG ASCs differentiating from B cells from mice 
challenged with Ag or adjuvant alone was similar to or lower than that of B cells from 
mice that were not challenged (Figure 2.6C). The number of high affinity IgG ASCs 
differentiating from B cells from mice challenged with Ag plus adjuvant was 5- to 20-
fold higher than those of mice without the challenge (Figure 2.6C). Among different 
adjuvants, Ag plus either Ribi or LPS generated the largest increase. To further 
confirm this result, we determined the frequency of NP-specific memory B cells by 








FIGURE 2.6.  Clonal expansion and differentiation of memory B cells in 
response to immunization of Ag or TLR agonists alone or in combination. 
C57BL/6 mice were twice immunized with NP-KLH plus Ribi adjuvant 4 weeks 
apart and rested for 6 weeks. The mice were immunized for the third time with NP-
KLH (400 μg/ml), Ribi adjuvant, CpG ODN (50 μg/mouse), or LPS (50 μg/mouse) 
alone or in combination. Controls included nonimmune mice and mice that did not 
receive the third immunization (None). A, Serum was collected from 1 day before and 
5 days after the challenge and analyzed for NP-specific high affinity and total IgG 
titers. Shown are average titers (±SE, n = 3~25). The serum titers of mice challenged 
with NP-KLH plus the adjuvant were significantly higher than those of mice that did 
not receive the third immunization or received the adjuvant alone for the third 
immunization. ***, p ≤ 0.001; *, p ≤ 0.05. B and C, B cells and plasma cells were 
enriched and frequencies of NP-specific IgG ASCs were determined by ELISPOT 
before (B) and after (C) culture with CpG ODN (2 μg/ml) in vitro for 5 days. D, The 
percentage of NP-specific memory B cells among the splenic B cells was determined 
by flow cytometry, as described in Figure 2.3. Shown are the representative results of 






 induced significant increases (5- to 20-fold) in the numbers of NP-specific memory 
B cells (Figure 2.6D). Ribi or LPS as adjuvants appeared to be more effective than 




Section 4 Discussion 
Humoral memory responses consist of two major components, long-lived plasma 
cells that secrete high affinity Ab and memory B cells, the precursors of long-lived 
plasma cells. In this study, we examined the role of TLR agonists in activation of 
humoral memory responses in vitro and in vivo by tracking these two major 
components of the humoral memory responses. We found that TLR4, 7, and 9 
agonists could directly stimulate the differentiation of memory B cells into high 
affinity plasma cells in vitro; however, TLR agonist alone was not sufficient to 
stimulate the clonal expansion and differentiation of memory B cells and specific Ab 
recall responses in vivo. 
 
Our study showed that when cultured with TLR4, 7, and 9 agonists, the splenic B 
cells from NP-KLH-immunized mice, either 5 days or 6 weeks post the second 
immunization, differentiated into NP-specific ASCs with most of IgG ASCs as high 
affinity and most of IgM ASCs as low affinity. Using sorted memory B cells, we 
further showed that among different populations of B cells cultured with TLR4 or 9 
agonist, NP-specific memory B cells exclusively differentiated into high affinity, 




low affinity IgM ASCs. This demonstrates that TLR agonists can directly act on 
memory B cells in vitro and polyclonally stimulate the differentiation of memory B 
cells into high affinity, isotype switched plasma cells in the absence of T cells. In 
contrast, TLR agonists stimulated unswitched B cells in vitro primarily into low 
affinity, unswitched ASCs. Specific differentiation of sorted memory B cells into 
high affinity IgG ASCs indicates that they are the precursors of high affinity plasma 
cells and confirms that B cells sorted based on the phenotypic characteristics consist 
of mainly Ag-specific memory B cells. Furthermore, the differentiation specificity in 
the in vitro culture with TLR agonists provides us a good tool to determine the 
frequency of memory B cells in a mixture of multi-subpopulations of B cells. The 
finding that splenic B cells isolated from mice 5 days and 6 weeks post the 
immunization responded to TLR4 and 9 agonists in a similar manner suggests the 
persistence of Ag-specific memory B cells in mice. 
 
The experimental definition of memory B cells is still controversial, especially in the 
murine system. McHeyzer-Williams et al. [109, 110]  established a multicolor flow 
cytometry method to follow NP-specific memory B cells in NP-KLH-immunized 
mice based on their phenotypic characteristics of post-germinal center B cells (B220+ 
IgD- IgG1+ NP+) and demonstrated that B cells with such phenotypes exhibited a high 
frequency of point mutations in their variable regions. Anderson et al. [407] recently 
suggested that CD80 and CD35 expression levels could be used to define B cell 
subtypes that have or have not undergone somatic hypermutation. Slifka and Ahmed 




lymphocytic choriomeningitis virus-specific memory B cells using the combination 
of limiting dilution and ELISPOT.  Taking advantage of the ability of CpG ODN to 
stimulate the differentiation of memory B cells into high affinity IgG ASCs in vitro, 
we determined the frequency of memory B cells using this in vitro culture system in 
addition to flow cytometry. Both flow cytometry analysis and the in vitro culture 
system showed dramatic increases in the number of Ag-specific memory B cells 5 
days after the second immunization and maintenance of a small, but significant, 
number of memory B cells 6 weeks after the second immunization. 
 
In addition to NP-specific, isotype switched B cells, a population of NP-binding, 
unswitched B cells were found in the immunized mice. This population of B cells was 
expanded in response to the second immunization, but returned to the basal level of 
unimmunized mice by 6 weeks. When cultured with TLR4 and 9 agonists, they 
differentiated into NP-specific IgM ASCs, most of which exhibited low affinity for 
the Ag. Although the exact nature of the NP-specific unswitched B cells is unclear, it 
may contain IgM-expressing memory B cells. The existence of IgM-expressing 
memory B cells is still controversial. The discovery of a subpopulation of 
CD27+IgM+, somatic mutated B cells in human peripheral blood [81] suggests the 
presence of IgM expressing memory B cells. Weller et al. [83] showed that this 
population of B cells was circulating spleen marginal zone B cells that mutated their 
Ig receptors during ontogeny, before their differentiation into T-independent Ag-
responsive cells. The role of this population of B cells in humoral memory responses 





Our studies present a first comparison of B cell responses to TLR4 and 9 agonists in 
vitro and in vivo. Our results showed that TLR4 and 9 agonists were equally effective 
in stimulating memory B cells to differentiate, but TLR4 agonist was much more 
efficient than TLR9 agonist in stimulating unswitched B cells from immunized mice 
to differentiate in vitro. This differential response can be explained by different 
expression levels of TLR4 and 9 in different subpopulations of B cells. We found that 
the immunization increased the expression levels of both TLR4 and 9 in mouse B 
cells, and the expression level of TLR9 was maintained and the expression of TLR4 
down-regulated when activated B cells differentiated into memory B cells. Our 
finding of an increase in TLR9 expression level by immunization is similar to the 
report of Bernasconi et al. [160] that human memory B cells, but not naive B cells, 
constitutively express TLR9. The biological significance of this differential 
expression of TLR9 and 4 among different B cell subpopulations remains to be 
explored. The higher expression level of TLR4 in naive and activated, unswitched B 
cells than memory B cells predicts that LPS preferentially induces primary humoral 
responses. 
 
The direct stimulatory effects of TLR9 and 4 agonists on memory B cells in vitro 
showed in this study and previous studies [112, 160] suggest their potential role in 
polyclonal activation of memory B cells in vivo. Our finding that TLR9 or 4 agonist 
alone failed to increase the frequencies of either Ag-specific high affinity IgG ASCs 




serum, does not support the polyclonal activation hypothesis. Our result that Ag in 
combination with TLR9 or 4 agonist was more effective than Ag alone for inducing 
clonal expansion and plasma cell differentiation suggests that the activation of 
memory B cells in vivo still requires more than one signal, Ag-triggered BCR-
mediated signal in combination with TLR-triggered signals or T cell help.  The 
findings that on day 5 post the third immunization, Ag alone induced a higher serum 
titer but a lower frequency of high affinity NP-specific IgG ACS in spleens than Ag 
plus CpG or LPS may reflect differences in the kinetics of B cell differentiation and 
plasma cell migrating from the spleen to the bone marrow in response to different 
stimuli. Some other factors may limit the direct role of TLRs on B cells, such as the 
competition between B cells and dendritic cells to interact with TLR agonists. TLR 
agonists are very effective in the induction of dendritic cell maturation. Dendritic 
cell-activated TH cells provide memory B cells with a second stimulation signal. 
Above all, requirement of both Ag and TLR agonists for the activation of memory B 
cells in vivo ensures the specificity of humoral memory responses. 
 
The necessity of TLRs in humoral memory responses is controversial. Disruption 
TLR signaling by knocking out MyD88 and/or Trif genes either did or did not 
significantly inhibit Ab responses against T-dependent Ags, depending on the specific 
experimental system [282, 288, 289]. The study presented here reveals a direct 
stimulatory role of TLR on memory B cell differentiation in vitro and the requirement 




vivo. These results strongly support a critical role for TLRs in recalling humoral 
memory responses. 
 




Chapter 3: Agonists of Toll-like receptors 7 and 9 enhance 
antibody affinity maturation in secondary immune responses in 
a mouse model 
 
Section 1 Introduction 
Successful vaccination for humoral immune responses depends on the B cells’ ability 
to undergo antibody affinity maturation.  Affinity maturation is an increase in the 
average binding strength for an organism’s antibodies to an antigen and is achieved 
by mutation of weakly binding antibodies to bind more strongly.  In immune 
responses to T cell-dependent (TD) antigen, affinity maturation occurs in germinal 
centers (GCs) that form in follicular regions of spleen and lymph nodes after 
exposure to antigen.  GCs support rapid proliferation of B cells and activation-
induced cytidine deaminase (AID)-dependent somatic hypermutation of the 
immunoglobulin (Ig) gene, which creates a diverse pool of closely related B cell 
clones.  Selection of B cells expressing high affinity Ig in their B cell antigen 
receptors (BCRs) occurs via competition for survival signals that are generated by 
interactions with antigen-presenting follicular dendritic cells (fDCs) in the GC 
(reviewed by McHeyzer-Williams et al., 2005) [13].   
 
The use of adjuvants, non-antigen additives, as part of immunogen is known to 
enhance immune responses.  However, whether adjuvants can induce or enhance the 
affinity maturation is unclear.  Many adjuvants serve as ‘danger-signals’, causing 




intradermal injection site; [329, 331-333]) or weak systemic inflammation (i.e. 
peritoneal injection of alum/CpG oligodeoxynucleotides; [340, 348, 352, 353, 409]).  
The most successful adjuvants for mice include Freunds and Ribi adjuvants, which 
contain several proinflammatory ingredients.  The major component of complete 
Freunds adjuvant is heat-killed mycobacteria in an oil-in-water emulsion [317]. Ribi 
adjuvant contains monophosphoryl lipid A (MPL; a TLR4 agonist) and trehalose 
dicorymycolate (TDM; a TLR2/4 agonist) also supplied in an oil-in-water emulsion 
[318, 410-412].  In humans, Freunds and Ribi adjuvants cause stronger inflammatory 
responses than in mice, sometimes even leading to septic shock in the recipient, and 
thus are not safe for human application [315].  Only two adjuvants are currently 
approved by the FDA for use in humans: aluminium salts (alum) and 
monophosphoryl lipid A (MPL) [313]. Alum is thought to precipitate the antigen, 
slowing its dilution and temporally extending its release (reviewed by Lindblad, 
2004) [413].  A separate mechanism for alum function has recently been proposed to 
work through stimulating uric acid production, a host cell damage signal rather than a 
microbial antigen [409], and through inflammasome activation [414]. Alum adjuvant 
has been shown to trigger Th2 type immune responses [413], inhibiting the release of 
proinflammatory Th1 cytokines [415-417].  Nevertheless, alum is very weak in its 
immunostimulatory properties and only minimally improves vaccination [314, 418]. 
Therefore, a stronger yet safe adjuvant is needed to improve human vaccine efficacy. 
MPL is a highly detoxified derivative of bacterial LPS [318, 411].  MPL weakly 




419].  Several different agonists of TLRs, including CpG ODN and gardiquimod, are 
also currently undergoing clinical trials. 
 
Toll-like receptors (TLR) are a family of pattern recognition receptors that recognize 
common pathogen-associated molecular patterns (PAMP) of bacteria and viruses, 
such as peptidoglycan [246, 247], flagellin [252], lipopolysaccharides (LPS) [229, 
230, 234, 237, 248, 249], single-stranded RNA [245, 253-255], and DNA with 
hypomethylated cytosine-guanine (CpG) motifs [161, 231, 256-259, 261].  TLR 
stimulation affects both innate and adaptive immune responses.  TLRs are highly 
expressed in cells of the innate immune system, such as macrophages and dendritic 
cells [230, 270], where they promote inflammation through the maturation of dentritic 
cells and stimulation of cytokine production (reviewed by Akria et al., 2006) [270].  
TLRs also are expressed in subsets of T and B lymphocytes. Mouse resting B cells 
express TLRs 2, 4, 7, and 9 [269, 273-277]. TLR stimulation provides a second 
signals for the activation of B cells in response to T cell-independent (TI) antigens 
[344].  In humans, while resting follicular B cells do not express TLRs, antigenic 
stimulation induces TLR expression. Human memory B cells express TLRs 2, 6, 7, 9, 
and 10 [160, 263, 271, 272, 278]. Therefore, TLRs impact adaptive immune 
responses directly through TLR expressed by lymphocytes and indirectly through the 
functional interaction of innate cells and lymphocytes.   
 
The signal transduction of TLRs primarily is mediated by the adaptor molecule 




NF-κB and other transcription factors involved in immune cell activation [270].  
MyD88-/- mice are hyporesponsive to IL-1R and most TLR stimulation.  MyD88-/- 
mice not only show no response to LPS in their macrophages, which makes them 
completely resistant to endotoxic shock from LPS [420], and inhibition of DC 
priming for cellular immune responses [282], but also exhibit impaired humoral 
immune responses to T cell-dependent antigen [282].  Schnare et al. showed that 
MyD88-/- mice immunized with OVA and complete Freund’s adjuvant had reduced 
titers of IgG2a subtype, while IgG1 and IgE responses were relatively normal [420].  It 
remains unclear, however, whether the defect is B cell intrinsic or due to lack of T 
cell help [289, 421].     
 
The strong immune stimulatory properties of TLR agonists made them good 
canadates of adjuvant.  Imiquimods  and unmethylated CpG-containing 
oligodeoxynucleotides (CpG ODN) are two families of synthetic TLR agonists that 
show promising ability to increase antibody response in animals [299, 301, 336, 337, 
340, 343-347, 349, 351, 422]. In addition, these two types of TLR agonists passed 
safety tests in phase 1 human clinical trials [329-333, 339, 354, 355, 357, 359-361].  
The structures of the imiquimod family molecules mimic single-stranded RNA. They 
stimulate TLR7 and TLR8 to various degrees depending on the structures of the 
molecules (reviewed by Ferratini et al, 2008) [328].  Gardiquimod (1-(4-amino-2-
ethylaminomethylimidazo-[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol; made by 
InvivoGen, San Diego, CA) predominantly binds to TLR7 [253, 423] and is about 10 




overexpressing human or mouse TLR7 [253].  Synthesized CpG ODNs stimulate 
through TLR9 [161, 231, 256-259, 261].  Class A CpG ODN are most efficient at 
stimulating dendritic cells and IFNα production (reviewed by Krieg, 2002) [262].  
Class B CpG ODNs are most efficient at stimulating B cell proliferation and 
differentiation into plasma cells [262].  Both class B CpG ODN and gardiquimod are 
able to increase antigen specific antibody titers, and typically increase the IgG2a/IgG2c 
and IgG2b antibody isotypes associated with the more pro-inflammatory Th1 
cytokines [253, 262, 299, 335, 340, 341, 423, 424].  However, little is known about 
these molecules’ ability to induce antibody affinity maturation or immune memory. 
 
In this study, we asked whether TLR agonists CpG ODN and gardiquimod would be 
able to increase antibody affinity in vivo using a mouse immunization model with T 
cell-dependent antigen.  Comparison of Ribi adjuvant, CpG ODN, and gardiquimod 
by three different methods shows they are equally able to induce antibody affinity 
maturation.  All three of these adjuvants reduced Th2 bias of the antigen.  Analysis of 
resting memory showed that despite elevated titers, the size of the antigen-specific 
mB and ll-PC populations is not significantly different between mice immunized with 








Section 2 Materials and Methods 
Mice and immunizations 
For  generating T cell-dependent humoral immune responses, 6-12 week-old 
C57BL/6 mice (Taconic, Inc., Gaithersburg, MD) were injected twice, 28 days apart, 
via intraperitoneal route with 100 μg/mouse NP19-KLH (NP, 4-hydroxy-3-
nitrophenylacetyl; KLH, keyhole limpet hemocyanin) (Biosearch Technologies, 
Novarto, CA) emulsified in 2.0% squalene oil (Sigma-Aldrich, St. Louis, MO) and 
0.2% Tween 80 (Sigma-Aldrich, St. Louis, MO) in sterile PBS alone or with Ribi 
adjuvant (MPL+TDM Adjuvant System, Sigma-Aldrich, St. Louis, MO), with 50 
μg/mouse completely phosphothyated unmethylated class B CpG –containing 
oligodeoxynucleotides (CpG ODN) (5’-TCCATGACGTTCCTGACGTT-3’, 
phosphorthiolated at every base, Operon Biotechnologies, Inc., Huntsville, AL) or  
with 50 μg/mouse Gardiquimod (InvivoGen, San Diego, CA).  Serum samples were 
collected from mice by tail vein bleed two and four weeks after first immunization 
and five days, two and four weeks, and 100 days after the second immunization.   
Sera were stored at -20oC before analysis. 
 
 Antibody titration by ELISA 
ELISA for detecting NP-specific antibody titer was performed as previously 
described [425]. Briefly, ELISA plates (Nalge Nunc International, Rochester, NY) 
were coated with 1 μg/mL of NP26-BSA (Biosearch Technologies, Novarto, CA) in 
50 mM NaHCO3 (pH 9.6) over night at 4oC and blocked with 0.3% milk, 1% FBS, 




the wells and incubated at room temperature for 2 h.  For plate-to-plate control, one 
row of wells was coated with 5 μg/mL of anti-mouse IgG+M antibody (Jackson 
ImmunoResearch, West Grove, PA) and incubated with mouse IgG standard (Jackson 
ImmunoResearch, West Grove, PA) during serum incubation step.  After washing the 
plates three times with PBST (0.1% Tween-20 in PBS), the plates were incubated 
with a cocktail of 1:1000 dilutions of horseradish peroxidase (HRP)-conjugated anti-
mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3 antibodies (Southern Biotech, 
Birmingham, AL).  After further washing the plates three times in PBST, the amount 
of plate-bound antibody was visualized by 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) (Sigma-Aldrich, St. Louis, MO) and 0.03% hydrogen peroxide 
(Fisher Scientific, Pittsburgh, PA) in phosphate-citrate buffer, pH 5.0 (Sigma-Aldrich, 
St. Louis, MO).  The reaction was stopped after 5 min with 0.5% SDS (Fisher 
Scientific, Pittsburgh, PA).  The absorbance at 405 nm was measured using a 
Spectramax plus 384 plate reader (Molecular Devices, Sunnyvale, CA).  The antigen-
specific antibody serum titer was determined in ELISA units (EU) on a linear trend 
line (least squares regression method) for the steepest/most linear portion of each titer 
curve (R2>0.9 data to linear fit), with definition of 100 EU correspond to an O.D. 
value of 1 (Figure 3.1).   The serum concentration corresponding to 2.5 EU were in 
the linear range for all serum samples, even when the colorimetric detection was 






Figure 3.1. Example of ELISA unit determinations.  Appropriate dilution was 
determined for each serum sample by intrapolation within the linear range.  10 EU 
was in the linear range for low titer anti-sera, but at time points following second 
immunization was at the cusp between the linear and non-linear range.  2.5 EU was in 





Antibody affinity analysis by descreasing densities of ELISA coating antigen 
ELISA plates are coated with 1 μg/mL of NP4-BSA (Biosearch Technologies, 
Novarto, CA) in a half of the wells to limit binding of low affinity antibodies, and  
coated with 1 μg/mL NP26-BSA, or 5 μg/mL of anti-mouse IgG+M antibody in the 
other half of the plate.  The ELISA analysis was performed as described above.  The 
levels of NP-specific antibodies that bind to NP4-BSA (high affinity) and NP26-BSA 
(total) were determined independently. The fraction of high affinity antibodies in the 
total NP-specific antibodies was determined. 
 
Antibody affinity analysis by chaotropic inhibition with urea 
Competitive ELISAs using chaotropic inhibition was performed as previously 
described [426].  Serum titers (ELISA Units) were determined using ELISA that was 
performed as described above except that serum was incubated with the plate for 20 
min rather than 2 h to match the optimal incubation time of the competitive assays.  
For chaotropic inhibition of ELISA, ELISA plates were coated with NP26-BSA and 
blocked as described above, incubated with 100 μl of serum, pre-diluted to 2.5 EU, 
for 20 min at room temperature, and washed three times with PBST.  Urea (Sigma-
Aldrich, St. Louis, MO) at varying concentrations (0.0-10.0 M in PBS) was added at 
100 μL/well and incubated for 10 min at room temperature. After washing with 
PBST, the amount of IgG bound to the plate was determined as described above, 
allowing 10 minutes for ABTS color change.  The concentration of urea necessary for 
a 50% decrease in antibody binding (OD of wells without urea or the average OD of a 




plateau (0%), divided by two) was determined using least squares regression trend 
line for the steepest/most linear section of each inhibition curve.  Pipetting error was 
determined by calculating variance of the OD without urea wash (10 min PBS wash).  
Only assays with variance of less than 5% of the average OD at maximal binding 
were analysed. The analyses were carried out for 3-6 replicates.   
   
Antibody affinity analysis by competitive ELISA with free antigen 
Competitive ELISAs with free antigen competition was performed as previously 
described [427].  Briefly, all serum samples were pre-diluted for a final concentration 
of 2.5 EU as described above (3.3.4).  Free antigen, NP-OH (Biosearch Technologies, 
Novarto, CA), was serially diluted in the blocking buffer.  Serum was pre-incubated 
with 0-50 mM NP-OH for 45 min at room temperature.  Plates that were coated and 
blocked as described above were incubated in triplicate with the mixture of serum and 
free antigen (100 μl) for 20 min at room temperature.  Then plates were washed with 
PBST, and the total IgG bound to the plate was determined as described above.  For 
each serum sample, the concentration of the free antigen that causes a 50% descrease 
in antibody binding to the antigen coated plate (IC50) was determined using a non-
linear fit equation “log(inhibitor) vs. response, variable slope” (GraphPad Prism 5.02, 
San Diego, CA), where inhibitor is the concentration of free antigen and response is 







Determination of the IgG isotypes of NP-specific antibody 
The isotypes of NP-specific IgG was determined by ELISA as described above with a 
few modifications.  NP4-BSA was used as the coating antigen, and  HRP-conjugated 
anti-mouse IgG1, IgG2a + IgG2c, IgG2b, or IgG3 antibodies (Southern Biotech, 
Birmingham, AL) were used as secondary antibodies individually to detect different 
isotypes of IgG.  The ratio of IgG1 to IgG2a + IgG2c was determined. 
 
Statistical analysis 
Statistical difference for serum titers (Figure 3.1) was carried out by one-way 
ANOVA and Tukey post-test, using 95% confidence interval.  Statistical significance 
comparing between immunization groups (Figures 3.2 - 3.5) was determined by two-
tailed Mann-Whitney t-test with cut off at p=0.05, and comparing the same animals at 
different time points by paired t-tests.  All statistical tests were carried out in 
GraphPad Prism (GraphPad Prism Software version 5.02, San Diego, CA). 
 
Section 3 Results  
TLR7 and 9 agonists increase antigen-specific antibody titers but are less effective 
than Ribi adjuvant 
To determine the abilities of TLR agonists to adjuvate antibody responses, we 
compared the titers of antigen-specific antibodies in mice immunized with NP19-KLH 
as antigen alone, antigen plus CpG ODN (TLR9 agonist), Gardiquimod (TLR7 
agonist), or Ribi adjuvant (an agonist predominantly for TLR4).  We focus on CpG 




people than Ribi adjuvant.  Mice were immunized twice, 28 days apart, and sera were 
collected every two weeks for the initial eight weeks of immunization, as well as on 
the fifth day and 100th day after second immunization (Figure 3.2A). The serum 
collecting schedule was established based on the general properties of antibody 
responses in mice: primary antibody responses peak at two weeks after an 
immunization, and secondary antibody responses can be observed before new 
primary antibody responses to booster immunization (five days) and sustain for long 
time (100 days), which reflects humoral memory (Figure 2.1) [41, 86, 98, 404-406].  
Because affinity maturation is often associated with isotype switching (reviewed by 
McHeyzer-Williams and McHeyzer-Williams, 2005) [13, 54], we focused on IgG.   
Mice that received any of the adjuvants had higher titers than those immunized 
without adjuvant.  However, CpG ODN and Gardiquimod did not increase the titer as 
much as Ribi adjuvant.  Across all immunization groups, most mice had a relatively 
low antigen-specific IgG titer at two weeks after primary immunization in 
comparison with that after the second immunization, regardless of whether or not 
they received an adjuvant (Figure 3.2B).  Two weeks after the first immunization, the 
serum titer of mice that received Ribi as adjuvant already was significantly higher 
than those of mice that received CpG ODN (p=0.0486) or gardiquimod (p=0.0188) as 
adjuvant, and those of mice that did not receive adjuvant (p=0.0096).  However, CpG 
ODN and gardiquimod did not significantly increase antibody titers at two weeks post 
fist immunization (Figure 3.2B).  By four weeks after first immunization, the 
antibody titer in mice that received immunization with adjuvant continued increasing, 





Figure 3.2. Immunizations with CpG ODN or Gardiquimod increase the 
antigen-specific IgG titer compared to immunization with antigen alone.   A. 
This schematic of the immunization indicates time of injection (black) with NP19-
KLH with or without indicated adjuvants and time of serum collection (red) in days. 
B. Antigen-specific IgG titer over the first eight weeks after immunization.  Each 
circle represents one mouse immunized with NP19-KLH alone (black), NP19-KLH + 
Ribi adjuvant (blue), NP19-KLH + CpG ODN (magenta), or NP19-KLH + 
gardiquimod (green). Lines connect group means; * p<0.05 compared to NP19-KLH 






the same as those two weeks post first immunization (Ribi p=0.0024, CpG ODN 
p=0.0039, gardiquimod p=0.0245 compared to no adjuvant).  After four weeks, the 
antibody titer of mice that had been immunized with CpG ODN as adjuvant was 
significantly higher than those immunized with Ribi as adjuvant (p=0.0096 compared 
to Ribi adjuvant) (Figure 3.2B). 
 
After second immunization, the NP-specific antibody IgG titers increased from 2-fold 
to 10-fold over those observed in primary response in all groups no matter if mice 
were immunized with or without adjuvant.  Mice that had shown the most increase at 
the 2nd and 4th week after primary immunization showed the least increase after the 
second immunization, indicating that there may be a cap on NP-specific IgG 
secretion. The mice that received Ribi as adjuvant had significantly higher titers than 
mice that received antigen alone at 5 days (p=0.0258), 2 weeks (p=0.0015), and 4 
weeks (p=0.0224) after the second immunization.  The titers in mice immunized with 
CpG ODN or gardiquimod as adjuvant were higher than those in mice immunized 
with NP19-KLH alone but lower than those in mice immunized with Ribi as adjuvant.  
However, the differences were not statistically significant (p>0.05) (Figure 3.2B).  At 
four weeks after second immunization, antibody titers in all groups had started to 
decline, albeit they were still significantly higher than those after first immunization 
(Figure 3.2B).  After 100 days resting, the NP-specific IgG titers were significantly 
lower than during peak secondary immune response, but were still approximately as 
high as during primary response in all groups (Figure 3.2B).  Following the response 




tag for the duration of the experiment and was not sufficient to establish mouse-to-
mouse variance in the response.  Taken together, our findings agree with previously 
published data that TLR7 and TLR 9 agonists are able to increase antibody titers but 
are somewhat less effective than TLR4-stimulating Ribi adjuvant (reviewed by Krieg, 
2002) [262, 337]. 
 
TLR7 and 9 agonists as adjuvant increases antibody affinity 
The efficacy of a vaccine is not only dependent on the amount of antibodies that the 
vaccine can induce, but also the affinity of antibodies to the antigen.  To determine 
the effect of CpG ODN or gardiquimod as adjuvants on affinity maturation of B cells, 
we compared the affinity of antibodies generated with these two adjuvants with those 
induced by antigen alone and antigen plus Ribi adjuvant. We mainly focused on two 
weeks after first (day 14) and second (day 42) immunizations when the primary and 
secondary antibody responses nearly peak respectively.  We first evaluated the 
relative affinity of antibody for NP using the urea resistance assay adapted from Dr. 
Kazutoya Miura’s laboratory [426].  Urea is a chaotropic agent and can interrupt the 
antibody-antigen interaction; the higher the affinity of interaction, the higher a 
concentration of urea is required to interrupt the interaction.  Control assays applying 
urea to antigen-coated plates before antibody binding show that the range of urea 
concentrations used for this assay does not affect the stability of the coating antigen 
(data not shown).  To minimize the effect of antibody avidity and concentration on 
this assay, we focused on IgG and diluted all serum samples to equal IgG titer, 2.5 




detection.  After serum incubation, the plate was washed with a range of 0-10 M urea, 
followed by incubation with a mixture of HRP-conjugated anti-mouse IgG1, IgG2a, 
IgG2b, IgG2c, and IgG3 secondary antibodies for detection. The amount of IgG 
remained bound to the antigen-coated plate after urea washes was determined. Plates 
that were incubated with PBS instead of urea were used as controls, as PBS was not 
able to decrease the amount of antibody binding to antigen coated plate significantly. 
Using these data, we determine the concentration of urea that is able to remove lower 
the OD by 50%.    Urea with increasing concentrations was able to remove up to 
100% of antibody binding (Figure 3.3, A-D).  A relatively higher concentration of 
urea necessary to drop the OD by 50% indicates a higher binding affinity of 
antibodies to NP.  The sera from all four groups showed similar resistances to urea 
wash two weeks after the first immunization.  All three types of adjuvant significantly 
increased resistance to urea wash following the second immunization, indicating 
increases in antibody affinity (Figure 3.3).  However, the second immunization with 
antigen alone did not increase the antibody binding strength significantly (Figure 3.3, 
A and E).  Importantly, although the titers of mice immunized with CpG ODN and 
gardiquimod as adjuvants were slightly lower than those with Ribi adjuvant (Figure 
3.2B), their urea resistance levels were similar when same amount of antibodies were 
present, indicating similar increases in antibody affinity in all three groups with 
adjuvant (Figure 3.3, B-E).  These results indicate that these adjuvants do increase 











Figure 3.3. Immunization with CpG ODN and Gardiquimod increases the 
antibody binding strength as much as Ribi adjuvant in a chaotropic inhibition 
(urea wash) ELISA. A-D. representative inhibition curves over increasing 
concentrations of urea comparing anti-sera at two weeks past 1st immunization (d14, 
blue) and two weeks past 2nd immunization (d42, red) symbols show technical 
replicates.  E. Quantification of antibody affinity by concentration of urea resulting in 
a 50% drop in OD.  Because the affinities of antisera on day 130 were significantly 
higher, they were analyzed separately.  Each circle represents one mouse, bars show 










Figure 3.4. Immunization with Gardiquimod but not CpG ODN increases the 
antibody affinity as much as Ribi adjuvant in a competitive ELISA with free 
antigen. A-D. Representative inhibition curves over increasing concentrations of NP-
OH comparing sera at two weeks past 1st immunization (d14, blue) and two weeks 
past 2nd immunization (d42, red) symbols show technical replicates.  E. 
Quantification of antibody affinity by concentration of NP-OH resulting in a 50% 






The low titer antibodies that remained at 100 days after booster immunization (dpb) 
demonstrated very high affinities that were outside of the measurable range of this 
assay.  Modifications of the assay allowed us to compare affinities among the 
different immunization groups at this time point, but no conditions that allowed for 
the simultaneous execution of all time points were found.  Separate analysis of the 
sera at 100 dpb showed no significant difference among any of the immunization 
groups (not shown). 
 
We employed a free antigen competition assay adapted from Nieto et al. [427] as a 
second method to determine the relative affinity of NP-specific serum IgG from mice 
immunized with different adjuvants.  We used free, soluble NP-OH to compete with 
NP26-BSA coated on the plate to bind antibodies.  Anti-sera with equal titers (2.5 
ELISA units) were first incubated with different concentrations of free NP-OH hapten 
to allow NP-OH to bind antibodies.  Then the antigen-coated plates were incubated 
with the sera-NP-OH mixtures for 20 min.  The concentration range of NP-OH used 
for this analysis was 100 nM to 50 mM.  The amount of antibody binding to the NP26-
BSA coated plate was measured.  Using these data, we determined the concentration 
of NP-OH that was required for a 50% reduction in the amount of antibodies binding 
to antigen coated plates.  The stronger the interaction between antibodies and free 
antigen is, the lower the NP-OH concentration is required for the 50% reduction, 
thereby indicating a relative higher binding affinity of the antibody to NP.  Our 
results show that immunization with antigen alone only slightly increased antibody 




Immunization with Ribi or gardiquimod as adjuvant significantly increased the 
affinity of NP-specific antibodies following second immunization (Figure 3.4, B and 
E).  Immunization using CpG ODN as adjuvant, however, showed wide range of 
changes in antibody affinity from individual mice (Figure 3.4, C and E).  
Immunization with gardiquimod as adjuvant showed the highest affinity among all 
four groups after both the first and second immunization (Figure 3.4, D and E).  
These results suggest that gardiquimod is a more effective adjuvant among three we 
tested in this immunization mouse model. 
Effect of TLR4, 7, and 9 agonists on Ig isotype switching 
While the primary antibody response is dominated by IgM, the secondary antibody 
response primarily consists of IgG. Antigenic stimulation and helper T cell 
engagement induce isotype switching of B cells. The isotype switch is also influenced 
by the immune environment of B cells. TLR agonists are known to promote isotype 
switch and to change the type of cytokine environment from Th2 to Th1 profile 
(reviewed by McHeyzer-Williams and McHeyzer-Williams, 2005) [13].  The Th1 
cytokines like IFNγ and Th2 cytokines like IL-4 induce isotype switching to IgG2a 
and IgG1, respectively [66, 70].  To investigate how adjuvant impacts the type of 
humoral responses, we determined the IgG isotype induced by immunization with 
CpG ODN or gardiquimod as adjuvant.  We determined titers for each of the four 
mouse IgG isotypes: IgG1, IgG2c (the alternate allele for IgG2a expressed in C57BL/6), 
IgG2b, and IgG3.  In addition, we evaluated the relative amount of high affinity 
antibody and the total amount of antigen-specific antibody in each isotype of IgG 




mice were immunized with or without adjuvant, in general, the second immunization 
increased the titer of all the IgG isotypes and the portion of high affinity antibody in 
all the IgG isotype (Fig. 3.5, A-D). IgG1 remained the dominant isotype in all 
immunized mice. Compared to the titer of mice immunized with antigen alone, all 
three types of adjuvant increased the titers of IgG2c and IgG3 by at least 10-fold, but 
did not change the titers of IgG1 and IgG2b after the second immunization (Figure 3.5, 
A-D).  Ribi adjuvant generated higheast titers of all the IgG isotypes after the first 
immunization, but the second immunization with Ribi adjuvant has less impact on the 
IgG titers than other adjuvants (Figure 3.5, A-D).  Although some of the observed 
differences were not statistically significant, a combination of the rise of IgG2c, IgG2b, 
and IgG3 titers is responsible for the increased total IgG titer shown in Figure 3.2.   
To investigate the impact of adjuvant on the Th1 and Th2 bias of humoral immune 
responses, we calculated the ratio of IgG1:IgG2a titers [428].  In absence of adjuvant, 
the antibody response exhibited a strong Th2 bias. Immunization with Ribi, CpG 
ODN or gardiquimod as adjuvants significantly dampened this Th2 bias (Figure 
3.5E).  These data are in agreement with previous studies that TLR agonists promote 
a Th1 response.  However, in this mouse immunization model, TLR agonists are not 










Figure 3.5. Immunization with Gardiquimod and CpG ODN increases diversity 
of Ig isotypes produced and lowers Th2 bias of the humoral immune response.  
A-D. Titers of mice immunized with NP19-KLH alone or with Ribi, CpG ODN, or 
gardiquimod adjuvants at two weeks past 1st (14dpi) and two weeks past 2nd (42 dpi) 
immunization on high density antigen-coated (total, filled circles) and low density 
antigen coated (high affinity, open circles) plates, using isotype-specific secondary 
antibodies (A: IgG1, B: IgG2a+IgG2c, C: IgG2b, and D: IgG3) for detection. E. Ratio of 








Section 4 Discussion 
This study addresses whether TLR agonists could impact antibody affinity maturation 
and memory development.  Ribi, CpG ODN, and gardiquimod used as adjuvants were 
each able to enhance antibody titers, which was mostly due to increased secretion of 
IgG2c and IgG3 in CpG ODN and gardiquimod immunized mice.  Ribi adjuvant 
additionally enhanced the titers of IgG1 and was overall a stronger enhancer of IgG 
titers than CpG ODN or gardiquimod.  On the other hand, affinity maturation is 
shown to be increased to a similar extent by all three adjuvants.  In some assays 
measuring affinity maturation, gardiquimod and Ribi adjuvants showed greater 
capacity to increase affinity maturation than CpG ODN.   
 
Our choice of specific TLR agonists to study was based on the expression of TLRs on 
B cells. Mouse TLRs 2, 4, 7, and 9 are expressed on FO B cells [269, 273-277], and 
human TLRs 7 and 9 are expressed only after B cell activation while TLR2 and 4 
expression remains low or undetectable [160, 263, 271, 272, 278].  Therefore, this 
study focused on a TLR9 agonist, Class B CpG ODN, and a TLR7 agonist, 
gardiquimod.  TLR2 agonists were excluded because clinical trials showed severe 
systemic side effects including asthenia and fever [429] and are thus of limited use in 
human vaccines.  Most TLR4 agonists can precipitate septic shock in humans making 
them unsafe for vaccine adjuvants as well.  However, since the roles of LPS and 
MPL, two TLR4 agonists, as adjuvants have been extensively studied in mice [319-
326], we included it for comparison.  In contrast to LPS (TLR4 agonist), TLR7 and 




[329-333, 339, 354, 355, 357, 359-361].  Imidazoquinolines are frequently used 
topically near the injection site of intradermal vaccine administrations for the 
recruitment of antigen-presenting cells [230, 253, 270, 299, 329-335].  Gardiquimod 
has also been shown to be safe and effective when injected as adjuvant in anti-tumor 
therapeutic vaccines [334].  CpG is being tested as an adjuvant in a variety of 
vaccines including vaccines to prevent viral infections such as influenza [355] and 
hepatitis B [361], and vaccines for parasite mediated tropical diseases such as malaria 
[356, 357, 359, 389, 430-432] and leishmaniasis [341] and for immunotherapies 
including sublingual therapy for food allergens [358] and cancer immunotherapy 
[339].  Three out of four stage 1 clinical trials showed that CpG ODN is safe to use as 
human vaccine adjuvant ([357, 359, 361, 432].  Most recipients of the vaccine with 
class B CpG ODN had only mild side effects such as transient neutropenia [357]. 
 
Previous studies have shown that the TLR9 ligand CpG ODN and the TLR7 ligand 
gardiquimod are both able to enhance IgG titers [336, 342, 343, 346-349].  IgG titers 
in response to intraperitoneal immunizations with the T cell-dependent antigen OVA 
had been shown to increase 10-20 –fold with CpG ODN, compared to immunization 
with the same immunogen minus CpG ODN [346].  Viral particles that had been 
stripped of all TLR agonists and had only single-stranded RNA added back in also 
were able to increase IgG titers approximately 10-fold, compared to the virus-like 
particles alone [342].  Here, we only detect a two- three fold increase in IgG titers.  
While multivalent antigens, such as NP19-KLH, are predicted to have high responses 




potential adjuvant effect of oil-in-water emulsion or potential LPS contamination 
used as the vehicle of the antigen, and thereby generating relatively high titers in the 
absence of TLR agonists (Figure 3.1).  Previous studies in humans showed that 
immunization with CpG ODN as adjuvant reduced the number of booster vaccines 
necessary to attain protective levels of antibodies for malaria vaccine [357] and 
hepatitis B vaccine [354], compared to preparations of the vaccines without CpG 
ODN.  This study shows sustained high titers following TLR adjuvanted vaccination 
that was especially strong with CpG ODN (Figure 3.1), which provides an 
explanation for a reduced number of required boosters.  Gardiquimod is a relatively 
new TLR7 agonist, and therefore little is known about its ability to increase antibody 
titers.  A recent study found that gardiquimod stimulation doubled the number of in 
vitro generated plasma cells from mice [299].   Intradermal and subcutaneous 
injections of a Mycobacterium tuberculosis fusion protein in mice showed enhanced 
IgG1 and IgG2a/IgG2c titers with the addition of gardiquimod [336].  Increased Ig 
titers with TLR stimulation may also partially be explained by increased ability to 
produce Abs in TLR stimulated plasma cells [279].  However, the effect of these TLR 
agonists as adjuvants on antibody affinity maturation had not been addressed.  We 
show here that TLR7 and 9 agonists are just as effective as TLR4 agonists in 
promoting antibody affinity maturation (Figures 3.2-3.4), despite their relatively low 
ability to increase antibody titers, compared to TLR4 agonists (Figure 3.1). 
 
We used three different methods to assess the affinity of antibodies: the ability of 




to urea washes, and specific competition of antibody binding to coated antigen 
against free antigen.  The low density antigen assay has been widely used for a rough 
estimate of the portion of relatively high affinity antibodies [327, 433, 434]. Using 
this assay, we show that antibody affinity maturation increases in all groups after 
second immunization (Figure 3.4).  This measure of relative affinity is quickest and 
technically easiest to perform, but is not quantitative.   
 
The urea wash assay can quantitatively measure antibody binding strength.  Urea, a 
chaotropic solvent, non-specifically interferes with antibody-antigen interaction.  
Contrary to exposure to fully denaturing conditions, the antibody can re-fold once 
urea is removed which allows detection by secondary antibodies [435].  Weakly 
binding antibodies can be eluted at lower concentrations of urea[436, 437].  However, 
the concentration of urea cannot be higher than 10 M because of its solubility. 
Therefore, we were unable to use this assay to distinguish differences among the very 
high affinity antibodies.      
 
The free antigen competition assay is also a quantitative assay to measure antibody 
affinity, with free antigen serving as a specific competitor for coated antigen.  On and 
off-rate of antibody-antigen binding contributes to the affinity measurement of this 
assay.  The higher the affinity of the antibody for the antigen is, the more time it will 
be interacting with the antigen, either through longer interactions (slower off-rate) or 
more frequent contact (higher on-rate).  Therefore, high affinity antibodies require 




Because of the specific nature of the competition, it yields a true inhibitory 
concentration (IC50) for the antibody-antigen binding. In addition, this quantitative 
assay works over a wide range of antibody affinities and has very low internal 
variability.  However, NP-specific antibodies of undetected isotypes (i.e. IgM, IgA, 
IgE) may compete for the free antigen, resulting in an artifactually increased IC50 
(lower affinity) reading.  Broad diversity of responses among mice immunized with 
NP19-KLH + CpG ODN may indicate the induction of one of these untested isotypes 
in a subset of the mice, probably IgM.  Differences in affinity measurements in the 
urea wash assay and the competitive ELISA with free antigen of the samples obtained 
after 100 days rest may also be a result of an untested isotype, probably IgE.  As these 
artifacts all exclusively lower the affinity estimates of the assay, the affinity is at least 
as high as indicated by the free antigen competition assay. 
 
Using these three different approaches, we were able to evaluate fully the affinity of 
antibody induced by immunization with different adjuvants. Our results show that 
both CpG ODN and gardiquimod as adjuvants increase IgG affinity maturation in 
mice immunized with NP19-KLH.  Whether these TLR agonists have a similar ability 
to promote antibody affinity maturation in humans remains to be determined.  While 
the general process of antibody affinity maturation is similar in both species, human 
B cells do not express TLRs prior to activation [160, 271].  This may delay the direct 
effects of TLR agonists on B cells in the human immune response.  B cells in the 
germinal center, where affinity maturation occurs, show enhanced expression of 




A study reported a mild decrease in the expression of TLR7 in human GC B cells 
[271], which argues against a role of TLR7 in affinity maturation process in human.  
However, human mB were shown to re-express TLR7 on the mRNA level [160].  
Along with our finding that TLR7 stimulation induced more affinity maturation than 
TLR4 or TLR9 stimulation, the TLR7 agonists show protential for overcoming one of 
the anomalies of CpG ODN adjuvants.  Human trial vaccines containing CpG ODN 
as adjuvant are generally effective at generating high Ab titers in North American 
populations [356, 361], but could not significantly boost immune responses of 
populations in endemic areas [431].  First contact with antigen leads to recruitment of 
a diverse set of antigen-specific B cells to fibroblastic conduits, which is taken as 
evidence for interclonal competition among B cells for antigen [86].  B cells with the 
highest affinity BCRs at this state were later excluded from germinal centers and 
instead differentiated into plasma cells extrafollicularly [403].  This interclonal 
competition may prevent most memory B cells from undergoing further affinity 
maturation upon re-exposure to antigen.  In our study, gardiquimod was able to 
increase antibody affinity significantly after both the first and second immunization 
(Figure 3.3).  This suggests that the block of further affinity maturation with pre-
existing high affinity B cells can be overcome under some TLR adjuvanted 
conditions. 
 
The mechanism by which TLR activation increases affinity maturation is unknown.  
The stimulation through TLRs could promote B cell proliferation, which is required 




Lymphocyte proliferation is reduced in MyD88 and various TLR knock-out mice 
(ref) [231, 253, 420].  B cells are able to secrete cytokines to exert autocrine and 
paracrine control.  B cells can secrete TNFα, IL-6, IL-10 for their own activation 
(reviewed by Pistoia and Corcione, 1995) [438] and sufficient amounts of IL-2, IFNγ, 
IL-12, and IL-4 to allow T cell polarization [14].  Barr and colleagues recently 
showed MyD88-dependent signals control the production of IL-6, IFNγ, and to some 
extent IL-10 by B cells, and that these are required by B cells for primary Th1 
responses [439].  While LPS is known to increase the number of B cells that isotype 
switch in response to cytokines, in the absence of cytokines LPS activates B cells 
without inducing isotype switching [69].  Therefore it is unlikely that the TLR 
signaling mechanism directly impacts the activation of activation induced cytosine 
deaminase (AID), a critical enzyme involved in both isotype switching and somatic 
hypermutation [54].  However, IgG2a production in mice immunized with virus-like 
particles and CpG ODN was completely TLR9-dependent [342].  IgG3 was partially 
dependent on TLR9 as well, but IgG1 titers were increased in the TLR9-/- mice [342].  
And in mice immunized with OVA in complete Freund’s adjuvant, IgG2a production, 
but not IgG1 or IgE production, was found to be MyD88-dependent as well [282].  
Immunization of MyD88-/- with LPS-conjugated OVA emulsified in incomplete 
Freund’s adjuvant reduced the titers of IgM and IgG1, and completely eliminated 
IgG2a/IgG2c titers.  When alum adjuvant was used, antibody production in MyD88-/- 
mice was similar to wild type [288].  However, in a mouse model that eliminates both 
the MyD88 and the TRIF adaptors, MyD88-/-TrifLps2/Lps2 mice, eliminating all known 




antigen TNP-hemocyanin elicited IgG2a/IgG2c titers that were as high as in responses 
to T cell-inedpendent antigen, despite lower pre-immune titers of IgG2a/IgG2c and 
some other subtypes [289].  This indicates that MyD88-dependent defect in signaling 
can be ascribed to lack of T cell help.  More potential pathways of indirect activity of 
TLR agonists on isotype swithching to IgG2a/IgG2c and affinity maturation includes 
TLR activation of follicular dendritic cells (fDCs). Mice treated with TLR4 blocking 
antibodies decrased the number of germinal centers, the number of B cells with a 
mutated Ig sequence, and lower high-affinity antiserum titers in mice immunized with 
OVA and LPS [327]. This suggests that TLR4 agonists play a role in germinal center 
formation.  This study further shows that chimeric mice with TLR4- fDCs display a 
similar defect, as well as causing reduced expression of AID in B cells [327].  In 
addition, DCs are known to be activated by TLR agonists, such as CpG ODN, leading 
to stimulation of Th1 maturation in T cells [440-443].  T cells can then activate B 
cells via CD154-CD40 interactions.  In humans, mutations in either CD40 or CD40L 
cause hyper-IgM syndrome 1 (HIGM1) [71, 72], a disease associated with lack of 
isotype switching and poor immunological memory. 
 
Our results show that both CpG ODN and gardiquimod increase Th1 antibody 
responses even though they were used as adjuvant with a Th2 antigen.  Previous 
studies had shown similar antibody responses agains CpG ODN adjuvanted OVA, 
virus-like particles, Hepatitis B, and Mycobacteria vaccines [336, 342, 346, 349].  In 
addition to adjuvant, the immunization routes have been shown to impact the 




showed gardiquimod was able to dampen the strong Th2 bias of Mycobacterium 
tuberculosis fusion protein ID83 toward Th1 in intradermal vaccine.  However, 
subcutaneous vaccine with the same concentration of ID83 and gardiquimod 
maintained a similar strong Th2 bias as un-adjuvanted response.  CpG ODN adjuvant 
in intradermal vaccine completely changed the ID83 bias to a strong Th1 response, 
while in subcutaneous injection it only weakly induced Th1 responses [336].  The 
ability of TLRs to promote Th1 antibody responses is mediated through induction of 
Th1 cytokine in marophages and dendritic cells and of Th1 T cell differentiation [231, 
348, 420, 444, 445].  Leaning towards Th1 responses could make vaccines more 




Chapter 4: General Discussion and Future Directions 
 
B cell activation and affinity maturation are critical events in the generation of 
immunological memory following vaccination as well as in the development of auto-
immune diseases.  This thesis asked how TLR stimulation affects B cell activation 
and affinity maturation to generate antibody responses in mice.   
 
Currently, there are two ways for TLR to contribute to B cell activation, indirect and 
direct activation, which could co-exist.   In the widely accepted indirect activation 
model, TLR agonists are thought to stimulate maturation of DCs and thereby improve 
the availability of T cell help and cytokines to amplify primary B cell activation 
(reviewed by Banchereau and Steinman 1998; Lee and Iwasaki 2007, Akira et al 
2006, Reis e Sousa 2006) [270, 378, 381, 446].  TLR-dependent maturation of DCs 
also affects the cytokine profile of the immune response, with wide-ranging effects on 
the activation of lymphocytes.  In contrast, models of direct B cell activation through 
TLR signaling are less well established.  They suggest independent signaling 
cascades for BCR and TLR dependent activation of transcription factors associated 
with proliferation and differentiation into plasma cells.  Activating B cells through 
LPS in vitro can increase proliferation and survival of B cells [322, 324, 325] and 
underline positive effects transmitted through T cell help in activation of B cells to a 
T cell dependent antigen (reviewed by Ruprecht and Lanzavecchia, 2006) [287].  
When in vitro LPS-stimulated B cells were adoptively transferred into mice, they 




ongoing immune responses [323].  Our finding that memory B cells differentiate into 
high affinity IgG secreting cells ex vivo with CpG ODN or LPS stimulation in 
absence of antigen stimulation or B cell receptor cross-linking support the existence 
of a B-cell intrinsic TLR activation pathway (Chapter 2).   
 
When TLR agonists are used as vaccine adjuvants, the kinetics of the secondary 
immune response were altered.  All TLR agonists appeared to slow the release of IgG 
in secondary responses, seen in lower NP-specific IgG titers in response to adjuvant-
containing immunogen compared to response to antigen immunization alone by 5 
days post-boost (Chapter 2) in parallel to increasing the frequency of plasma cells.  
The difference in the timing of plasma cell emergence from the spleen and IgG 
secretion should result in fewer IgG-containing immune complexes to be formed.  We 
would predict that these kinetic differences protect the newly differentiated plasma 
cells from Fc receptor cross-linking and the associated apoptosis [447].    
 
We also find that there is a difference in the extent of B cell activation depending on 
which TLR is engaged (Chapters 2 and 3), with TLR9 stimulation allowing maximal 
in vitro differentiation into antibody secreting cells from memory B cells, but only 
moderate effect on IgM-expressing B cells.  Thus, there is a bias toward memory B 
cell activation (memory bias) by CpG ODNs in vitro (Chapter 2).  However, it is 
unclear whether CpG ODN can stimulate affinity maturation due to differences in the 
results between nonspecific inhibition and specific competition assays (Chapter 3).  




explain the difference.    TLR9 stimulation also appears to have a strong temporal 
elongation of primary immune responses (Chapter 3).  Mice immunized with CpG 
ODN as adjuvant had significantly higher NP-specific IgG titers than mice 
immunized with Ribi as adjuvant (highest titers at all other time points) at the 4th 
week after immunization.  At this time point the newly generated memory B cells 
should have emerged from the germinal centers [86].  A similar extension of 
responses was observed in one of the clinical trials with CpG ODN as adjuvant [357].  
CpG ODN allowed the gradual increase of protective titers, and thus required fewer 
booster vaccines.  To verify that this phenomenon uniquely affects post-germinal 
center B cells, IgM titers should be compared in mice immunized with CpG ODN or 
Ribi as adjuvant.  The underlying mechanism of the memory bias by CpG ODNs is 
unknown, but a more focused study on both of these effects will reveal the full 
duration and final outcomes.  In our hands, the TLR7 ligand gardiquimod induced the 
most affinity maturation of the three TLR agonists tested (Chapter 3). 
 
Here, we found that memory B cells down regulate TLR4, but not TLR9 expression, 
which can contribute to this memory bias of CpG ODN (Chapter 2).  The additional 
explanation may lay on differences in the activation mechanism of TLRs. TLR4, 
TLR7, and TLR9 use MyD88 signaling pathway.  TLR4 is also able to associate with 
the TRIF adaptor, which may allow different contribution to the B activation 
(reviewed by Akira, et al, 2006) [270].  TRIF recruitment to TLR4 only occurs after 
TLR4 internalization. Whether TLR4 is internalized in B cells and whether TLR4 is 





In human B cells, TLR stimulation has been implicated for polyclonal activation of 
memory B cells to maintain memory B cell and long-lived plasma cell populations.  
Bernasconi and colleagues noticed a subtle increase in circulating plasma cells 
secreting IgG antibodies with other specificities during the response to tetanus 
booster vaccines in human volunteers [112].  It was unclear whether these plasma 
cells were newly generated from non-specific memory B cell turnover, or were older 
long-lived plasma cells displaced from the bone marrow (reviewed by Radbruch, 
2006) [134].  We tested for activation of memory B cells in mice by administering 
TLR4 and TLR9 agonists in the absence of antigen and were unable to see an 
immune response (Chapter 2), indicating that TLR stimulation is not sufficient for 
memory B cell activation in this model.   While TLR stimulation alone was unable to 
activate memory B cells polyclonally to generate secondary immune responses in 
vivo, they did enhance antibody affinity maturation, particularly after the booster 
vaccination, compared with immunization with antigen alone (Chapter 3).  These data 
indicate that TLR stimulation may play a role in the generation of memory B cells.  
Current paradigms about the contribution of TLR stimulation to B cell affinity 
maturation hold that TLR stimulation leads to a stronger germinal center (GC) 
response.  Stimulation with LPS had been shown to activate innate immune cells to 
establish new B cell follicles and GCs in lymph nodes [321].  Recently, TLR4 
stimulation has also been shown to enhance maturation of follicular dendritic cell 
(fDC) networks [327].  Since fDCs are essential to the establishment of germinal 




Germain, 2009; Carter and Myers, 2008) [11, 448], these findings also support an 
indirect role for TLRs to support B cell affinity maturation.  TLR4 stimulation and 
other signals allow the maturation of fDCs in locations outside of secondary 
lymphoid oragans, allowing the formation of tertiary lymphoid tissues that can form 
germinal centers and support B cell affinity maturation [11].  TLR4 deficiency in 
fDCs results in fewer and smaller GCs as well as fewer mutations in B cells and 
lower high-affinity titers [327].  A small but significant indirect effect on B cell 
expression of AID was also described [327].  Furthermore, LPS stimulation of B cells 
triggered class-switching in vitro but was insufficient for somatic hyper-mutation 
[54].  MyD88-/- mice are significantly slower at isotype switching [282, 449].  
Gargano and colleagues showed that in MyD88-/- mice only few B cells were able to 
enter germinal centers [449], so one possible mechanism for TLRs to enhance 
antibody affinity maturation further may be allowing naïve and memory B cells entry 
into germinal centers.  However, a recent study suggests that MyD88 is also involved 
in innate stimuli of B cells via BAFF and APRIL signaling  pathways to induce 
isotype class switching, independent of TLR stimulation of B cells as MyD88 directly 
binds to the BAFF/APRIL receptor TACI [450].  Therefore, it is possible that TLR 
stimulation leads to signaling cross-talk downstream of TACI.  This hypothesis is 
further supported by a previous study showing auto-antibody production depends on 
MyD88 signaling in a BAFF transgenic mouse model [451].  On the other hand, it is 
likely that previous studies using MyD88-/- to study the effects of TLR stimulation on 
B cells also blocked the TACI pathway in B cells.   This may account for the few 




stimulation.  Furthermore, maximum IgG titers in MyD88-/- mice also were shown to 
be similar to those of WT mice, although with delayed kinetics [449], which argues 
against a role of TLR in B cell affinity maturation.  Thus, the roles of TLRs on B cell 
affinity maturation remain poorly understood.  This study demonstrates that TLR4, 7, 
and 9 stimulations in the presence of antigen were able to increase antibody affinity 
following second immunization (Chapter 3).  This is the first study on the effects of 
TLR agonists other than LPS on antibody affinity.  Our study also confirmed previous 
reports that CpG and gardiquimod increased isotype switching in vivo [301, 351, 361, 
452] (Chapter 3).   
 
TLR activation of B cells has been implicated in the activation of autoreactive B cells 
and production of autoantibodies that leads to autoimmune diseases in mice and 
humans (reviewed by Marshak-Rothstein, 2006; Krieg and Vollmer, 2007; 
Lanzavecchia and Sallusto, 2007; Deane and Bolland, 2006) [286, 379, 380, 382].  
How TLRs contribute to the generation and activation of autoreactive B cells is 
unknown.  TLRs could stimulate chemokine production in stromal cells and 
lymphocytes, which enhance the formation of tertiary lymphoid tissues that further 
amplify immune and autoimmune responses [453-456].  Polyclonal activation 
capability of TLRs could break tolerance of auto-reactive B cells [457, 458].  On the 
other hand, some pathogens induce a form of tolerance [356, 389, 430, 459].  
Therefore, understanding the mechanisms by which TLRs directly and indirectly 
activate B cells is important for the application of TLR targeted adjuvant for vaccines 




Section 1 Future Directions 
 
Some of the important questions that remain are (1.) to establish the molecular basis 
for differences in in vitro stimulation with different TLR agonists, (2.) to establish 
molecular mechanism for the intrinsically higher responsiveness to in vitro TLR 
stimulation by memory B cells compared to unswitched B cells (3.) to establish the 
molecular mechanisms of TLR-induced enhancement of B cell affinity maturation, 
and (4.) to test if the enhanced affinity allows more memory B cells and long-lived 
plasma cells to be maintained and enhance protection in antigen challenge in mice 
immunized with TLR-based adjuvants. 
 
To understand the molecular basis for the difference between TLR4 and TLR9 
activation of B cells, we should first test whether the greater enhancement of Ribi 
adjuvant to antibody titers is TRIF-dependent.   TRIF-/- mice will be used to carry out 
the immunization study to determine whether TRIF deficiency will abolish the 
difference in antibody responses induced by TLR4 and TLR9 agonists as adjuvant.  
 
To determine whether TLR9 in mB and naïve B cells mediates signaling through 
similar mechanism, we will analyze the cellular distribution of TLR9. In naïve B 
cells, TLR9 stimulation alone typically results in MyD88 re-localization to late 
endosomes [206].  However, when the BCR is stimulated either alone or together 




autophagosome-like compartment.  We can compare the subcellular distribution of 
TLR9 in mB and naïve B cells in the presence of TLR9 and/or BCR ligands. 
 
Data from chapter 3 indicate a possibility that immunization with adjuvant altered the 
kinetics of antibody secretion in both the primary and secondary anti-NP immune 
responses.  Previous reports suggest that the kinetics of the primary anti-NP immune 
response should be completed by the fourth week (GC forming within 1 week of 
exposure and dissolving approximately 2 weeks later), with peak antibody secretion 
of the primary immune response at two weeks past immunization, while secondary 
responses show higher IgG titers without the lag period for germinal center formation 
[41, 86, 98, 404-406].  In our hands, the responses to TD antigen did not follow the 
model exactly.  Notably antibody titers failed to decline between the 2nd and 4th week 
after primay immunization, and we observed a continuous increase in IgG titers 
between the 2nd and 4th week in most mice that were immunized with an adjuvant.  
And while secondary immune responses are reported to retain high titers for at least 
six weeks after immunization, we observed that IgG titers already decline between 2 
and 4 weeks after the second immunization.   However, by 100 days after 
immunization, the latest time point in this study, IgG titers were still almost as high as 
two weeks into the primary immune response (Chapter 3).  Some changes to this 
preliminary study should be undertaken for studying the effect of TLRs on kinetics of 
humoral responses.  In order to simulate reported kinetics more closely in the no 
adjuvant control, a lower dose of antigen should be administered.  In the literature, 




immunization ranges from 10 - 400 μg/mouse [28, 86, 397-400, 402, 460, 461].  In 
order to evaluate the extension of responses by adjuvants fully, delivery of the second 
injection will be postponed until the primary antibody levels have declined.   This 
may also result in a greater boosting effect.  To consider whether TLR agonists 
actually reach memory B cells in vivo, this experiment will be carried out in two sets 
of mice receiving the immunogen either by the intraperitoneal route, as before, or by 
intravenous route to increase likelihood of lymphocyte exposure to the agonists. 
 
To address the question of B cell-intrinsic differences in the activation of memory 
and follicular B cells that enable memory B cells to produce a more robust response, 
we propose to follow expression level and phosphorylation kinetics of B cell 
activation-related molecules.  Our first goal is to determine the activation threshold 
for memory B cells.  For this experiment CFSE-labeled B cells will be incubated in 
serial dilutions of antigen and suboptimal concentrations of TLR agonists, and the 
ability to proliferate and differentiate into plasma cells will be analyzed. 
 
Second, we would like to assess differences in the activation kinetics of naïve and 
memory B cells.  Our preliminary data show diminished expression of CD21, 
complement receptor 2, on memory B cells compared to naïve follicular B cells (see 
appendix).  We will therefore focus on known CD21 interaction partners.  CD21 is a 
component in the B cell co-receptor complex that signals through CD19.  The 
expression level of CD19 is similar in memory and naïve B cells.  We will compare 




intracellular tail phosphorylation kinetics by flow cytometry.  Phosphorylated CD19 
recruits PI3K, and we will also assess kinetics of local changes in the PI3K product 
PI(3,4,5)P3 (PIP3) as well as kinetics of signal molecules downstream of the BCR and 
calcium responses to TLR and antigen stimulation.  CD21 is also known to interact 
with the low affinity IgE receptor, CD23, which has been shown to regulate IgE and 
IgG1 responses [462-464].  Preliminary data show that in mouse mB the CD23 
expression level is also reduced.  CD23 signaling uses the transcription factor Notch, 
and we will follow the nuclear translocation of the active Notch intracellular domain 
following TLR and antigen stimulation by microscopy.  
 
To test whether TLR-based adjuvants affect the generation of memory B cells or their 
maintenance, we plan to quantify the frequency of antigen-specific memory B cells 
four weeks after each immunization.  To follow up on the alternate kinetics of 
humoral responses, we will track anti-sera of all Ig isotypes following one single 
immunization with CpG ODN, gardiquimod, Ribi, and alum as adjuvant or PBS 
weekly until a significant decline in NP-specific titers is evident.  After this, the 
booster immunization can be administered, and we will follow the secondary immune 
response, paying special attention to further isotype switching, such as to IgE.  In 
mice the sequence of Ig heavy chain gene segments is IgM/D – IgG3 – IgG1 – IgG2b 







Different co-receptor expression profile on memory and follicular B cells 
Introduction 
The rapid and robust secondary antibody response suggests a lower signaling 
threshold and faster kinetics of mB activation.  However, the signaling does not 
happen through the BCR alone.  An extensive network of both positive and negative 
co-regulators modulates BCR signaling.  We here focus on CD19 (B cell co-
receptor), CD21 (complement receptor 2), CD23 (Fc epsilon receptor II).   
 
CD19 is a major co-stimulatory molecule to the BCR.  Its expression is unique to B 
cells and it serves as a marker for these from early B cell development (CD19 
expression commences in the pre-B cell stage after DJ rearrangement of the Ig heavy 
chains has occurred, and is triggered by IL-7 in vitro.) up to plasma cell 
differentiation in humans and mice.  CD19 can be expressed in the membrane as an 
individual transmembrane protein, but in mature B cells CD19 usually forms 
signaling complexes with complement receptor 2 (CR2; CD21), and with tetraspan 
family of transmembrane proteins member CD81 (reviewed by Tedder et al, 1997) 
[223, 465].  When coligated with the BCR,  CD19 enhances proliferation induced by 
high affinity-BCR interactions with its antigen and to a lesser extent enables the 
proliferation after low affinity-BCR interactions with its antigen [223].  CD19/CD21 
interaction with the BCR extends the transient BCR association with the 




rafts [466].  CD19 also serves as adaptor recruiting several signaling molecules. 
CD19 is phosphorylated, and thereby activated, by Lyn. Phosphorylated CD19 
provides a binding site for PI3K [467].  PI3K, in turn, phosphorylates PIP2 to produce 
the second messenger PIP3.  PIP3 recruits Btk to the plasma membrane, which leads to 
Btk activation.  It has also been observed that CD19 co-ligation with BCR increases 
the percentage of the surface BCR in lipid rafts and retains the BCR there longer than 
what is seen in antigenic activation [186, 466] (reviewed by Cheng et al. [468] and by 
Pierce [469]). Thus CD19 functions in both phosphorylation signaling and in 
clustering of the BCR in FO B cells. While CD19 over-expression results in 2-3 fold 
threshold reduction of BCR signaling, CD19 co-ligation with BCR results in a 1000-
10,000-fold threshold reduction for antigen stimulation [223, 470, 471]. 
 
CD21 is complement receptor 2 (CR2).  CD21 is expressed predominantly on B cells 
[472].  FDCs express a slightly longer isoform of CD21 that has one more of the 
consensus repeats [472]. Some activated T cells and epithelial cells also express the 
short isoform of CD21 [473]. CD21 has several known ligands including C3 
fragments [474-476], IFNα, and Epstein-Barr Virus [477]. In the absence of 
coligation with the BCR, CD21 can also associate with CD35, the complement 
receptor 1 (CR1) that aids in the degradation of C3b to make the C3d substrate for the 
CD21 receptor [223].  Interestingly, in human, CD21 also binds CD23 (IgE receptor).  
 
C3-depletion by cobra venom factor inhibits humoral immune responses [478], 




inhibited humoral response to challenges with T cell-dependent and T cell-
independent antigens [479, 480].  These mice also have low levels of natural antibody 
and are sensitive to infections.  The germinal centers in these mice are few and 
underdeveloped, probably due to apoptosis of germinal center B cells (reviewed by 
Carroll, 2004) [21].  Uptake of immune complexes by FDCs is inhibited 
(CD21/CD35 is involved in transferring ICs from the MZ B cells to the FDCs) [481-
484].  Defects in the germinal center appear to be dominated by missing complement 
receptors in the B cells, because chimeric mice with WT bone marrow and B cells in 
a Cr2-/- background (FDCs are KO) appear to be fine, except for long-term 
maintainance of antibody and memory B cells [479, 485] (The antigen requirement 
for maintainance of memory B cells is controversial.)  Most recent evidence suggests 
that the symptoms of Cr2-/- mice are effects of increased inflammation in the spleen 
caused by too much C3a release as CD21 limits complement convertase activity, and 
depletion of C3 restores IgG3 production and gene expression patterns the Cr2-/- mice 
[486]. 
 
Bachmann and collegues observed that IgG responses were more affected than early 
IgM responses by the absence of CD21 in Cr2-/- mice; a higher epitope density was 
required for producing robust IgG titers [487], indicating that the CD19/CD21/CD81 
complex may play a larger role in mB than in nB.  CD19 deficiency hinders memory 
B-cell development [488].  In CD21-deficient mice, mB fail to differentiate into 
plasma cells, while primary antibody responses and development of mB are 




found in some patients with autoimmune diseases [490].  It is therefore reasonable to 
hypothesize that the CD19/CD21/CD81 complex plays an important role in mB 
activation. 
 
CD23 (FcεRII) is a C-type lectin.  CD23 is a low affinity receptor for IgE antibodies.  
On B cells, CD23 interaction with IgE containing immune complexes negatively 
regulates B cell activation, thus limiting the synthesis of new IgE [462-464].  
Curiously, over-expression of CD23 in mice also significantly decreased IgG1 
secretion [463, 464].  That the transcription of IgG1 and IgE sites of the Ig gene may 
have similar regulation is not completely unexpected:  Mouse B cells stimulated with 
IL-4 undergo class-switching to both IgG1 and IgE [66].  CD23 signaling pathways 
are largely unknown, but the same metalloproteinase that cleaves CD23, ADAM10, 
also activates the Notch1 signaling pathway [491, 492].  Notch2 has also recently 
been shown to play a role in allowing CD23 to be cleaved in vivo [493].  Notch 
family proteins are a unique class of signal regulators, acting both as membrane 
sensors and transcription factors.  After cleavage, the intracellular domain (NICD) 
directly translocates to the nucleus, without amplification through any signaling 
cascades (reviewed by Fürthauer and Gonzalez-Gaitán, 2009) [494].  
 
One other possibility of how CD23 regulates B cell signaling is through interacting 
with CD21 to recruit CD21 away from CD19 co-receptor, making CD21 less 
available for immune complex mediated cross-linking of BCR and CD19 [495].  




497].  Whether this binding recruits CD21 away from CD19 and its role in the co-
receptor complex is unknown.  It is also uncertain whether CD23 and CD21 
interaction is limited to cell-cell contacts such as between a mast cell and a B cell, or 
whether they are able to assume a configuration to interact with each other on the 
same cell.  In addition to receptor internalization, CD23 can be cleaved by 
metalloproteinases resulting in CD23 shedding from cell surfaces [491].  The 
interaction between CD23 and CD21 is strong enough that after the shedding of 
CD23 in vitro, the extracellular domain is often found in association with CD21 in the 
cell culture media and serum [498, 499].  In cells that shed CD23, the synthesis of 
CD23 is usually thought to be up-regulated to compensate for the loss and maintain 
membrane homeostasis of CD23.  CD23 and CD21 are frequently co-expressed 
owing to similar regulatory elements in their respective genes [500-502]. To date, 
nothing is known about CD23 on mouse memory B cells. 
 
Materials and Methods 
B cell enrichment  
Mice were immunized twice, 28 days apart, with NP19-KLH + Ribi adjuvant.  B cells 
were isolated from the spleen and bone marrow of mice at 5 days (activated) or 6 
weeks (resting) after second immunization.  Spleens were mechanically ground to 
create single cell suspensions in the complete medium (RPMI 1640 with 2 mM 
glutamine (Gibco/Invitrogen, Carlsbad, CA), 10% fetal bovine serum (FBS), 55 µM 
β-Mercaptoethanol, 100 µM non-essential amino acids, 1 mM sodium pyruvate, and 




blood cells were lysed with ACK lysis buffer (Lonza, Basel, Switzerland).  After 
washing, T cells were removed using complement-mediated T cell lysis by targeting 
the T cells with anti-CD90.2 (Thy1.2) antibody (BD Biosciences, San Diego, CA) in 
10% guinea pig complement (Rockland Immunochemicals, Gilbertsville, PA) in 
Hank’s buffered salts solution, pH 7.4 (HBSS) (Sigma-Aldrich, St. Louis, MO) at 
37oC for 30 min.  Remaining complement was washed out with HBSS.  Adherent 
cells were removed by panning in 10% CM at 37oC, 5% CO2 for 1 h. 
 
Flow cytometry analysis 
The protein expression level of CD19, CD21, and CD23 on memory B cells in spleen 
was analyzed by flow cytometric analysis.  All labeling steps were performed on ice.  
B cells were pre-incubated with anti-mouse CD16/CD32 (BD Biosciences, San 
Diego, CA) in PBS containing 2% FBS for 10 min to block FcγR from binding to 
antibody, and labeled for 30 min with the following fluorescently conjugated 
antibodies and reagents: PerCP-Cy5.5-anti-B220, PE-anti-CD138, PE-Cy7-anti-IgM 
(all from BD Biosciences, San Diego, CA), biotin-anti-IgD (Southern Biotech, 
Birmingham, AL), and APC-NP12 for the identification of naïve follicular and 
memory B cell subsets, and either FITC-anti-CD19, FITC-anti-CD21, or PE-anti-
CD21 and FITC-anti-CD23 (all from BD Biosciences, San Diego, CA) for surface 
expression of these receptors.  APC-NP was generated by conjugating NP-OSu 
(Biosearch Technologies, Novato, CA) to APC.  After washing three times with 2% 
FBS/PBS, cells were incubated with AF430-conjugated streptavidin for 20 min.  




fixing with 2% paraformaldehyde in PBS for 10 min, followed by an additional wash 
with PBS prior to be analyzed on a flow cytometer (BD Canto II, BD Biosciences, 
San Jose, CA).  Data analysis was performed using FACSDiva (BD Biosciences, San 
Jose, CA) and FlowJo (Treestar Inc., Ashland, OR) software. The frequency of 
memory B cells, defined as isotype-switched antigen-binding B cells (B220+CD138-
IgM-IgD-NP+) [109, 110], was determined. 
 
Results 
To explore the underlying mechanism for more robust activation of memory B cells 
compared to activation of naïve B cells, we tested the expression profile of memory B 
cells of activation co-receptors.  B cell-enriched splenocytes were stained for the 
identification of memory and naïve B cell subsets as well as antibodies against CD19, 
CD21 (complement receptor 2; CR2), and CD23 (FcεRII).  CD19 levels were similar 
in all of the mature B cell subsets (Figure A.1, A, B). Memory B cells expressed 
significantly lower levels of CD21 than follicular B cells (Figure A.1, A, C).  CD23 
surface expression level also was lower in memory B cells (Figure A.1, A, D).  Cells 
with the lowest expression of CD21 were also dimmest for CD23 (Figure A.1 E).  
Similar trends were observed in follicular and memory B cell subsets isolated from 












Figure A.1. The expression levels of CD21 and CD23, but not CD19, are reduced 
in memory B cells compared to isotype unswitched B cells.  A.  Expression profile 
of indicated B cell subsets from a representative mouse 5dpb.  The following subsets 
were identified by gating on surface markers: NP-binding memory B cells (NP+ mB) 
B220+ CD138- IgM- IgD- NP+, memory B cells (mB) B220+ CD138- IgM- IgD- NP+/-, 
NP-binding unswitched B cells (NP+ FO) B220+ CD138- IgMint IgD+ NP+, naïve 
follicular B cells (FO) B220+ CD138- IgMint IgD+ NP-.  B-D.  Quantification of  
CD19 (B), CD21 (C), and CD23 (D) expression levels. Each circle represents one 
mouse, bars show mean and SEM. (E) 2-dimensional histogram of CD21 and CD23 
fluorescence intensity shows partial correlation of CD21 and CD23 down-regulation.  
This graph was gated on resting isotype-switched B cells (6 weeks past second 







Long-term memory induced by TLR4, 7, and 9 agonists 
 
Introduction 
Long-term humoral immunity is maintained by two cell types, memory B cells and 
long-lived plasma cells.  While long-lived plasma cells continually secrete protective 
antibodies, memory B cells are resting until re-exposure to antigen prompts their 
differentiation into new plasma cells.  We had previously tested the ability of 
different TLR agonists to induce affinity maturation, an essential step in memory 
development (Chapter 3).  We then asked whether TLR agonists as adjuvants can 
influence the maintainance of memory B cells and long-lived plasma cells. 
 
Materials and Methods 
Mice were immunized twice, 28 days apart, with NP19-KLH alone or with Ribi, 
gardiquimod, or CpG ODN as adjuvant.  B cells were isolated from the spleen and 
bone marrow of mice at 100 days after second immunization and enriched as 
described above.  The frequency of antigen-specific memory B cells in spleen and 
bone marrow B cells was analyzed by flow cytometric analysis as described above.   
 
ELISpot analysis 
The frequency of bone marrow cells that secrete specific antibodies (ASC) was 
determined by ELISpot assay as previously described [162] at 100 days after second 
immunization.  ELISpot plates (MHAB pore size 0.45 μm; Millipore, Billerica, MA) 




high and low affinity antibodies, NP4-BSA for ASC secreting antibodies with 
relatively high affinity, or donkey-anti-mouse IgG+M (Jackson ImmunoResearch, 
West Grove, PA) for all ASC.  Plates were blocked with 10% FBS/PBS for 1 h. Bone 
marrow cells, after T cell deletion and panning, were serially diluted and cultured in 
the plate for 5 h.  The plates were washed three times with PBS and three times with 
PBST.  A cocktail of biotinylated goat-anti-mouse IgG antibodies (IgG1, IgG2a, IgG2b, 
IgG3 from Southern Biotech, Birmingham, AL) in 1% FBS/PBST was applied for 1 h 
at room temperature.  Plates were washed in PBST and visualized using streptavidin-
HRP and True Blue reagents (Kirkegaard and Perry Laboratories, Gaithersburg, MD).  
Plates were washed with distilled water and dried overnight with in the dark before 
scanning with a C.T.L. plate scanner using ImmunoCapture software (Cellular 
Technology Ltd., Shaker Heights, OH).  Spots were counted using C.T.L. 
ImmunoSpot counting software and verified by manually counting randomly selected 
wells from each plate.   
 
Results 
To test whether immunization with CpG ODN or gardiquimod as adjuvants can 
increase long term immunity in the NP-immunized mouse model, we determined the 
Ig titer and affinity and the frequencies of NP-specific memory B cells in the spleen 
and NP-specific antibody secreting cells in the bone marrow in more than 14 weeks 
after second immunization.  The NP-specific serum titers (Figure 3.1B) were 
relatively low, compared to those shortly after immunization in most mice.  The 




(Figure 3.2E and not shown) and by specific competition with antigen (Figure 3.3E).  
The affinity of the antibodies remained high, although the titers had decreased since 
the second immunization.  We determined the frequency of NP-specific memory B 
cells using flow cytometry. The memory B cells were definded as B220+ CD138- 
IgMlow IgD- NP+ (Figure A.2, A and B).  We used the frequency along with the 
number of cells isolated from each spleen prior to staining to determine the number of 
NP-specific memory B cells in each mouse’s spleen (Figure A.2C).  Compared with 
immunization without adjuvant, mice immunized with Ribi and  gardiquimod as 
adjuvant on average had retained 8-fold more NP-specific memory B cells, but CpG 
ODN adjuvant did not increase the number of NP-specific memory B cells that were 
retained in the spleen (Figure A.2, A-C).  We determined the frequency of NP-
specific ASC in the bone marrow using ELISpot assay, and estimate their relative 
affinity using low density coating antigen (NP4-BSA) (Figure A.1D).  There were 
significant numbers of NP-specific IgG ASCs in the bone marrow of all the 
immunization groups, indicating the presence of long lived plasma cells.  The number 
of antigen-specific long-lived plasma cells did not differ between mice immunized 
with antigen alone or antigen plus adjuvant.  It should be noted that due to low 
sample number in each immunization group, the differences we observed between 
mice immunized with antigen alone or with any of the adjuvants were not statistically 








Figure A.2. No significant difference between the different adjuvants or without 
adjuvant on long-term immunity.  A-C. The frequency of NP-sepecifc memory B 
cells were analyzed in spleens 100 days after second immunization with NP19-KLH 
and the indicated adjuvant.  B cell-enriched spenocytes were stained for B220, 
CD138, IgM and IgD, and incubated with allophytocyanin-conjugated NP without 
allowing internalization to assay antigen-binding ability. Representative histograms 
for flow cytometric analysis of memory B cells are shown in A.    Histograms are 
gated on singlets, small lymphocytes by light scatter profile, B220+ CD138- and IgM-.  
IgD- NP+ cells (top left) are antigen-specific memory B cells.  Unswitched (IgD+) NP-
binding cells are included as control population (top right).  The frequency of these 
cells as a percentage of all B220+ CD138- B cells is indicated above each histogram 
(A) and quantification is shown in (B).  The frequency of NP-binding memory B cells 
was multiplied by the number of cells isolated from each spleen to obtain memory B 
cell counts per spleen (C).  D.  NP-specific bone marrow antibody secreting cells 
(ASC), representing long-lived plasma cells, were quantified in the same mice by 
ELISpot analysis on high density antigen-coated (total, filled circles) and low density 
antigen coated (high affinity, open circles) directly after B cell enrichment.  Each 











1. Menezes, H.J., Carlos, Immunity in plants and animals: common ends through 
different means using similar tools. Comp Biochem Physiol C - Toxicol 
Pharmacol, 2002. 132(1): p. 1-7. 
 
2. Pancer, Z. and M.D. Cooper, The evolution of adaptive immunity. Annu Rev 
Immunol, 2006. 24: p. 497-518. 
 
3. Aderem, A. and D.M. Underhill, Mechanisms of phagocytosis in 
macrophages. Annu Rev Immunol, 1999. 17: p. 593-623. 
 
4. Ochsenbein, A.F. and R.M. Zinkernagel, Natural antibodies and complement 
link innate and acquired immunity. Immunol Today, 2000. 21: p. 624-630. 
 
5. Bebbington, C. and G. Yarranton, Antibodies for the treatment of bacterial 
infections: current experience and future prospects. Curr Opin Biotechnol, 
2008. 19: p. 613-619. 
 
6. Law, M. and L. Hangartner, Antibodies against viruses: passive and active 
immunization. Curr Opin Immunol, 2008. 20: p. 486-492. 
 
7. Danilova, N., The evolution of immune mechanisms. J Exp Zool (Mol Dev 
Evol), 2006. 306b(6): p. 496-520. 
 
8. Pone, E.J., et al., Toll-like receptors and B cell receptors synergize to induce 
immunoglobulin class-switch DNA recombination: relevance to microbial 
antibody responses. Crit Rev Immunol, 2010. 30(1): p. 1-29. 
 
9. Cellular and molecular immunology. 5th ed, ed. A.K. Abbas and A.H. 
Lichtman. 2005, Philadelphia: Elsevier Saunders. 
 
10. Rappuoli, R., H.I. Miller, and S. Falkow, Medicine: the intangible value of 
vaccination. Science, 2002. 297. 
 
11. Mueller, S.N. and R.N. Germain, Stromal cell contributions to the 
homeostasis and functionality of the immune system. Nat Rev Immunol, 2009. 
9(9): p. 618-29. 
 
12. Hinton, H.J., A. Jegerlehner, and M.F. Bachmann, Pattern recognition by B 
cells: The role of antigen repetitiveness versus Toll-like receptors. Current 





13. McHeyzer-Williams, L.J. and M.G. McHeyzer-Williams, Antigen-specific 
memory B cell development. Annu Rev Immunol, 2005. 23: p. 487-513. 
 
14. Harris, D.P., et al., Reciprocal regulation of polarized cytokine production by 
effector B and T cells. Nat Immunol, 2000. 1(6): p. 475-82. 
 
15. Warner, N.L. and A. Szenberg, The immunological function of the bursa of 
Fabricius in the chicken. Annu Rev Microbiol, 1964. 18: p. 253-266. 
 
16. Duchosal, M.A., B-cell development and differentiation. Semin Hematol, 
1997. 34(1 Suppl 1): p. 2-12. 
 
17. Hardy, R.R. and K. Hayakawa, B cell development pathways. Annu Rev 
Immunol, 2001. 19: p. 595-621. 
 
18. Kondo, M., I.L. Weissman, and K. Akashi, Identification of clonogenic 
common lymphoid progenitors in mouse bone marrow. Cell, 1997. 91: p. 661-
672. 
 
19. Hardy, R.R., et al., Resolution and characterization of Pro-B and Pre-Pro B 
cell stages in normal mouse bone marrow. J Exp Med, 1991. 173: p. 1213-
1225. 
 
20. Sanderson, R.D., P. Lalor, and M. Bernfield, B lymphocytes express and lose 
syndecan at specific stages of differentiation. Cell Regulation, 1989. 1: p. 27-
35. 
 
21. Carroll, M.C., The complement system in B cell regulation. Mol Immunol, 
2004. 41(2-3): p. 141-6. 
 
22. Kantor, A.B. and L.A. Herzenberg, Origin of murine B cell lineages. Annu 
Rev Immunol, 1993. 11: p. 501-538. 
 
23. Hockenbery, D.M., et al., BCL2 protein is topographically restricted in tissues 
characterized by apoptotic cell death. Proc Natl Acad Sci U S A, 1991. 88: p. 
6961-6965. 
 
24. Oliver, A.M., F. Martin, and J.F. Kearney, Mouse CD38 is down-regulated on 
germinal center B cells and mature plasma cells. J Immunol, 1997. 158(3): p. 
1108-1115. 
 
25. Waldschmidt, T.J., D.H. Conrad, and R.G. Lynch, The expression of B cell 
surface receptors. 1. The ontogeny and distribution of the murine B cell IgE 




26. Ridderstad, A. and D.M. Tarlinton, Kinetics of establishing the memory B cell 
population as revealed by CD38 expression. J Immunol, 1998. 160(10): p. 
4688-95. 
 
27. Shinall, S.M., et al., Identification of murine germinal center B cell subsets 
defined by the expression of surface isotypes and differentiation antigens. J 
Immunol, 2000. 164(11): p. 5729-5738. 
 
28. Wolniak, K.L., R.J. Noelle, and T.J. Waldschmidt, Characterization of (4-
hydroxy-3-nitrophenyl)acetyl (NP)-specific germinal center B cells and 
antigen-binding B220(-) cells after primary NP challenge in mice. J Immunol, 
2006. 177(4): p. 2072-2079. 
 
29. Gray, D., A role for antigen in the maintenance of immunological memory. 
Nat Rev Immunol, 2002. 2(1): p. 60-65. 
 
30. Dogan, I., et al., Multiple layers of B cell memory with different effector 
functions. Nat Immunol, 2009. 10(12): p. 1292-9. 
 
31. Yanaba, K., et al., The development and function of regulatory B cells 
expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR 
signals. J Immunol, 2009. 182(12): p. 7459-72. 
 
32. Fillatreau, S., et al., B cells regulate autoimmunity by provision of IL-10. Nat 
Immunol, 2002. 3(10): p. 944-50. 
 
33. Bouaziz, J.D., K. Yanaba, and T.F. Tedder, Regulatory B cells as inhibitors of 
immune response and inflammation. Immunol Rev, 2008. 224(1): p. 201-214. 
 
34. Rathmell, J.C., et al., CD95 (Fas) dependent elimination of self-reactive B-
cells upon interaction with CD4(+) T-cells. Nature, 1995. 376(6536): p. 181-
184. 
 
35. Goodnow, C.C., et al., Altered immunoglobulin expression and functional 
silencing of self-reactive lymphocytes-B in transgenic mice. Nature, 1988. 
334(6184): p. 676-682. 
 
36. Merrell, K.T., et al., Identification of anergic B cells within a wild-type 
repertoire. Immunity, 2006. 25(6): p. 953-962. 
 
37. Shapiro-Shelef, M., et al., Blimp-1 is required for the formation of 
immunoglobulin secreting plasma cells and pre-plasma memory B cells. 
Immunity, 2003. 19: p. 607-620. 
 
38. Moser, K., et al., Stromal niches, plasma cell differentiation and survival. 





39. Shapiro-Shelef, M., et al., Blimp-1 is required for maintenance of long-lived 
plasma cells in the bone marrow. J Exp Med, 2005. 202(11): p. 1471-6. 
 
40. Tarlinton, D., et al., Plasma cell differentiation and survival. Curr Opin 
Immunol, 2008. 20: p. 162-169. 
 
41. Slifka, M.K., M. Matloubian, and R. Ahmed, Bone marrow is a major site of 
long-term antibody production after acute viral infection. J Virol, 1995. 69(3): 
p. 1895-902. 
 
42. Skok, J.A., et al., Nonequivalent nuclear location of immunoglobulin alleles in 
B lymphocytes. Nat Immunol, 2001. 2(9): p. 848-54. 
 
43. Alt, F.W., et al., Activity of multiple light chain genes in murine myeloma cells 
producing a single, functional light chain. Cell, 1980. 21: p. 1-12. 
 
44. Nussenzweig, M.C., et al., Allelic exclusion in transgenic mice that express 
the membrane form of immunoglobulin mu. Science, 1987. 236: p. 816-819. 
 
45. Mostoslavsky, R., et al., Kappa light chain monoallelic demethylation and the 
establishment of allelic exclusion. Genes Dev, 1998. 12: p. 1801-1811. 
 
46. Mostoslavsky, R., et al., Asynchronous replication and allelic exclusion in the 
immune system. Nature, 2001. 414: p. 221-225. 
 
47. Moore, K.W., et al., Expression of IgD may use both DNA rearrangement and 
RNA splicing mechanisms. Proc Natl Acad Sci U S A, 1981. 78(3): p. 1800-
1804. 
 
48. Preud'homme, J.L., et al., Structural and functional properties of membrane 
and secreted IgD. Mol Immunol, 2000. 37(15): p. 871-87. 
 
49. Calame, K.L., K.I. Lin, and C. Tunyaplin, Regulatory mechanisms that 
determine the development and function of plasma cells. Annu Rev Immunol, 
2003. 21: p. 205-30. 
 
50. Tarlinton, D., B-cell memory: are subsets necessary? Nat Rev Immunol, 
2006. 6(10): p. 785-90. 
 
51. MacLennan, I.C.M., Germinal centers. Annu Rev Immunol, 1994. 12: p. 117-
39. 
 
52. Grewal, I.S. and R.A. Flavell, CD40 and CD154 in cell-mediated immunity. 





53. Banchereau, J., et al., The CD40 antigen and its ligand. Annu Rev Immunol, 
1994. 12: p. 881–922. 
 
54. Muramatsu, M., et al., Class switch recombination and hypermutation require 
activation-induced cytidinedeaminase (AID), a potential RNA editing enzyme. 
Cell, 2000. 102: p. 553–63. 
 
55. Teng, G., et al., MicroRNA-155 is a negative regulator of activation-induced 
cytidine deaminase. Immunity, 2008. 28: p. 621-629. 
 
56. Dorsett, Y., et al., MicroRNA-155 suppresses activation-induced cytidine 
deaminase-mediated Myc-Igh translocation. Immunity, 2008. 28(5): p. 630-8. 
 
57. Revy, P., et al., Activationinduced cytidine deaminase (AID) deficiency causes 
the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell, 
2000. 102: p. 565-75. 
 
58. Okazaki, I.M., et al., The AID enzyme induces class switch recombination in 
fibroblasts. Nature, 2002. 416(6878): p. 340-345. 
 
59. Martin, A. and M.D. Scharff, Somatic hypermutation of the AID transgene in 
B and non-B cells. Proc Natl Acad Sci U S A, 2002. 99(19): p. 12304-8. 
 
60. Yoshikawa, K., et al., AID enzyme-induced hypermutation in an actively 
transcribed gene in fibroblasts. Science, 2002. 296(5575): p. 2033-2036. 
 
61. Martin, A., et al., Activation-induced cytidine deaminase turns on somatic 
hypermuation in hybridomas. Nature, 2002. 415(6873): p. 802-806. 
 
62. Shen, H.M., et al., Expression of AID transgene is regulated in activated B 
cells but not in resting B cells and kidney. Mol Immunol, 2008. 45(7): p. 
1883-92. 
 
63. Stavnezer, J., Immunoglobulin class switching. Curr Opin Immunol, 1996. 
8(2): p. 199-205. 
 
64. Caron, G., et al., CXCR4 expression functionally discriminates centroblasts 
versus centrocytes within human germinal center B cells. J Immunol, 2009. 
182: p. 7595-7602. 
 
65. Allen, C.D.C., et al., Imaging of Germinal Center Selection Events During 
Affinity Maturation. Science, 2007. 315: p. 528-531. 
 
66. Snapper, C.M. and W.E. Paul, Interferon-gamma and B-cell stimulatory 
factor-I reciprocally regulate Ig isotype production. Science, 1987. 





67. Mao, C. and J. Stavnezer, Differential regulation of mouse germline Ig 
gamma 1 and epsilon promoters by IL-4 and CD40. J Immunol, 2001. 167(3): 
p. 1522-1534. 
 
68. Sonoda, E., et al., Transforming growth factor-beta induces IgA production 
and acts additively with interleukin-5 for IgA production. J Exp Med, 1989. 
170(4): p. 1415-1420. 
 
69. Coffman, R.L., D.A. Lebman, and B. Shrader, Transforming growth factor-
beta specifically enhances IgA production by lipopolysaccharide-stimulated 
murine lymphocytes-B. J Exp Med, 1989. 170(3): p. 1039-1044. 
 
70. Finkelman, F.D., et al., IFN-gamma regulates the isotypes of Ig secreted 
during in vivo humoral immune responses. J Immunol, 1988. 140(4): p. 1022-
1027. 
 
71. Allen, R.C., et al., CD40 ligand gene defects responsible for X-linked Hyper-
IgM Syndrome. Science, 1993. 259(5097): p. 990-993. 
 
72. Ferrari, S., et al., Mutations of CD40 gene cause an autosomal recessive form 
of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A, 2001. 
98(22): p. 12614-12619. 
 
73. Grammer, A.C., et al., Expression, regulation, and function of B cell-
expressed CD154 in germinal centers. J Immunol, 1999. 163(8): p. 4150-
4159. 
 
74. Sen, G., et al., In vivo humoral immune responses to isolated pneumococcal 
polysaccharides are dependent on the presence of associated TLR ligands. J 
Immunol, 2005. 175(5): p. 3084-3091. 
 
75. Pecanha, L.M.T., et al., Dextran-conjugated anti-Ig antibodies as a model for 
T cell-independent type 2 antigen-mediated stimulation of Ig secretion in 
vitro. I. Lymphokine dependence. J Immunol, 1991. 146: p. 833-9. 
 
76. Snapper, C.M. and J.J. Mond, A model for induction of T cell-independent 
humoral immunity in response to polysaccharide antigens. J Immunol, 1996. 
157: p. 2229-2233. 
 
77. Xu, J.C., et al., Mice deficient for the CD40 ligand. Immunity, 1994. 1(5): p. 
423-431. 
 
78. Garcia de Vinuesa, C., et al., T-independent type 2 antigens induce B cell 
proliferation in multiple splenic sites, but exponential growth is confined to 




79. Ceruti, A., The regulation of IgA class switching. Nat Rev Immunol, 2008. 8: 
p. 421-434. 
 
80. Klein, U., et al., Somatic hypermutation in normal and transformed human B 
cells. Immunol Rev, 1998. 162: p. 261-280. 
 
81. Klein, U., K. Rajewsky, and R. Kuppers, Human immunoglobulin 
(Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface 
antigen carry somatically mutated variable region genes: CD27 as a general 
marker for somatically mutated (memory) B cells. J Exp Med, 1998. 188: p. 
1679-1689. 
 
82. Weller, S., et al., Somatic diversification in the absence of antigen-driven 
responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in 
infants. J Exp Med, 2008. 205(6): p. 1331-42. 
 
83. Weller, S., et al., Human blood IgM "memory" B cells are circulating splenic 
marginal zone B cells harboring a prediversified immunoglobulin repertoire. 
Blood, 2004. 104(12): p. 3647-3654. 
 
84. Kruetzmann, S., et al., Human immunoglobulin M memory B cells controlling 
Streptococcus pneumoniae infections are generated in the spleen. J Exp Med, 
2003. 197(7): p. 939-945. 
 
85. Camacho, S.A., M.H. Kosco-Villbois, and C. Berek, The dynamic structure of 
the germinal center. Immunol Today, 1998. 19(11): p. 511-514. 
 
86. Jacob, J., R. Kassir, and G. Kelsoe, In situ studies of the primary immune 
response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics 
of responding cell populations. J Exp Med, 1991. 173(5): p. 1165-75. 
 
87. Schwickert, T.A., et al., In vivo imaging of germinal centres reveals a 
dynamic open structure. Nature, 2007. 446: p. 83-87. 
 
88. Lanzavecchia, A., et al., Understanding and making use of human memory B 
cells. Immunol Rev, 2006. 211: p. 303-9. 
 
89. Anderson, S.M., M.M. Tomayko, and M.J. Shlomchik, Intrinsic properties of 
human and murine memory B cells. Immunol Rev, 2006. 211: p. 280-94. 
 
90. Höfer, T., et al., Adaptation of humoral memory. Immunol Rev, 2006. 211: p. 
295-302. 
 
91. Panum, P.L., Beobachtungen uber das Maserncontagium. Virchows Archiv, 





92. Crotty, S., et al., Cutting edge: long-term B cell memory in humans after 
smallpox vaccination. J Immunol, 2003. 171(10): p. 4969-73. 
 
93. Hammarlund, E., et al., Duration of antiviral immunity after smallpox 
vaccination. Nat Med, 2003. 9(9): p. 1131-1137. 
 
94. Amanna, I.J., N.E. Carlson, and M.K. Slifka, Duration of humoral immunity 
to common viral and vaccine antigens. N Engl J Med, 2007. 357(19): p. 1903-
15. 
 
95. Hopkins, R.J., et al., Safety and pharmacokinetic evaluation of intravenous 
vaccinia immune globulin in healthy volunteers. Clin Infect Dis, 2004. 39(6): 
p. 759-766. 
 
96. Raman, V.S., et al., Ligation of CD27 on B cells in vivo during primary 
immunization enhances commitment to memory B cell responses. J Immunol, 
2003. 171(11): p. 5876-5881. 
 
97. Chappell, C.P. and J. Jacob, Identification of memory B cells using a novel 
transgenic mouse model. J Immunol, 2006. 176(8): p. 4706-15. 
 
98. McHeyzer-Williams, M.G., et al., Antigen driven B cell differentiation in vivo. 
J. Exp. Med. , 1993. 178: p. 295–307. 
 
99. Hayakawa, K., et al., Isolation of high-affinity memory B cells: phycoerythrin 
as a probe for antigen-binding cells. Proc Natl Acad Sci U S A, 1987. 84(5): 
p. 1379-83. 
 
100. Lalor, P.A., et al., Functional and molecular characterization of single, (4-
hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-
secreting and memory B cell pathways in the C57BL/6 immune response to 
NP. Eur J Immunol, 1992. 22(11): p. 3001-11. 
 
101. Guttormsen, H.K., et al., Immunologic memory induced by a glycoconjugate 
vaccine in a murine adoptive transfer model. Infect Immun, 1998. 66(5): p. 
2026-2032. 
 
102. Guriola, M., et al., Immunologic memory response induced by a 
meningococcal serogroup C conjugate vaccine using the P64k recombinant 
protein as carrier. FEMS Immunol Med Microbiol, 2006. 46(2): p. 169-179. 
 
103. Toyama, H., et al., Memory B cells without somatic hypermutation are 
generated from Bcl6-deficient B cells. Immunity, 2002. 17(3): p. 329-39. 
 
104. Chappell, C.P. and J. Jacob, Germinal center-derived B cell memory. Adv Exp 





105. Bakkus, M.H., et al., Myeloma isotype-switch variants in the murine 5T 
myeloma model: evidence that myeloma IgM and IgA expressing subclones 
can originate from the IgG expressing tumour. Leukemia, 2001. 15(7): p. 
1127-1132. 
 
106. Knight, K.L., et al., Transchromosomally derived Ig heavy chains. J Immunol, 
1995. 155(2): p. 684-691. 
 
107. Song, H. and J. Cerny, Functional heterogeneity of marginal zone B cells 
revealed by their ability to generate both early antibody-forming cells and 
germinal centers with hypermutation and memory in response to a T-
dependent antigen. J Exp Med, 2003. 198(12): p. 1923-35. 
 
108. McHeyzer-Williams, L.J., M. Cool, and M.G. McHeyzer-Williams, Antigen-
specific B cell memory: Expression and replenishment of a novel B220(-) 
memory B cell compartment. J Exp Med, 2000. 191(7): p. 1149-1165. 
 
109. Driver, D.J., et al., Development and maintenance of a B220- memory B cell 
compartment. J Immunol, 2001. 167: p. 1393–1405. 
 
110. McHeyzer-Williams, L.J., M. Cool, and M.G. McHeyzer-Williams, Antigen-
specific B cell memory: expression and replenishment of a novel b220(-) 
memory b cell compartment. J Exp Med, 2000. 191(7): p. 1149-66. 
 
111. Bell, J. and D. Gray, Antigen-capturing cells can masquerade as memory B 
cells. J Exp Med, 2003. 197(10): p. 1233-44. 
 
112. Bernasconi, N.L., E. Traggiai, and A. Lanzavecchia, Maintenance of 
serological memory by polyclonal activation of human memory B cells. 
Science, 2002. 298(5601): p. 2199-202. 
 
113. Askonas, B.A., A.R. Williamson, and B.E.G. Wright, Selection of a single 
antibody-forming cell clone and its propagation in syngeneic mice. Proc Natl 
Acad Sci U S A, 1970. 67(3): p. 1398-1403. 
 
114. Gray, D. and H. Skarvall, B-cell memory is short-lived in the absence of 
antigen. Nature, 1988. 336(6194): p. 70-73. 
 
115. Tew, J.G., et al., Follicular dendritic cells as accessory cells. Immunol Rev, 
1990. 117: p. 185-211. 
 
116. Mandel, T.E., et al., The follicular dendritic cell -- long-term antigen retention 





117. Tew, J.G., R.P. Phipps, and T.E. Mandel, The maintainance and regulation of 
the humoral immune-response -- persisting antigen and the role of follicular 
antigen-binding dendritic cells as accessory cells. Immunol Rev, 1980. 53: p. 
175-201. 
 
118. Tew, J.G. and T.E. Mandel, Prolonged antigen half-life in the lymphoid 
follicles of specifically immunized mice. Immunology, 1979. 37(1): p. 69-76. 
 
119. Hannum, L.G., et al., Germial center initiation, variable gene region 
hypermutation, and mutant B cell selection without detectable immune 
complexes on follicular dendritic cells. J Exp Med, 2000. 192(7): p. 931-942. 
 
120. Maruyama, M., K.P. Lam, and K. Rajewsky, Memory B-cell persistence is 
independent of persisting immunizing antigen. Nature, 2000. 407(6804): p. 
636-42. 
 
121. Cassese, G., et al., Plasma cell survival is mediated by synergistic effects of 
cytokines and adhesion-dependent signals. J Immunol, 2003. 171(4): p. 1684-
1690. 
 
122. Minges-Wols, H.A., et al., The role of bone marrow-derived stromal cells in 
the maintenance of plasma cell longevity. J Immunol, 2002. 169(8): p. 4213-
4221. 
 
123. Manz, R.A., A. Thiel, and A. Radbruch, Lifetime of plasma cells in the bone 
marrow. Nature, 1997. 388(6638): p. 133-134. 
 
124. Tokoyoda, K., et al., Cellular niches controlling B lymphocyte behavior 
within bone marrow during development. Immunity, 2004. 20: p. 707–718. 
 
125. Slifka, M.K., et al., Humoral immunity due to long-lived plasma cells. 
Immunity, 1998. 8(3): p. 363-72. 
 
126. Manz, R.A., et al., Survival of long-lived plasma cells is independent of 
antigen. Int Immunol, 1998. 10: p. 1703-1711. 
 
127. Moreaux, J., et al., BAFF and APRIL protect myeloma cells from apoptosis 
induced by interleukin 6 deprivation and dexamethasone. Blood, 2004. 
103(8): p. 3148-3157. 
 
128. O'Connor B, P., et al., BCMA is essential for the survival of long-lived bone 
marrow plasma cells. J Exp Med, 2004. 199(1): p. 91-97. 
 
129. Kawano, M.M., et al., Differentiation of early plasma-cells on bone-marrow 
stromal cells requires interleukin-6 for escaping from apoptosis. Blood, 1995. 





130. Roldan, E. and J.A. Brieva, Terminal differentiation of human bone-marrow 
cells capable of spontaneous and high-rate imunoglobulin secretion - role of 
bone-marrow stromal cells and interleukin-6. Eur J Immunol, 1991. 21(11): p. 
2671-2677. 
 
131. Spets, H., et al., Expression of the bcl-2 family of pro- and anti-apoptotic 
genes in multiple myeloma and normal plasma cells: regulation during 
interleukin-6 (IL-6)-induced growth and survival. Eur J Haematol, 2002. 69: 
p. 76-89. 
 
132. Puthier, D., et al., Differential expression of Bcl-2 in human plasma cell 
disorders according to proliferation status and malignancy. Leukemia, 1999. 
13: p. 289-294. 
 
133. Tarte, K., et al., Gene expression profiling of plasma cells and plasmablasts: 
toward a better understanding of the late stages of B-cell differentiation. 
Blood, 2003. 102(2): p. 592-600. 
 
134. Radbruch, A., et al., Competence and competition: the challenge of becoming 
a long-lived plasma cell. Nat Rev Immunol, 2006. 6(10): p. 741-50. 
 
135. Mamani-Matsuda, M., et al., The human spleen is a major reservoir for long-
lived vaccinia virus-specific memory B cells. Blood, 2008. 111(9): p. 4653-
4659. 
 
136. Martinez-Gamboa, L., et al., Role of the spleen in peripheral memory B-cell 
homeostasis in patients with autoimmune thrombocytopenia purpura. Clin 
Immunol, 2009. 130(2): p. 199-212. 
 
137. Hikida, M., et al., PLC-gamma2 is essential for formation and maintenance of 
memory B cells. J Exp Med, 2009. 206(3): p. 681-9. 
 
138. Lam, K.P., R. Kuhn, and K. Rajewsky, In vivo ablation of surface 
immunoglobulin on mature B cells by inducible gene targeting results in rapid 
cell death. Cell, 1997. 90(6): p. 1073-83. 
 
139. Kraus, M., et al., Survival of resting mature B lymphocytes depends on BCR 
signaling via the Igalpha/beta heterodimer. Cell, 2004. 117(6): p. 787-800. 
 
140. Avery, D.T., et al., BAFF selectively enhances the survival of plasmablasts 
generated from human memory B cells. J Clin Invest, 2003. 112(2): p. 286-97. 
 
141. Benson, M.J., et al., Cutting edge: the dependence of plasma cells and 
independence of memory B cells on BAFF and APRIL. J Immunol, 2008. 





142. Tangye, S.G., et al., Intrinsic differences in the proliferation of naive and 
memory human B cells as a mechanism for enhanced secondary immune 
responses. J Immunol, 2003. 170(2): p. 686-94. 
 
143. Vieira, P. and K. Rajewsky, Persistence of memory B cells in mice deprived of 
T cell help. Int Immunol, 1990. 2(6): p. 487-94. 
 
144. Karrer, U., et al., Antiviral B cell memory in the absence of mature follicular 
dendritic cell networks and classical germinal centers in TNFR1-/- mice. J 
Immunol, 2000. 164: p. 768–778. 
 
145. Weng, N.P., L. Granger, and R.J. Hodes, Telomere lengthening and 
telomerase activation during human B cell differentiation. Proc Natl Acad Sci 
U S A, 1997. 94(20): p. 10827-32. 
 
146. Norrback, K.F., et al., Telomerase activation in normal B lymphocytes and 
non-Hodgkin's lymphomas. Blood, 1996. 88: p. 222-229. 
 
147. Norrback, K.F., et al., Telomerase regulation and telomere dynamics in 
germinal centers. Eur J Haematol, 2001. 67: p. 309-317. 
 
148. Weng, N.P., L. Granger, and R.J. Hodes, Telomere lengthening and 
telomerase activation during human B cell differentiation. Proc Natl Acad Sci 
U S A, 1997. 94(10827-10832). 
 
149. Igarashi, H. and N. Sakaguchi, Telomerase activity is induced in human 
peripheral B lymphocytes by the stimulation to antigen receptor. Blood, 1997. 
89: p. 1299-1307. 
 
150. Hu, B.T., et al., Telomerase is up-regulated in human germinal center B cells 
in vivo and can be re-expressed in memeory B cells activated in vitro. J 
Immunol, 1997. 159: p. 1068-1071. 
 
151. Klein, U., et al., Transcriptional analysis of the B cell germinal center 
reaction. Proc Natl Acad Sci U S A, 2003. 100(5): p. 2639-44. 
 
152. Gray, D., I.C. MacLennan, and P.J. Lane, Virgin B cell recruitment and the 
lifespan of memory clones during antibody responses to 2,4-di-nitrophenyl-
hemocyanin. Eur J Immunol, 1986. 16: p. 641-648. 
 
153. Schittek, B. and K. Rajewsky, Maintenance of B-cell memory by long-lived 






154. Good, K.L. and S.G. Tangye, Decreased expression of Kruppel-like factors in 
memory B cells induces the rapid response typical of secondary antibody 
responses. Proc Natl Acad Sci U S A, 2007. 104(33): p. 13420-5. 
 
155. Shimoda, M., et al., Role of MHC class II on memory B cells in post-germinal 
center B cell homeostasis and memory response. J Immunol, 2006. 176(4): p. 
2122-2133. 
 
156. Duddy, M., et al., Distinct Effector Cytokine Profiles of Memory and Naive 
Human B Cell Subsets and Implications in Multiple Sclerosis. J Immunol, 
2007. 178: p. 6092-6099. 
 
157. Fecteau, J.F. and S. Neron, CD40 stimulation of human peripheral B 
lymphocytes: distinct response from naive and memory cells. J Immunol, 
2003. 171(9): p. 4621-9. 
 
158. Arpin, C., J. Banchereau, and Y.J. Liu, Memory B cells are biased towards 
terminal differentiation: a strategy that may prevent repertoire freezing. J Exp 
Med, 1997. 186(6): p. 931-40. 
 
159. Rijkers, E.S., et al., The inhibitory CD200R is differentially expressed on 
human and mouse T and B lymphocytes. Mol Immunol, 2007. 0(0): p. 0. 
 
160. Bernasconi, N.L., N. Onai, and A. Lanzavecchia, A role for Toll-like receptors 
in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B 
cells and constitutive expression in memory B cells. Blood, 2003. 101(11): p. 
4500-4. 
 
161. Krieg, A.M., et al., CpG motifs in bacterial DNA trigger direct B-cell 
activation. Nature, 1995. 374(6522): p. 546-9. 
 
162. Crotty, S., et al., Tracking human antigen-specific memory B cells: a sensitive 
and generalized ELISPOT system. J Immunol Methods, 2004. 286. 
 
163. Kim, H.J., et al., Plasma cell development in synovial germinal centers in 
patients with rheumatoid arthritis. J Immunol, 1999. 162(5): p. 3053-3062. 
 
164. Schroder, A.E., et al., Differentiation of B cells in the non-lympoid tissue of 
the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad 
Sci U S A, 1996. 93(1): p. 221-225. 
 
165. Harwood, N.E. and F.D. Batista, New insights into the early molecular events 
underlying B cell activation. Immunity, 2008. 28(5): p. 609-19. 
 
166. Stoddart, A., et al., Lipid rafts unite signaling cascades with clathrin to 




167. Clark, M.R., et al., Molecular mechanisms of B cell antigen receptor 
trafficking. Ann. N Y Acad. Sci., 2003. 987: p. 26-37. 
 
168. Malhorta, S., et al., B cell antigen receptor endocytosis and antigen 
presentation to T cells require Vav and Dynamin. J Biol Chem, 2009. 
284(36): p. 24088-24097. 
 
169. Stoddart, A., A.P. Jackson, and F.M. Brodsky, Plasticity of B cell receptor 
internalization upon conditional depletion of clathrin. Mol Biol Cell, 2005. 
16(5): p. 2339-2348. 
 
170. Ma, H., et al., Visualization of Syk-antigen receptor interactions using green 
fluorescent protein: Differential roles for Syk and Lyn in te regulation of 
receptor capping and internalization. J Immunol, 2001. 166(3): p. 1507-1516. 
 
171. Cherukuri, A., et al., The CD19/CD21 complex functions to prolong B cell 
antigen receptor. Immunity, 2001. 14(2): p. 169-79. 
 
172. Gazumyan, A., A. Reichlin, and M.C. Nussenzweig, Igβ tyrosine residues 
contribute to the control of B cell receptor signaling by regulating receptor 
internalization. J. Exp. Med., 2006. 203: p. 1785–94. 
 
173. Shinohara, H. and T. Kurosaki, Genetic analysis of B cell signaling. Subcell. 
Biochem. , 2006. 40: p. 145–87. 
 
174. Tolar, P., et al., The constant region of the membrane immunoglobulin 
mediates B-cell receptor clustering and signaling in response to membrane 
antigens. Immunity, 2009. 30(1): p. 44-55. 
 
175. Pape, K.A., et al., The humoral immune response is initiated in lymph nodes 
by B cells that acquire soluble antigen directly in the follicles. Immunity, 
2007. 26: p. 491–502. 
 
176. Sohn, H.W., H. Gu, and S.K. Pierce, Cbl-b negatively regulates B cell antigen 
receptor signaling in mature B. J Exp Med, 2003. 197(11): p. 1511-24. 
 
177. Batista, F.D., D. Iber, and M.S. Neuberger, B cells acquire antigen from 
target cells after synapse formation. Nature, 2001. 411(6836): p. 489-94. 
 
178. Qi, H., et al., Extrafollicular activation of lymph node B cells by antigen-
bearing dendritic cells. Science, 2006. 312: p. 1672 – 1676. 
 
179. Carrasco, Y.R. and F.D. Batista, B cells acquire particulate antigen in a 
macrophage-rich area at the boundary between the follicle and the 





180. Depoil, D., et al., CD19 is essential for B cell activation by promoting B cell 
receptor-antigen microcluster formation in response to membrane-bound 
ligand. Nat Immunol, 2008. 9(1): p. 63-72. 
 
181. Kabak, S., et al., The direct recruitment of BLNK to immunoglobulin alpha 
couples the B-cell antigen receptor to distal signaling pathways. Mol Cell 
Biol, 2002. 22(8): p. 2524-2535. 
 
182. Engels, N., B. Wollscheid, and J. Wienands, Association of SLP-65/BLNK 
with the B cell antigen receptor through a non-ITAM tyrosine of Ig-alpha. Eur 
J Immunol, 2001. 31(7): p. 2126-2134. 
 
183. Sohn, H.W., P. Tolar, and S.K. Pierce, Membrane heterogeneities in the 
formation of B cell receptor-Lyn kinase microclusters and the immune 
synapse. J Cell Biol, 2008. 182(2): p. 367-79. 
 
184. Tolar, P., H.W. Sohn, and S.K. Pierce, The initiation of antigen-induced B cell 
antigen receptor signaling viewed in living cells by fluorescence resonance 
energy transfer. Nat Immunol, 2005. 6(11): p. 1168-76. 
 
185. Hanke, J.H., et al., Discovery of a novel, potent and Src family-selective 
tyrosine kinase inhibitor. J Biol Chem, 1996. 271: p. 695-701. 
 
186. Sohn, H.W., et al., Fluorescence resonance energy transfer in living cells 
reveals dynamic membrane changes in the initiation of B cell signaling. Proc 
Natl Acad Sci U S A, 2006. 103(21): p. 8143-8. 
 
187. Dykstra, M.L., A. Cherukuri, and S.K. Pierce, Floating the raft hypothesis for 
immune receptors: access to rafts. Traffic, 2001. 2(3): p. 160-6. 
 
188. Sada, K., et al., Structure and function of Syk protein-tyrosine kinase. J 
Biochem, 2001. 130(2): p. 177-186. 
 
189. Deindl, S., et al., Structural basis for the inhibition of tyrosine kinase activity 
of ZAP-70. Cell, 2007. 129: p. 735–46. 
 
190. Kulathu, Y., G. Grothe, and M. Reth, Autoinhibition and adapter function of 
Syk. Immunol Rev, 2009. 232: p. 286-299. 
 
191. Ishiai, M., et al., BLNK required for coupling Syk to PLC gamma 2 and Rac1-
JNK in B cells. Immunity, 1999. 10(1): p. 117-125. 
 
192. Kurosaki, T. and S. Tsukada, BLNK: Connecting Syk and Btk to calcium 





193. Cambier, J.C. and K.S. Campbell, Membrane immunoglobulin and its 
accomplices-new lessons from an old receptor. FASEB J, 1992. 6(13): p. 
3207-3217. 
 
194. Takata, M. and T. Kurosaki, A role fo Bruton's tyrosine kinase in B cell 
antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp 
Med, 1996. 184(1): p. 31-40. 
 
195. Hashimoto, A., et al., Involvement of guanosine triphosphatases and 
phospholipase C-gamma 2 in extracellular signal-regulated kinase, c-Jun 
NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by 
the B cell antigen receptor. J Exp Med, 1998. 188(7): p. 1287-1295. 
 
196. Kurosaki, T. and M. Hikida, Tyrosine kinases and their substrates in B cells. 
Immunol Rev, 2009. 228(132-148). 
 
197. Sharma, S., G. Orlowski, and W. Song, Btk regulates B cell receptor-mediated 
antigen processing and presentation by controlling actin cytoskeleton 
dynamics in B cells. J Immunol, 2009. 182(1): p. 329-339. 
 
198. Okada, T., et al., BCAP: The tyrosine kinase substrate that connects B cell 
receptor to phosphoinositide 3-kinase activation. Immunity, 2000. 13(6): p. 
817-827. 
 
199. Thomas, J.D., et al., Colocalization of X-linked agammaglobulinemia and X-
linked immunodeficiency genes. Science, 1993. 261(5119): p. 355-358. 
 
200. Rawlings, D.J., et al., Mutation of unique region of Bruton's tyrosine kinase in 
immunodeficient XID mice. Science, 1993. 261(5119): p. 358-361. 
 
201. Deane, J.A. and D.A. Fruman, Phosphoinositide 3-kinase: Diverse roles in 
immune cell activation. Annu Rev Immunol, 2004. 22(563-598). 
 
202. Werlen, G., et al., Calcineurin preferentially synergizes with PKC-theta to 
activate JNK and IL-2 promoter in T lymphocytes. EMBO J, 1998. 17(11): p. 
3101-3111. 
 
203. Brown, B.K. and W.X. Song, The actin cytoskeleton is required for the 
trafficking of the B cell antigen receptor to the late endosomes. Traffic, 2001. 
2(6): p. 414-427. 
 
204. Schafer, D.A., Coupling actin dynamics and membrane dynamics during 





205. Snyder, M.D. and S.K. Pierce, A mutation in Epstein-Barr virus LMP2A 
reveals a role for phospholipase D in B-cell antigen receptor trafficking. 
Traffic, 2006. 7(8): p. 993-1006. 
 
206. Chaturvedi, A., D. Dorward, and S.K. Pierce, The B cell receptor governs the 
subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-
containing antigens. Immunity, 2008. 28(6): p. 799-809. 
 
207. Clark, M.R., et al., B-cell antigen receptor signaling requirements for 
targeting antigen to the MHC class II presentation pathway. Curr Opin 
Immunol, 2004. 16(3): p. 382-387. 
 
208. McHeyzer-Williams, L.J., L.P. Malherbe, and M.G. McHeyzer-Williams, 
Checkpoints in memory B-cell evolution. Immunol Rev, 2006. 211: p. 255-
268. 
 
209. Onishi, K., et al., The PI3K-Akt pathway promotes microtubule stabilization 
in migrating fibroblasts. Genes to Cells, 2007. 12(4): p. 535-546. 
 
210. Zhao, Y., I. Gaidarov, and J.H. Keen, Phosphoinositide 3-kinase C2 alpha 
links clathrin to microtubule-dependent movement. J Biol Chem, 2007. 
282(2): p. 1249-1256. 
 
211. Lin, K.-I., et al., Blimp-1-dependent repression of Pax-5 is required for 
differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol 
Cell Biol, 2002. 22(13): p. 4771-4780. 
 
212. Schaffer, A.L., et al., XBP1, downstream of Blimp-1, expands the secretory 
apparatus and other organelles, and increases protein synthesis in plasma 
cell differentiation. Immunity, 2004. 21: p. 81-93. 
 
213. Reimold, A.M., et al., Plasma cell differentiation requires the transcription 
factor XBP-1. Nature, 2001. 412(6844): p. 300-307. 
 
214. Klein, U., et al., Transcription factor IRF4 controls plasma cell differentiation 
and class-switch recombination. Nat Immunol, 2006. 7(7): p. 773-82. 
 
215. Sciammas, R., et al., Graded expression of interferon regulatory factor-4 
coordinates isotype switching with plasma cell differentiation. Immunity, 
2006. 25(2): p. 225-236. 
 
216. Liu, W., et al., Intrinsic properties of immunoglobulin IgG1 isotype-switched 
B cell. Immunity, 2010. 32(6): p. 778-89. 
 
217. Dorshkind, K., IL-1 inhibits B cell differentiation in long term bone marrow 





218. Kaisho, T., F. Schwenk, and K. Rajewsky, The roles of gamma 1 heavy chain 
membrane expression and cytoplasmic tail in IgG1 responses. Science, 1997. 
276(5311): p. 412-5. 
 
219. Wakabayashi, C., et al., A distinct signaling pathway used by the IgG-
containing B cell antigen receptor. Science, 2002. 298(5602): p. 2392-5. 
 
220. Horikawa, K., et al., Enhancement and suppression of signaling by the 
conserved tail of IgG memory-type B cell antigen receptors. J Exp Med, 2007. 
204(4): p. 759-769. 
 
221. Martin, S.W. and C.C. Goodnow, Burst-enhancing role of the IgG membrane 
tail as a molecular determinant of memory. Nat Immunol, 2002. 3(2): p. 182-
8. 
 
222. Engels, N., et al., Recruitment of the cytoplasmic adaptor Grb2 to surface IgG 
and IgE provides antigen receptor-intrinsic costimulation to class-switched B 
cells. Nat Immunol, 2009. 10(9): p. 1018-25. 
 
223. Tedder, T.F., M. Inaoki, and S. Sato, The CD19-CD21 complex regulates 
signal transduction thresholds governing humoral immunity and 
autoimmunity. Immunity, 1997. 6(2): p. 107-118. 
 
224. Carter, R.H. and D. Fearon, CD19: Lowering the Threshold for Antigen 
Receptor Stimulation of B Lymphocytes. Science, 1992. 256: p. 105-107. 
 
225. Lyubchenko, T., et al., Cutting edge: Complement (C3d)-Linked antigens 
break B cell anergy. J Immunol, 2007. 179(5): p. 2695-2699. 
 
226. Takai, T., Fc receptors and their role in immune regulation and 
autoimmunity. J Clin Immunol, 2005. 25(1): p. 1-18. 
 
227. Lemaitre, B., et al., The dorsoventral regulatory gene cassette 
spatzle/Toll/cactus controls the potent antifungal response in Drosophila 
adults. Cell, 1996. 86(6): p. 973-983. 
 
228. Chaudhary, P.M., et al., Cloning and characterization of two Toll/interleukin-
1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor 
family in humans. Blood, 1998. 91: p. 4020–4027. 
 
229. Qureshi, S.T., et al., Endotoxin-tolerant mice have mutations in Toll-like 





230. Medzhitov, R., P. Preston-Hurlburt, and C.A.J. Janeway, A human homologue 
of the Drosophila Toll protein signals activation of adaptive immunity. 
Nature, 1997. 388(6640): p. 394-7. 
 
231. Hemmi, H., et al., A Toll-like receptor recognizes bacterial DNA. Nature, 
2000. 408(6813): p. 740-5. 
 
232. Takeuchi, O., et al., TLR6: a novel member of an expanding Toll-like receptor 
family. Gene, 1999. 231: p. 59–65. 
 
233. Rock, F., et al., A family of human receptors structurally related to 
Drosophila Toll. Proc. Natl. Acad. Sci. USA, 1998. 95: p. 588–593. 
 
234. Poltorak, A., et al., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr 
mice: mutations in Tlr4 gene. Science, 1998. 282: p. 2085–2088. 
 
235. Sebastiani, G., et al., Cloning and Characterization of the Murine Toll-like 
Receptor 5 (Tlr5) Gene: Sequence and mRNA Expression Studies in 
Salmonella-Susceptible MOLF/Ei Mice. Genomics, 2000. 64: p. 230–240. 
 
236. Heine, H., et al., Cells that carry a null allele for Toll-like receptor 2 are 
capable of responding to endotoxin. J. Immunol., 1999. 162: p. 6971–6975. 
 
237. Hoshino, K., et al., Toll-like receptor 4 (TLR4)-deficient mice are 
hyporesponsive to lipopolysaccharide: evidence for Tlr4 as the Lps gene 
product. J Immunol, 1999. 162: p. 3749–3752. 
 
238. Yarovinsky, F., et al., TLR11 activation of dendritic cells by a protozoan 
profilin-like protein. Science, 2005. 308(5728): p. 1626-1629. 
 
239. Tabeta, K., et al., Toll-like receptors 9 and 3 as essential components of innate 
immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci 
U S A, 2004. 101(10): p. 3516-21. 
 
240. Miyake, K., et al., Murine B cell proliferation and protection from apoptosis 
with and antibody against a 105-kD molecule: unresponsiveness of X-linked 
immunodeficient B cells. J Exp Med, 1994. 180(1217-1224). 
 
241. Miyake, K., et al., RP105, a novel B cell surface molecule implicated in B cell 
activation, is a member of the leucine-rich repeat protein family. J Immunol, 
1995. 154: p. 3333-3340. 
 
242. Heil, F., et al., The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine 
uncovers a strong relationship with the TLR7, 8 and 9 subfamily. Eur J 





243. Ahmad-Nejad, P., et al., Bacterial CpG-DNA and lipopolysaccharides 
activate Toll-like receptors at distinct cellular compartments. Eur J Immunol, 
2002. 32(7): p. 1958-68. 
 
244. Barton, G.M., J.C. Kagan, and R. Medzhitov, Intracellular localization of 
Toll-like receptor 9 prevents recognition of self DNA but facilitates access to 
viral DNA. Nat Immunol, 2006. 7(1): p. 49-56. 
 
245. Akira, S., TLR Signaling. Current Topics in Microbiology and Immunology, 
2006. 311: p. 1-16. 
 
246. Yoshimura, A., et al., Recognition of gram-positive bacterial cell wall 
comonents by the innate immune system occurs via Toll-like receptor 2. J. 
Immunol., 1999. 163: p. 1-5. 
 
247. Schwander, R., et al., Peptidoglycan- and lipoteichoic acid-induced cell 
activation is mediated by Toll-like receptor 2. J. Biol. Chem, 1999. 274: p. 
17406–17409. 
 
248. Yang, R., et al., Toll-like Receptor-2 mediates Lipopolysaccharide-induced 
cellular signalling. Nature, 1998. 395: p. 284–288. 
 
249. Kirschning, C.J., et al., Human Toll-like receptor 2 confers responsiveness to 
bacterial lipopolysaccharide. J. Exp. Med., 1998. 188: p. 2091–2097. 
 
250. Massari, P., et al., Cutting edge: Immune stimulation by neisserial porins is 
toll-like receptor 2 and MyD88 dependent. J Immunol, 2002. 168(4): p. 1533-
7. 
 
251. Alexopoulou, L., et al., Recognition of double-stranded RNA and activation of 
NF-kappaB by Toll-like receptor 3. Nature, 2001. 413: p. 732-738. 
 
252. Hayashi, F., et al., The innate immune response to bacterial flagellin is 
mediated by Toll-like receptor 5. Nature, 2001. 410: p. 1099-1103. 
 
253. Hemmi, H., et al., Small antiviral compounds activate immune cells via the 
TLR7 MyD88-dependent signaling pathway. Nat Immunol, 2002. 3: p. 196-
200. 
 
254. Jurk, M., et al., Human TLR7 or TLR8 independently confer responsiveness to 
the antiviral compound R-848. Nat Immunol, 2002. 3. 
 
255. Diebold, S.S., et al., Innate antiviral responses by means of TLR7-mediated 




256. Hartmann, G., et al., Delineation of a CpG phosphorothioate 
oligodeoxynucleotide for activating primate immune responses in vitro and in 
vivo. J Immunol, 2000. 164: p. 1617-1624. 
 
257. Hartmann, G. and A.M. Krieg, Mechanism and function of a newly identified 
CpG DNA motif in human primary B cells. J Immunol, 2000. 164: p. 944-953. 
 
258. Bauer, S., et al., Human TLR9 confers responsiveness to bacterial DNA via 
species-specific CpG motif recognition. Proc Natl Acad Sci U S A, 2001. 98: 
p. 9237-9242. 
 
259. Takeshita, F., et al., Cutting edge: Role of Toll-like receptor 9 in CpG DNA-
induced activation of human cells. J Immunol, 2001. 167(7): p. 3555-8. 
 
260. Coban, C., et al., Toll-like receptor 9 mediates innate immune activation by 
the malaria pigment hemozoin. J Exp Med, 2005. 201: p. 19-25. 
 
261. Haas, T., et al., The DNA sugar backbone 2' deoxyribose determines Toll-like 
receptor 9 activation. Immunity, 2008. 28(3): p. 315-323. 
 
262. Krieg, A.M., CpG motifs in bacterial DNA and their immune effects. Annu 
Rev Immunol, 2002. 20: p. 709-60. 
 
263. Hasan, U., et al., Human TLR10 is a functional receptor, expressed by B cells 
and plasmacytoid dendritic cells, which activates gene transcription through 
MyD88. J Immunol, 2005. 174(5): p. 2942-50. 
 
264. Zhang, D.K., et al., A Toll-like receptor that prevents infection by 
uropathogenic bacteria. Science, 2004. 303(5663): p. 1522-1526. 
 
265. Yuan, X. and K.R. Wilhelmus, Toll-like receptors involved in the 
pathogenesis of experimental Candida albicans Keratitis. Investigative 
Ophthalmology & Visual Science, 2010. 51(4): p. 2094-2100. 
 
266. Shi, Z., et al., Transcriptional regulation of the novel Toll-like receptor Tlr13. 
J Biol Chem, 2009. 284(31): p. 20540-7. 
 
267. Mishra, B.B., U.M. Gundra, and J.M. Teale, Expression and distribution of 
Toll-like receptors 11-13 in the brain during murine neurocysticerosis. J 
Neuroinflammation, 2008. 5(1). 
 
268. Ogata, H., et al., The toll-like receptor protein RP105 regulates 





269. Nagai, Y., et al., The radioprotective 105/MD-1 complex links TLR2 and 
TLR4/MD-2 in antibody response to microbial membranes. J Immunol, 2005. 
174(11): p. 7043-9. 
 
270. Akira, S., S. Uematsu, and O. Takeuchi, Pathogen recognition and innate 
immunity. Cell, 2006. 124(4): p. 783-801. 
 
271. Bourke, E., et al., The toll-like receptor repertoire of human B lymphocytes: 
inducible and selective expression of TLR9 and TLR10 in normal and 
transformed cells. Blood, 2003. 102(3): p. 956-63. 
 
272. Dasari, P., et al., Expression of toll-like receptors on B lymphocytes. Cell 
Immunol, 2005. 236(1-2): p. 140-5. 
 
273. Barr, T.A., et al., TLR-mediated stimulation of APC: Distinct cytokine 
responses of B cells and dendritic cells. Eur J Immunol, 2007. 37(11): p. 
3040-53. 
 
274. Genestier, L., et al., TLR agonists selectively promote terminal plasma cell 
differentiation of B cell subsets specialized in thymus-independent responses. 
J Immunol, 2007. 178(12): p. 7779-86. 
 
275. Gururajan, M., J. Jacob, and B. Pulendran, Toll-like receptor expression and 
responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS 
ONE, 2007. 2(9): p. e863. 
 
276. Takahashi, K., et al., A protein associated with Toll-like receptor (TLR) 4 
(PRAT4A) is required for TLR-dependent immune responses. J Exp Med, 
2007. 204(12): p. 2963-76. 
 
277. Meyer-Bahlburg, A., S. Khim, and D.J. Rawlings, B cell intrinsic TLR signals 
amplify but are not required for humoral immunity. J Exp Med, 2007. 
204(13): p. 3095-101. 
 
278. Good, K.L., D.T. Avery, and S.G. Tangye, Resting human memory B cells are 
intrinsically programmed for enhanced survival and responsiveness to diverse 
stimuli compared to naive B cells. J Immunol, 2009. 182(2): p. 890-901. 
 
279. Dorner, M., et al., Plasma cell toll-like receptor (TLR) expression differs from 
that of B cells, and plasma cell TLR triggering enhances immunoglobulin 
production. Immunology, 2009. 128(4): p. 573-9. 
 
280. Yang, Y., et al., Heat shock protein gp96 is a master chaperone for Toll-like 
receptors and is important in the innate function of macrophages. Immunity, 





281. Kiyokawa, T., et al., A single base mutation in the PRAT4A gene reveals 
differential interaction of PRAT4A with Toll-like receptors. Int Immunol, 
2008. 20(11): p. 1407-1415. 
 
282. Schnare, M., et al., Toll-like receptors control activation of adaptive immune 
responses. Nat. Immunol, 2001. 2: p. 947–950. 
 
283. Day, N., et al., Interleukin receptor-associated kinase (IRAK-4) deficiency 
associated with bacterial infections and failure to sustain antibody responses. 
J Pediatrics, 2004. 144(4): p. 524-526. 
 
284. Ehlers, M., et al., TLR9/MyD88 signaling is required for class switching to 
pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med, 2006. 203(3): p. 
553-61. 
 
285. Ehlers, M. and J.V. Ravetch, Opposing effects of Toll-like receptor 
stimulation induce autoimmunity or tolerance. Trends in Immunol, 2007. 
28(2): p. 74-79. 
 
286. Deane, J.A. and S. Bolland, Nucleic acid-sensing TLRs as modifiers of 
autoimmunity. J Immunol, 2006. 177: p. 6573-6578. 
 
287. Ruprecht, C.R. and A. Lanzavecchia, Toll-like receptor stimulation as a third 
signal required for activation of human naive B cells. Eur J Immunol, 2006. 
36(4): p. 810-6. 
 
288. Pasare, C. and R. Medzhitov, Control of B-cell responses by Toll-like 
receptors. Nature, 2005. 438(7066): p. 364-8. 
 
289. Gavin, A.L., et al., Adjuvant-enhanced antibody responses in the absence of 
toll-like receptor signaling. Science, 2006. 314(5807): p. 1936-8. 
 
290. Pasparakis, M., et al., Immune and inflammator responses in TNF alpha-
deficient mice: A critical requirement for TNF alpha in the formation of 
primary B cell follicles, follicular dendritic cell networks and germinal 
centers, and in the maturation of the humoral immune response. J Exp Med, 
1996. 184(4): p. 1397-1141. 
 
291. Muraguchi, A., et al., The essential role of B cell stimulatory factor 2 (BSF-
2/IL-6) for the terminal differentiation of B cells. J Exp Med, 1988. 167(2): p. 
332-344. 
 
292. Trinchieri, G., Interleukin-12: a cytokine produced by antigen-presenting cells 
with immunoregulatory functions in the generation of T-helper cells, type 1 





293. Rahman, A.H., D.K. Taylor, and L.A. Turka, The contribution of direct TLR 
signaling to T cell responses. Immunologic Research, 2009. 45(1): p. 25-36. 
 
294. Ozaki, K., et al., Regulation of B cell differentiation and plasma cell 
generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol., 2004. 
173: p. 5361–5371. 
 
295. Ettinger, R., et al., IL-21 induces differentiation of human naive and memory 
B cells into antibody-secreting plasma cells. J Immunol, 2005. 175(12): p. 
7867-79. 
 
296. Ettinger, R., et al., IL-21 and BAFF/BLyS synergize in stimulating plasma cell 
differentiation. J Immunol, 2007. 178(5): p. 2872-82. 
 
297. Ozaki, K., et al., A critical role for IL-21 in regulating immunoglobulin 
production. Science, 2002. 298: p. 1630–1634. 
 
298. Akashi-Takemura, S. and K. Miyake, TLR accessory molecules. Curr Opin 
Immunol, 2008. 20: p. 420-425. 
 
299. Ma, Y., et al., Assessing the immunopotency of Toll-like receptor agonists in 
an in vitro tissue-engineered immunological model. Immunology, 2010. 
130(3): p. 374-87. 
 
300. Bishop, G.A., et al., Molecular mechanisms of B lymphocyte activation by the 
immune response modifier R-848. J Immunol, 2000. 165(10): p. 5552-7. 
 
301. Weeratna, R.D., et al., TLR agonists as vaccine adjuvants: comparison of 
CpG ODN and Resiquimod (R-848). Vaccine, 2005. 23(45): p. 5263-70. 
 
302. Kindler, V. and R.H. Zubler, Memory, but not naive, peripheral blood B 
lymphocytes differentiate into Ig-secreting cells after CD40 ligation and 
costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. J 
Immunol, 1997. 159(5): p. 2085-90. 
 
303. Jung, J., et al., Distinct response of human B cell subpopulations in 
recognition of an innate immune signal, CpG DNA. J Immunol, 2002. 169(5): 
p. 2368-73. 
 
304. Christensen, S.R., et al., Toll-like receptor 9 controls anti-DNA autoantibody 
production in murine lupus. J Exp Med, 2005. 202(2): p. 321-31. 
 
305. Lau, C.M., et al., RNA-associated autoantigens activate B cells by combined B 
cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med, 2005. 





306. Nickerson, K.M., et al., TLR9 regulates TLR7- and MyD88-dependent 
autoantibody production and disease in a murine model of lupus. J Immunol, 
2010. 184(4): p. 1840-8. 
 
307. Christensen, S.R., et al., Toll-like receptor 7 and TLR9 dictate autoantibody 
specificity and have opposing inflammatory and regulatory roles in a murine 
model of lupus. Immunity, 2006. 25(3): p. 417-28. 
 
308. Pisitkun, P., et al., Autoreactive B cell responses to RNA-related antigens due 
to TLR7 gene duplication. Science, 2006. 312(5780): p. 1669-72. 
 
309. Deane, J.A., et al., Control of toll-like receptor 7 expression is essential to 
restrict autoimmunity and dendritic cell proliferation. Immunity, 2007. 27(5): 
p. 801-10. 
 
310. Yu, P., et al., Toll-like receptor 9-independent aggravation of 
glomerulonephritis in a novel model of SLE. Int Immunol, 2006. 18(8): p. 
1211-9. 
 
311. Lartigue, A., et al., Role of TLR9 in anti-nucleosome and anti-DNA antibody 
production in lpr. J Immunol, 2006. 177(2): p. 1349-54. 
 
312. Plotkin, S.A., Correlates of vaccine-induced immunity. Clin Infect Dis, 2008. 
47(3): p. 401-409. 
 
313. U. S. Department of Health & Human Services. Vaccines, Blood & Biologics: 
Common Ingredients in U. S. Licensed Vaccines.  2010 03/29/10 [cited 2010 
10/9/10]; approved adjuvants are: 1. aluminum salts (aluminum hydroxide, 
aluminum phosphate, alum (potassium aluminum sulfate)) 2. AS04  (approved 
for use starting October 16, 2009; contains aluminum hydroxide + 
monophosphoryl lipid A (MPL); currently only in Cervarix vaccine for human 




314. Baldridge, J.R., et al., Taking a Toll on human disease: Toll-like receptor 4 
agonsist as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol 
Ther, 2004. 4(7): p. 1129-1138. 
 
315. Karima, R., et al., The molecular pathogenesis of endotoxic shock and organ 
failure. Mol Med Tod, 1999. 5(3): p. 123-132. 
 
316. Didierlaurent, A.M., et al., AS04, an aluminum salt- and TLR4 agonist-based 
adjuvant system, induces a transient localized innate immune response 





317. Freund, J., J. Casals, and E.P. Hosmer, Sensitization and antibody formation 
after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med, 
1937. 37: p. 509–513. 
 
318. Ribi, E., et al., Lipid A and Immunotherapy. Rev Infect Dis, 1984. 6(4): p. 
567-572. 
 
319. Andersson, J., O. Sjoberg, and G. Moller, Induction of immunoglobulin and 
antibody synthesis in vitro by lipopolysaccharides. Eur J Immunol, 1972. 2: p. 
349 –353. 
 
320. den Haan, J.M.M., G. Kraal, and M.J. Bevan, Cutting Edge: 
Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that 
suppress the CD8+ T cell response. J Immunol, 2007. 178(9): p. 5429-5433. 
 
321. Horie, K. and H. Hoshi, Induction of lymph follicle formation with several 
mitogens and adjuvants in the mouse popliteal lymph node. Histol 
Histopathol, 1989. 4(1): p. 17-25. 
 
322. Hu, X.L., et al., Lipopolysaccharide induces the antiapoptotic molecules, A1 
and A20 in microvascular endothelial cells. Blood, 1998. 92(8): p. 2759-2765. 
 
323. Hwang, I.Y., et al., TLR4 signaling augments B lymphocyte migration and 
overcomes the restriction that limits access to germinal center dark zones. J 
Exp Med, 2009. 206(12): p. 2641-57. 
 
324. Snapper, C.M., et al., B cells lacking RelB are defective in proliferative 
responses, but undergo normal B cell maturation to Ig secretion and Ig class 
switching. J Exp Med, 1996. 184(4): p. 1537-1541. 
 
325. Souvannavong, V., C. Lemaire, and R. Chaby, Lipopolysaccharide protects 
primary B lymphocytes from apoptosis by preventing mitochondrial 
dysfunction and bax translocation to mitochondria. Infect Immun, 2004. 
72(6): p. 3260-3266. 
 
326. Souvannavong, V., N. Saidji, and R. Chaby, Lipopolysaccharide from 
Salmonella enterica activates NF-kappa B through both classical and 
alternative pathways in primary B lymphocytes. Infect Immun, 2007. 75(10): 
p. 4998-5003. 
 
327. Garin, A., et al., Toll-like receptor 4 signaling by follicular dendritic cells is 
pivotal for germinal center onset and affinity maturation. Immunity, 2010. 





328. Ferrantini, M., I. Capone, and F. Belardelli, Dendritic cells and cytokines in 
immune rejection of cancer. Cytokine Growth Factor Rev, 2008. 19(1): p. 93-
107. 
 
329. Adams, S., et al., Immunization of malignant melanoma patients with full-
length NY-ESO-1. J Immunol, 2008. 181(1): p. 776-84. 
 
330. Daayana, S., et al., Phase II trial of imiquimod and HPV therapeutic 
vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer, 
2010. 102(7): p. 1129-36. 
 
331. Feyerabend, S., et al., Novel multi-peptide vaccination in Hla-A2+ hormone 
sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009. 
69(9): p. 917-27. 
 
332. Firbas, C., et al., Immunogenicity and safety of different injection routes and 
schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine, 2010. 
28(12): p. 2397-407. 
 
333. Roukens, A.H., et al., Intradermal hepatitis B vaccination in non-responders 
after topical application of imiquimod (Aldara). Vaccine, 2010. 28(26): p. 
4288-93. 
 
334. Dumitru, C.D., et al., NK1.11 cells mediate the antitumor effects of a dual 
Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. 
Cancer Immunol Immunother, 2009. 58: p. 575–587. 
 
335. Ma, F., J. Zhang, and C. Zhang, The TLR7 agonists imiquimod and 
gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell 
Mol Immunol, 2010. 
 
336. Baldwin, S.L., et al., Intradermal immunization improves protective efficacy 
of a novel TB vaccine candidate. Vaccine, 2009. 27(23): p. 3063-71. 
 
337. Fransen, F., et al., Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates 
for use as adjuvants in an outer membrane vaccine against Neisseria 
meningitidis serogroup B. Infect Immun, 2007. 75(12): p. 5939-46. 
 
338. Honda, K., et al., IRF-7 is the master regulator of type-I interferon-dependent 
immune responses. Nature, 2005. 434(7034): p. 772-7. 
 
339. Murad, Y.M. and T.M. Clay, CpG oligodeoxynucleotides as TLR9 agonists: 
therapeutic applications in cancer. BioDrugs, 2009. 23(6): p. 361-75. 
 
340. Walker, P.S., et al., Immunostimulatory oligodeoxynucleotides promote 




and IFN-gamma-dependent mechanisms. Proc. Natl. Acad. Sci. USA, 1999. 
96: p. 6970–6975. 
 
341. Raman, V.S., et al., Applying TLR synergy in immunotherapy: implications in 
cutaneous leishmaniasis. J Immunol, 2010. 185(3): p. 1701-10. 
 
342. Jegerlehner, A., et al., TLR9 signaling in B cells determines class switch 
recombination to IgG2a. J Immunol, 2007. 178(4): p. 2415-20. 
 
343. Brynjolfsson, S.F., et al., Neonatal immune response and serum bactericidal 
activity induced by a meningococcal conjugate vaccine is enhanced by LT-
K63 and CpG2006. Vaccine, 2008. 26(35): p. 4557-62. 
 
344. Coutinho, A., et al., Mechanism of thymus-independent immunocyte 
triggering: mitogenic activation of B cells results in specific immune 
responses. J Exp Med, 1974. 139: p. 74-92. 
 
345. Davis, H.L., et al., CpG DNA is a potent enhancer of specific immunity in 
mice immunized with recombinant hepatitis B surface antigen. J Immunol 
1998. 160(2): p. 870–6. 
 
346. Klinman, D.M., K.M. Barnhart, and J. Conover, CpG motifs as immune 
adjuvants. Vaccine, 1999. 17(1): p. 19-25. 
 
347. Klinman, D.M., et al., Contribution of cells at the site of DNA vaccination to 
the generation of antigen-specific immunity and memory. J Immunol, 1998. 
160(5): p. 2388-92. 
 
348. Klinman, D.M., et al., CpG motifs present in bacteria DNA rapidly induce 
lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. 
Proc Natl Acad Sci USA, 1996. 93(7): p. 2879–83. 
 
349. McCluskie, M.J. and H.L. Davis, CpG DNA is a potent enhancer of systemic 
and mucosal immune responses against hepatitis B surface antigen with 
intranasal administration to mice. J Immunol, 1998. 161(9): p. 4463-6. 
 
350. Richard, K., S.K. Pierce, and W. Song, The agonists of TLR4 and 9 are 
sufficient to activate memory B cells to differentiate into plasma cells in vitro 
but not in vivo. J Immunol, 2008. 181(3): p. 1746-52. 
 
351. Tross, D. and D.M. Klinman, Effect of CpG oligonucleotides on vaccine-
induced B cell memory. J Immunol, 2008. 181(8): p. 5785-90. 
 
352. Weighardt, H., et al., Increased resistance against acute polymicrobial sepsis 




related to an enhanced innate effector cell response. J. Immunol, 2000. 165: 
p. 4537–4543. 
 
353. Zimmermann, S., et al., CpG oligodeoxynucleotides trigger protective and 
curative Th1 responses in lethal murine Leishmaniasis. J. Immunol., 1998. 
160: p. 3627–3630. 
 
354. Cooper, C.L., et al., CPG 7909, an immunostimulatory TLR9 agonist 
oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy 
adults: a double-blind phase I/II study. J Clin Immunol, 2004. 24(6): p. 693-
701. 
 
355. Cooper, C.L., et al., Safety and immunogenicity of CPG 7909 injection as an 
adjuvant to Fluarix. Vaccine, 2004. 22(23-24): p. 3136-43. 
 
356. Crompton, P.D., et al., The TLR9 ligand CpG promotes the acquisition of 
Plasmodium falciparum-specific memory B cells in malaria-naive individuals. 
J Immunol, 2009. 182(5): p. 3318-26. 
 
357. Ellis, R.D., et al., Phase 1 trial of the Plasmodium falciparum blood stage 
vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria 
naive adults. PLoS ONE, 2010. 5(1): p. e8787. 
 
358. Marcucci, F., et al., The future of sublingual immunotherapy. Int J 
Immunopathol Pharmacol, 2009. 22(4 Suppl): p. 31-3. 
 
359. Mullen, G.E., et al., Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an 
asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One, 
2008. 13(3(8)): p. e2940. 
 
360. Sagara, I., et al., A randomized and controlled Phase 1 study of the safety and 
immunogenicity. Vaccine, 2009. 27(52): p. 7292-8. 
 
361. Siegrist, C.A., et al., Co-administration of CpG oligonucleotides enhances the 
late affinity maturation process of human anti-hepatitis B vaccine response. 
Vaccine, 2004. 23(5): p. 615-22. 
 
362. Rahman, Z.S., et al., Normal induction but attenuated progresion of germinal 
center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med, 
2003. 198: p. 1157-1169. 
 
363. Ray, S.K., C. Putterman, and B. Diamond, Pathogenic autoantibodies are 
routinely genrated during the response to foreign antigen: a paradigm for 





364. von Boehmer, H. and F. Melchers, Checkpoints in lymphocyte development 
and autoimmune disease. Nat Immunol, 2010. 11: p. 14-20. 
 
365. Wardemann, H., et al., Predominant autoantibody production by early human 
B cell precursors. Science, 2003. 301: p. 1374-1377. 
 
366. Charles, P.J., et al., Assessment of antibodies to double-stranded DNA induced 
in rheumatoid arthritis patients following treatment with infliximab, a 
monoclonal antibody to tumor necrosis factor alpa - Findings in open-label 
and randomized placebo-controlled trials. Arthritis and Rheumatism, 2000. 
43(11): p. 2383-2390. 
 
367. Lenschow, D.J., et al., CD28/B7 regulation of Th1 and Th2 subsets in the 
development of autoimmune diabetis. Immunity, 1996. 5(3): p. 285-293. 
 
368. Peng, S.L., J. Moslehi, and J. Craft, Roles of interferon-gamma and 
interleukin-4 in murine lupus. J Clin Invest, 1997. 99(8): p. 1936-1946. 
 
369. Martinuzzo, M.E., R.R. Forastiero, and L.O. Carreras, Anti-beta(2)-
glycoprotein-I antibodies - detection and association with thrombosis. Brit J 
Haematol, 1995. 89(2): p. 397-402. 
 
370. Amoura, Z., et al., Presence of antinucleosome autoantibodies in a restricted 
set of connective tissue diseases. Arthritis and Rheumatism, 2000. 43(1): p. 
76-84. 
 
371. Desperes, et al., The Sa system - a novel antigen-antibody system-specific for 
rheumatoid arthritis. J Rheumatol, 1994. 21(6): p. 1027-1033. 
 
372. Xiao, B.G., C. Linnington, and H. Link, Antibodies to myelin-oligodendrocye 
glycoprotein n cerebrospinal-fluid from patients with multiple-sclerosis and 
controls. J Neuroimmunol, 1991. 31(2): p. 91-96. 
 
373. Miller, J.J. and L.J. Cole, Radiation resistance of long-lived lymphocytes and 
plasma cells in mouse and rat lymph nodes. J Immunol, 1967. 98(5): p. 982-
988. 
 
374. Alwayn, I.P.J., et al., Effects of specific anti-B and/or anti-plasma cell 
immunotherapy on antibody production in baboons: depletion of CD20 and 
CD22-positive B cells does not result in significantly decreased production of 
anti-alpha Gal antibody. Xenotransplantation, 2001. 8(3): p. 157-171. 
 
375. Grobler, P., et al., Cellular bases for relative radioresistance of antibody-
forming system at advanced stages of secondary response to tetanus toxoid in 





376. Hoyer, B.F., et al., Short-lived plasmablasts and long-lived plasma cells 
contribute to chronic humoral autoimmunity in  NZB/W mice. J Exp Med, 
2004. 199(11): p. 1577-1584. 
 
377. Zand, M.S., et al., Polyclonal rabbit antithymocyte globulin triggers B-Cell 
and plasma cell apoptosis by multiple pathways. Transplantation, 2005. 
79(11): p. 1507-1515. 
 
378. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of 
immunity. Nature, 1998. 392(6673): p. 245-252. 
 
379. Krieg, A.M. and J. Vollmer, Toll-like receptors 7, 8, and 9: linking innate 
immunity to autoimmunity. Immunol Rev, 2007. 220: p. 251-269. 
 
380. Lanzavecchia, A. and F. Sallusto, Toll-like receptors and innate immunity in 
B-cell activation and antibody responses. Curr Opin Immunol, 2007. 19(3): p. 
268-74. 
 
381. Lee, H.K. and A. Iwasaki, Innate control of adaptive immunity: Dendritic 
cells and beyond. Semin Immunol, 2007. 19(1): p. 48-55. 
 
382. Marshak-Rothstein, A., Toll-like receptors in systemic autoimmune disease. 
Nat Rev Immunol, 2006. 6(11): p. 823-835. 
 
383. Viglianti, G.A., et al., Activation of autoreactive B cells by CpG dsDNA. 
Immunity, 2003. 19(6): p. 837-847. 
 
384. Fenner, F., et al., Smallpox and its Eradication (WHO, Geneva, 1988). 1988. 
 
385. Strebel, P.M., et al., Epidemiology of poliomyelitis in the United States one 
decade after teh last reported case of indigenous wild virus-associated 
disease. Clin Infect Dis, 1992. 14(2): p. 568-579. 
 
386. Couch, R.B. and J.A. Kasel, Immunity to influenza in man. Annu Rev 
Microbiol, 1983. 37: p. 529-549. 
 
387. Marsh, K. and S. Kinyanjui, Immune effector mechanisms in malaria. Parasite 
Immunol, 2006. 28(1-2): p. 51-60. 
 
388. Langhorne, J., et al., Immunity to malaria: more questions than answers. Nat 
Immunol, 2008. 9(7): p. 725-732. 
 
389. Weiss, G.E., et al., The Plasmodium falciparum-specific human memory B cell 
compartment expands gradually with repeated malaria infections. PLoS 





390. Ghani, A.C., et al., Loss of population levels of immunity to malaria as a 
result of exposure-reducing interventions: Consequences for interpretation of 
disease trends. PLoS ONE, 2009. 4(2): p. e4383. 
 
391. Vekemans, J. and W.R. Ballou, Plasmodium falciparum malaria vaccines in 
development. Expert Rev Vaccines, 2008. 7(2): p. 223-240. 
 
392. Martin, R.M., J.L. Brady, and A.M. Lew, The need for IgG2c specific 
antiserum when isotyping antibodies from C57BL/6 and NOD mice. J 
Immunol Methods, 1998. 212: p. 187-192. 
 
393. Morokata, T., J. Ishikawa, and T. Yamada, Antigen dose defines T helper 1 
and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice 
independently of splenic responses. Immunol Lett, 2000. 72: p. 119-126. 
 
394. Butler, N.S., et al., Altered IL-4 mRNA stability correlates with Th1 and Th2 
bias and susceptibility to hypersensitivity pneumoinitis in two inbred strains of 
mice. J Immunol, 2002. 169: p. 3700-3709. 
 
395. Fan, J., et al., The role of post-transcriptional regulation in chemokine gene 
expression in inflammation and allergy. Eur Respirat J, 2005. 26(5): p. 933-
947. 
 
396. Obukhanych, T.V. and M.C. Nussenzweig, T-independent type II immune 
responses generate memory B cells. J Exp Med, 2006. 203(2): p. 305-10. 
 
397. Jack, R.S., T. Imanishi-Kari, and K. Rajewsky, Idiotypic analysis of the 
response of C57BL/6 mice to the (4-hydroxy-3-nitrophenyl)acetyl group. Eur J 
Immunol, 1977. 7(8): p. 559-65. 
 
398. Mäkelä, O. and K. Karjalainen, Inherited immunoglobulin idiotypes of the 
mouse. Immunol Rev, 1977. 34: p. 119-138. 
 
399. Reth, M., G.J. Hämmerling, and K. Rajewsky, Analysis of repertoire of anti-
NP antibodies in C57BL-6 mice by cell fusion. 1. Characterization of antibody 
families in primary and hyper-immune response. Eur J Immunol, 1978. 8(6): 
p. 393-400. 
 
400. Bothwell, A.L., et al., Heavy chain variable region contribution to the NPb 
family of antibodies: somatic mutation evident in a gamma 2a variable region. 
Cell, 1981. 24(3): p. 625-37. 
 
401. Cumano, A. and K. Rajewsky, Structure of primary anti-(4-hydroxy-3-
nitrophenyl)acetyl (NP) antibodies in normal and idiotypically suppressed 





402. Cumano, A. and K. Rajewsky, Clonal recruitment and somatic mutation in 
the generation of immunological memory to the hapten NP. EMBO J, 1986. 
5(10): p. 2459-68. 
 
403. O'Connor B, P., et al., Imprinting the fate of antigen-reactive B cells through 
the affinity of the B cell receptor. J Immunol, 2006. 177(11): p. 7723-32. 
 
404. Han, S., et al., Cellular interaction in germinal centers. Roles of CD40 ligand 
and B7-2 in established germinal centers. J Immunol, 1995. 155(2): p. 556-
67. 
 
405. Hollowood, K. and J.C. Macartney, Cell kinetics of the germinal center 
reaction - a stathmokinetic study. Eur J Immunol, 1992. 22(1): p. 261-266. 
 
406. Kinoshita, K., et al., Immunological memory to tetanus toxoid is established 
and maintained in the vitamin A-depleted rat. FASEB J, 1991. 5(10): p. 2473-
2481. 
 
407. Anderson, S.M., et al., New markers for murine memory B cells that define 
mutated and unmutated subsets. J Exp Med, 2007. 204(9): p. 2103-14. 
 
408. Slifka, M.K. and R. Ahmed, Limiting dilution analysis of virus-specific 
memory B cells by an ELISPOT assay. J Immunol Methods, 1996. 199(1): p. 
37-46. 
 
409. Kool, M., et al., Alum adjuvant boosts adaptive immunity by inducing uric 
acid and activating inflammatory dendritic cells. J Exp Med, 2008. 205(4): p. 
869–82. 
 
410. Nishizawa, M., et al., Effective synthesis of four isomeric trehalose 
dicorymycolates (TDCMs) and their immnoadjuvant activities. Syn Lett, 
1996. 1996(5): p. 452-4. 
 
411. Ulrich, J.T. and K.R. Myers, Monophosyphoryl lipid A as an adjuvant.  Past 
experiences and new directions. Pharm Biotechnol, 1995. 6: p. 495-524. 
 
412. Ribi, E.S., et al., Peptides as requirement for immunotherapy of the guinea-
pig line-10 tumor with endotoxins. Cancer Immunol Immunother, 1979. 7(43-
58). 
 
413. Lindblad, E.B., Aluminium adjuvants - in retrospect and prospect. Vaccine, 
2004. 22(27-28): p. 3658-3668. 
 
414. Eisenbarth, S.C., et al., Crucial role for the Nalp3 inflammasome in the 
immunostimulatory properties of aluminum adjuvants. Nature, 2008. 





415. Ouyang, W., et al., Inhibition of Th1 development mediated by GATA-3 
through and IL-4 independent mechanism. Immunity, 1998. 9: p. 745-755. 
 
416. Ho, I.C., et al., The proto-oncogene c-maf is responsible for tissue-specific 
expression of interleukin-4. Cell, 1996. 85: p. 873-983. 
 
417. Zheng, W. and R.A. Flavell, The transcription factor GATA-3 is necessary 
and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell, 1997. 
587-596. 
 
418. Thoelen, et al., Safety and immunogenicity of a hepatitis B vaccine formulated 
with a novel adjuvant system. Vaccine, 1998. 16(7): p. 708-714. 
 
419. Thompson, B.S., et al., The low-toxicity versions of LPS, MPL (R) adjuvant 
and RC529, are efficient adjuvants for CD4(+) T cells. J Leukoc Biol, 2005. 
78(6): p. 1273-1280. 
 
420. Kawai, T., et al., Unresponsiveness of MyD88-deficient mice to endotoxin. 
Immunity, 1999. 11(1): p. 115-22. 
 
421. Pasare, C. and R. Medzhitov, Toll-dependent control mechanisms of CD4 T 
cell activation. Immunity, 2004. 21(5): p. 733-41. 
 
422. Bishop, G.A., et al., The immune response modifier resiquimod mimics CD40-
induced B cell activation. Cell Immunol, 2001. 208(1): p. 9-17. 
 
423. Gibson, S.J., et al., Plasmacytoid dendritic cells produce cytokines and mature 
in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol, 
2002. 218: p. 74-86. 
 
424. Du, J., et al., TLR8 agonists stimulate newly recruited monocyte-derived cells 
into potent APCs that enhance HBsAg immunogenicity. Vaccine, 2010. 
28(38): p. 6273-81. 
 
425. Kendall, C., I. Ionescu-Matiu, and G.R. Dreesman, Utilization of the biotin 
avidin system to amplify the sensitivity of hte enzyme-linked immunosorbent-
assay (ELISA). J Immunol Methods, 1983. 56(3): p. 329-339. 
 
426. Cheru, L., et al., The IC(50) of anti-Pfs25 antibody in membrane-feeding 
assay varies among. Vaccine, 2010. 28(27): p. 4423-9. 
 
427. Nieto, A., et al., Direct measurement of antibody-affinity distribution by 






428. Hochreiter, R., et al., T(H)1-promoting DNA immunization against allergens 
modulates the ratio of IgG1/IgG2a but does not affect the anaphylactic 
potential of IgG1 antibodies: No evidence for the synthesis of nonanaphylactic 
IgG1. J Aller Clin Immunol, 2003. 112(3): p. 579-584. 
 
429. Durier, C., et al., Clinical safety of HIV lipopeptides used as vaccines in 
healthy volunteers and HIV-infected adults. AIDS, 2006. 20(7): p. 1039–49. 
 
430. Crompton, P.D., et al., A prospective analysis of the Ab response to 
Plasmodium falciparum before. Proc Natl Acad Sci U S A, 2010. 107(15): p. 
6958-63. 
 
431. Traore, B., et al., The TLR9 agonist CpG fails to enhance the acquisition of 
Plasmodium falciparum-specific memory B cells in semi-immune adults in 
Mali. Vaccine, 2009. 27(52): p. 7299-303. 
 
432. Ellis, R.D., et al., A Phase 1 study of the blood-stage malaria vaccine 
candidate. Vaccine, 2009. 27(31): p. 4104-9. 
 
433. Han, S., et al., Enhanced differentiation of splenic plasma cells but 
dimininshed long-lived high-affinity bone marrow plasma cells in aged mice. J 
Immunol, 2003. 170: p. 1267-1273. 
 
434. Beatty, J.D., B.G. Beatty, and W.G. Vlahos, Measurement of monoclonal-
antibody affinity by noncompetitive enzyme-immunoassay. J Immunol 
Methods, 1987. 100(1-2): p. 173-179. 
 
435. Narhi, L.O., et al., Fractionation and characterization of polyclonal 
antibodies using three progressively more chaotropic solvents. Analyt 
Biochem, 1997. 253: p. 246-252. 
 
436. Klinman, D.M., et al., CpG oligonucleotides improve the protective immune 
response induced by the anthrax vaccination of rhesus macaques. Vaccine, 
2004. 22: p. 2881–6. 
 
437. Gray, J.J., Avidity of EBV VCA-specific IgG antibodies: distinction between 
recent primary infection, past infection and reactivation. J Virol Methods, 
1995. 52: p. 95-104. 
 
438. Pistoia, V. and A. Corcione, Relationships between B cell cytokine production 
in secondary lymphoid follicles and apoptosis of germinal center B 
lymphocytes. Stem Cells, 1995. 13(5): p. 487-500. 
 
439. Barr, T.A., et al., TLR and B Cell Receptor Signals to B Cells Differentially 
Program Primary and Memory Th1 Responses to Salmonella enterica. J 





440. Jakob, T., et al., Activation of cutaneous dendritic cells by CpG-containing 
oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 
responses by immunostimulatory DNA. J Immunol, 1998. 161: p. 3042-3049. 
 
441. Sparwasser, T., et al., Bacterial DNA and immunostimulatory CpG 
oligonucleotides trigger maturation and activation of murine dendritic cells. 
Eur J Immunol, 1998. 28(2045-2054). 
 
442. Hartmann, G., G.J. Weiner, and A.M. Krieg, CpG DNA: a potent signal for 
growth, activation, and maturation of human dendritic cells. Proc Natl Acad 
Sci U S A, 1999. 96: p. 9305-9310. 
 
443. Hacker, H., et al., Cell type-specific activation of mitogen-activated protein 
kinases by CpG-DNA controls interleukin-12 release from antigen-presenting 
cells. EMBO J, 1999. 18: p. 6973-6982. 
 
444. Sparwasser, T. and e. al., Macrophages sense pathogens via DNA motifs: 
induction of tumor necrosis factor-a-mediated shock. Eur. J. Immunol., 1997. 
27: p. 1671-9. 
 
445. Hacker, H., et al., Immune cell activation by bacterial CpG-DNA through 
myeloid differentiation marker 88 and tumor necrosis factor receptor-
associated factor (TRAF) 6. J Exp Med, 2000. 192(4): p. 595-600. 
 
446. Reis e Sousa, C., Dendritic cells in a mature age. Nat Rev Immunol, 2006. 
6(6): p. 476-483. 
 
447. Tzeng, S.J., et al., The B cell inhibitory Fc receptor triggers apoptosis by a 
novel c-Abl family kinase-dependent pathway. J Biol Chem, 2005. 280(42): p. 
35247-54. 
 
448. Carter, R.H. and R. Myers, Germinal center structure and function: lessons 
from CD19. Semin Immunol, 2008. 20(1): p. 43-8. 
 
449. Gargano, L.M., J.M. Moser, and S.H. Speck, Role for MyD88 signaling in 
murine gammaherpesvirus 68 latency. J Virol, 2008. 82(8): p. 3853-63. 
 
450. He, B., et al., The transmembrane activator TACI triggers immunoglobulin 
class switching by activating B cells through the adaptor MyD88. Nat 
Immunol, 2010. 11(9): p. 836-45. 
 
451. Groom, J.R., et al., BAFF and MyD88 signals promote a lupuslike disease 




452. Klinman, D.M., et al., Immunostimulatory CpG oligonucleotides: Effect on 
gene expression and utility as vaccine adjuvants. Vaccine, 2010. 28(8): p. 
1919-23. 
 
453. Hsu, H.C., et al., Interleukin 17-producing T helper cells and interleukin 17 
orchestrate autoreactive germinal center development in autoimmune BXD2 
mice. Nat Immunol, 2008. 9(2): p. 166-75. 
 
454. Carragher, D.M., J. Rangel-Moreno, and T.D. Randall, Ectopic lymphoid 
tissues and local immunity. Semin Immunol, 2008. 20(1): p. 25-42. 
 
455. Luzina, I.G., et al., Spontaneous formation of germinal centers in autoimmune 
mice. J Leukoc Biol, 2001. 70(4): p. 578-584. 
 
456. Moyron-Quiroz, J.E., et al., Role of inducible bronchus associated lymphoid 
tissue (iBALT) in respiratory immunity. Nat Med, 2004. 10(9): p. 927-934. 
 
457. William, J., et al., B cell tolerance checkpoints that restrict pathways of 
antigen-driven differentiation. J Immunol, 2006. 176(4): p. 2142-51. 
 
458. Cappione, A., et al., Germinal center exclusion of autoreactive B cells is 
defective in human systemic lupus erythematosus. J Clin Invest, 2005. 
115(11): p. 3205-3216. 
 
459. Weiss, G.E., et al., Atypical memory B cells are greatly expanded in 
individuals living in a malaria-endemic area. J Immunol, 2009. 183(3): p. 
2176-82. 
 
460. Rajewsky, K., et al., The requirement of more than one antigenic determinant 
for immunogenicity. J Exp Med, 1969. 129(6): p. 1131-43. 
 
461. Tao, W., F. Hardardottir, and A.L. Bothwell, Extensive somatic mutation in 
the Ig heavy chain V genes in a late primary anti-hapten immune response. 
Mol Immunol, 1993. 30(6): p. 593-602. 
 
462. Yu, P., et al., Negative feedback regulation of IgE synthesis by murine CD23. 
Nature, 1994. 369(6483): p. 753-756. 
 
463. Cho, S.W., et al., B cell activation and Ig, especially IgE, production is 
inhibited by high CD23 levels in vivo and in vitro. Cellular Immunology, 
1997. 180(1): p. 36-45. 
 
464. Payet, M.E., E.C. Woodward, and D.H. Conrad, Humoral response 






465. Tedder, T., L. Zhou, and P. Engel, The CD19/CD21 signal-transduction 
complex of B-lymphocytes. Immunol Today, 1994. 15(9): p. 437-442. 
 
466. Cherukuri, A., et al., The CD19/CD21 complex functions to prolong B cell 
antigen receptor signaling from lipid rafts. Immunity, 2001. 14(2): p. 169-79. 
 
467. Tuveson, D., et al., CD19 of B-Cells as a Surrogate Kinase Insert Region to 
Bind Phosphatidylinositol 3-Kinase. Science, 1993. 260: p. 986-989. 
 
468. Cheng, P.C., et al., Floating the raft hypothesis: the roles of lipid rafts in B 
cell antigen receptor function. Semin Immunol, 2001. 13(2): p. 107-114. 
 
469. Pierce, S.K., Lipid rafts and B-cell activation. Nat Rev Immunol, 2002. 2(2): 
p. 96-105. 
 
470. Dempsey, P.W., et al., C3d of complement as a molecular adjuvant: bridging 
innate and acquired immunity. Science, 1996. 271(5247): p. 348-350. 
 
471. Carter, R.H. and D.T. Fearon, CD19: lowering the threshold for antigen 
receptor stimulation of B lymphocytes. Science, 1992. 256(5053): p. 105-7. 
 
472. Kurtz, C.B., et al., The murine complement receptor gene family: IV. 
Alternative splicing. J Immunol, 1990. 144: p. 3581-3591. 
 
473. Molina, H., et al., Distinct receptor and regulatory properties. J Exp Med, 
1992. 175: p. 121-129. 
 
474. Molina, H., et al., Analysis of C3b/C3d binding sites. J Immunol, 1994. 153: p. 
789-795. 
 
475. Rickert, R.C., Regulation of B lymphocyte activation by complement C3 and 
the B cell coreceptor complex. Curr Opin Immunol, 2005. 17(3): p. 237-43. 
 
476. Molina, H., et al., Characterization of a complement receptor 2 (CR2, CD21) 
ligand binding. J Immunol, 1995. 154(10): p. 5426-35. 
 
477. Molina, H., et al., Analysis of Epstein-Barr virus-binding sites on complement 
receptor 2. J Biol Chem, 1991. 266(19): p. 12173-9. 
 
478. Pepys, M.B., Role of complement in induction. J Exp Med, 1974. 140: p. 126-
145. 
 
479. Ahearn, J.M., et al., Disruption of the Cr2 locus results in a reduction in B-1a 
cells and in an impaired B cell response to T-dependent antigen. Immunity, 




480. Molina, H., et al., Markedly impaired humoral immune response in mice 
deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A, 1996. 
93(8): p. 3357-61. 
 
481. Guinamard, R., et al., Absence of marginal zone B cells in Pyk-2-deficient 
mice defines their role in the humoral response. Nat Immunol, 2000. 1(1): p. 
31-6. 
 
482. Pozdnyakova, O., et al., Impaired antibody response to group B streptococcal 
type III capsular. J Immunol, 2003. 170(1): p. 84-90. 
 
483. Whipple, E.C., et al., Analyses of the in vitro trafficking. J Immunol, 2004. 
173: p. 2297-2306. 
 
484. Ferguson, A.R., M.E. Yourd, and R.B. Corley, Marginal zone B cells 
transport. Int Immunol, 2004. 16: p. 1411-1422. 
 
485. Fang, Y., et al., Expression of complement receptors 1 and 2 on follicular 
dendritic cells is necessary for the generation of a strong antigen-specific IgG 
response. J Immunol, 1998. 160(11): p. 5273-9. 
 
486. Jacobson, A.C., J.J. Weis, and J.H. Weis, Complement receptors 1 and 2 
influence the immune environment in a B cell receptor-independent manner. J 
Immunol, 2008. 180(7): p. 5057-66. 
 
487. Jegerlehner, A., et al., Regulation of IgG antibody responses by epitope 
density and CD21-mediated costimulation. Eur J Immunol, 2002. 32(11): p. 
3305-3314. 
 
488. Fehr, T., et al., Antiviral protection and germinal center formation, but 
impaired B cell memory in the absence of CD19. J Exp Med, 1998. 188(1): p. 
145-55. 
 
489. Gatto, D., et al., Complement receptors regulate differentiation of bone 
marrow plasma cell precursors expressing transcription factors Blimp-1 and 
XBP-1. J Exp Med, 2005. 201(6): p. 993-1005. 
 
490. Culton, D.A., et al., Similar CD19 dysregulation in two autoantibody-
associated autoimmune diseases suggests a shared mechanism of B-cell 
tolerance loss. J Clin Immunol, 2007. 27(1): p. 53-68. 
 
491. Weskamp, G., et al., ADAM10 is a principal 'sheddase' of the low-affinity 





492. Hartmann, D., et al., The disintegrin/metalloprotease ADAM 10 is essential 
for Notch signalling but not for a-secretase activity in fibroblasts. Hum Mol 
Genet, 2002. 11: p. 2615-2624. 
 
493. Gibb, D.R., et al., ADAM10 is essential for Notch2-dependent marginal zone 
B cell development and CD23 cleavage in vivo. J Exp Med, 2010. 207(3): p. 
623-635. 
 
494. Fürthauer, M. and M. Gonzalez-Gaitán, Endocytic regulation of Notch 
signaling during development. Traffic, 2009. 10: p. 792-802. 
 
495. Barrington, R.A., et al., Uncoupling CD21 and CD19 of the B-cell coreceptor. 
Proc Natl Acad Sci U S A, 2009. 106(34): p. 14490-5. 
 
496. Aubry, J.P., et al., CD23 interacts with a new functional extracytoplasmic 
domain involving N-linked oligosaccharides on CD21. J Immunol, 1994. 153: 
p. 5806-5813. 
 
497. Henchoz-Lecoanet, S., et al., The Epstein-Barr virus-binding site on CD21 is 
involved in CD23 binding and interleukin-4-induced IgE and IgG4 production 
by human B cells. Immunology, 1996. 88: p. 35-39. 
 
498. Lowe, J., et al., Soluble forms of CD21 and CD23 antigens in the serum in B 
cell chronic. Immunol Lett, 1989. 20(2): p. 103-9. 
 
499. Fremeaux-Bacchi, V., et al., Soluble CD21 (sCD21) forms biologically active 
complexes with CD23: sCD21. Int Immunol, 1998. 10(10): p. 1459-66. 
 
500. Horcher, M., A. Souabni, and M. Busslinger, Pax5/BSAP maintains the 
identity of B cells in late B lymphopoiesis. Immunity, 2001. 14: p. 779-790. 
 
501. Gorelik, L., et al., Cutting edge: BAFF regulates CD21/35 and CD23 
expression independent of its B cell survival function. J Immunol, 2004. 
172(2): p. 762-6. 
 
502. Debnath, I., et al., Defining a transcriptional fingerprint of murine splenic B-
cell development. Genes and Immunity, 2008. 9: p. 706-720. 
 
 
